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About the Core Curriculum on Tuberculosis:  
What the Clinician Should Know
Purpose
The Core Curriculum on Tuberculosis: What the Clinician Should Know (Core Curriculum) presents 
information about tuberculosis (TB) for health-care professionals. This document, produced by the 
Centers for Disease Control and Prevention (CDC) Division of Tuberculosis Elimination (DTBE), 
updates the 2000 Core Curriculum. It is intended for use as a reference manual for clinicians caring 
for persons with or at high risk for TB disease or infection. In addition, it was designed to be 
useful in developing educational programs. It is not meant to provide detailed answers to all public 
health or clinical questions about TB, nor is it meant as a substitute for any specific guidelines. It is 
anticipated that new guidelines will be published at future dates that will supersede information in 
the Core Curriculum, and these new guidelines will be posted on the CDC DTBE website:  
www.cdc.gov/tb.
An update on TB for clinicians is critical today. Research to find new treatment regimens and more 
effective use of current ones continues as multidrug-resistant and extensively drug-resistant TB cases 
challenge the public health community. The increased complexity of TB and HIV co-infection 
has required updated guidelines for prevention and treatment. Testing, diagnosis, and patient 
management and public health practice have also been revised.
Target Audience
The audience for this course includes clinicians who are caring for persons with or at high risk for TB 
disease or infection.
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Goal
The goal of the Core Curriculum is to provide the reader with information about TB. Upon 
completion of this educational activity, the reader should possess a clear working knowledge  
of the diagnosis, treatment, and prevention of TB infection and disease.
Materials
The Curriculum
The Core Curriculum includes the following materials: 
 • Print-based self-study manual with the following 8 chapters: 
 » Chapter 1. Overview of Tuberculosis Epidemiology in the United States 
 » Chapter 2. Transmission and Pathogenesis of Tuberculosis
 » Chapter 3. Testing for Tuberculosis Infection and Disease
 » Chapter 4. Diagnosis of Tuberculosis
 » Chapter 5. Treatment of Latent Tuberculosis Infection
 » Chapter 6. Treatment of Tuberculosis Disease
 » Chapter 7. Tuberculosis Infection Control
 » Chapter 8. Community Tuberculosis Control
 • Each chapter includes
 » Chapter objectives
 » Content topics with study questions
 » Chapter summary
 » References
 • Appendix A– Glossary
 • Appendix B– Answers to the study questions
 • Appendix C– PowerPoint slides
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Estimated Time for Completion
The curriculum is designed in a self-study format so that each person can work at his or her  
own pace. The actual time it takes to complete the Core Curriculum may differ from person to 
person. Listed below are estimates of the time needed to complete each chapter and the entire 
8-chapter course.
Core Curriculum on Tuberculosis: What the Clinician Should Know 
Estimated Time for Completion 
Chapter Title Estimated Time for Completion
1 Overview of Tuberculosis Epidemiology in the 
United States
15 minutes
2 Transmission and Pathogenesis of Tuberculosis 25 minutes
3 Testing for Tuberculosis Infection and Disease 45 minutes
4 Diagnosis of Tuberculosis 50 minutes
5 Treatment of Latent Tuberculosis Infection 55 minutes
6 Treatment of Tuberculosis Disease 100 minutes
7 Tuberculosis Infection Control 65 minutes
8 Community Tuberculosis Control 35 minutes
TOTAL 6 hours and 30 minutes
Study Questions 
Study questions are included throughout each chapter to provide a review of the content and help 
the reader apply the content to real-life situations. The format of the questions includes either 
multiple choice or matching. For each question, select the ONE BEST ANSWER. Answers to the 
study questions are available in Appendix B.
PowerPoint Slide Set 
The Core Curriculum is accompanied by a PowerPoint slide set for use in presentations and training 
programs. Images of the slides are included in Appendix C. The slide set may be downloaded from 
the CDC DTBE website at  . 
To View or Order the Core Curriculum on Tuberculosis
To view or download the Core Curriculum, please visit: www.cdc.gov/tb. 
If you would like to request a print copy of the Core Curriculum, please use the CDC publication 
online ordering system at www.cdc.gov/tb.
All copies are free of charge.
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Course Objectives
The overall objectives for the entire Core Curriculum are listed below. 
 • Identify TB disease trends in the United States.
 • Describe the transmission and pathogenesis of TB.
 • Identify appropriate TB testing methods.
 • Describe the five components of a TB medical evaluation.
 • Describe LTBI treatment regimens.
 • Describe treatment regimens for TB disease.
 • List common adverse drug reactions to TB medications.
 • Discuss the three levels of an effective TB infection control program.   
 • Describe the roles and responsibilities for TB control and prevention in the public and private 
health care sectors.
Continuing Education
Continuing education (CE) is offered free of charge for various professions based on approximately 
6.5 hours of instruction. In order to receive CE credit/contact hours, you must complete an exam 
and course evaluation. No minimum score is necessary to receive credit/contact hours. Upon 
successful completion of the course, exam, and evaluation, your CE certificate will be issued by  
CDC Training and Continuing Education Online.
Continuing Education Registration and Test
You can register and take the test for CE credits/contact hours online for the Core Curriculum. 
 • Origination Date: February 15, 2011
 • Renewal Date: February 15, 2013
 • Expiration Date: Check the online registration website to determine the expiration date of the 
CE credits/contact hours. 
Continuing Education Credits/Contact Hours
The following CE credits/contact hours are available free of charge for the Core Curriculum: 
 • Continuing education units (CEUs) 
The CDC has been approved as an Authorized Provider by the International Association  
for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, 
McLean, VA 22102. The CDC is authorized by IACET to offer 0.6 ANSI/IACET CEUs  
for this program.
 • Continuing medical education (CMEs) 
The CDC is accredited by the Accreditation Council for Continuing Medical Education 
(ACCME®) to provide continuing medical education for physicians.
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The CDC designates this enduring material for a maximum of 6.5 AMA PRA Category 
1 Credits™. Physicians should only claim credit commensurate with the extent of their 
participation in the activity.
 • Continuing nursing education (CNEs) 
The CDC is accredited as a provider of Continuing Nursing Education by the American 
Nurses Credentialing Center’s Commission on Accreditation. 
This activity provides 6.5 contact hours.
 • Continuing education contact hours in health education (CECH) 
Sponsored by the CDC, a designated provider of continuing education contact hours (CECH) 
in health education by the National Commission for Health Education Credentialing, Inc. 
This program is designed for Certified Health Education Specialists (CHES) and/or Master 
Certified Health Education Specialists (MCHES) to receive up to 6.5 Category I continuing 
education contact hours. Maximum advanced level continuing education contact hours 
available are 0. CDC provider number GA0082.
Online Registration and Test
To receive continuing education, you must register for this specific course and submit an evaluation 
at the CDC Training and Continuing Education Online website.
 • Go to www2a.cdc.gov/TCEonline
 • Log in as a participant. (Note: If you are a first-time user of this online system, you will need to 
log in as a new participant and create a participant profile.) 
 » When you receive your reset password by e-mail, log in as a participant and  
change the password. 
 • At Participant Services, click on Search and Register, type a keyword from the course title into 
the keyword search, such as “Core,” and click View. You can also find the course by typing in 
the course number. The course number for this activity is SS1604.
 • Click on the title, Core Curriculum on Tuberculosis, select the type of credit/contact hours you 
wish to receive at the bottom, and click Submit.
 • Verify the demographic information and click Submit at the bottom.
 • Complete the course evaluation. 
 • Complete the course posttest (if applicable).
 • At Participant Services, click on Certificates and Transcripts and print your continuing 
education certificate. 
For assistance with the online system, call 1(800)-41-TRAIN Monday through Friday from  
8:00 AM to 4:00 PM Eastern Standard Time, or e-mail ce@cdc.gov.
Disclosure Statement
CDC, our planners, and our reviewers wish to disclose they have no financial interests or other 
relationships with the manufacturers of commercial products, suppliers of commercial services, or 
commercial supporters. Planners have reviewed content to ensure there is no bias.
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Content does not include any discussion of the unlabeled use of a product or a product under 
investigation with the exception of Levofloxacin, Moxifloxacin, Gatifloxacin, and Rifabutin.
The CDC does not accept commercial support.
Key Tuberculosis Resources
Tuberculosis Reporting, Guidelines, and Recommendations
Clinicians should immediately contact their state health department if they have a patient with 
suspected or confirmed TB disease. The health department can assist in providing guidance and 
overall public health management of the patient. Contact information for each state TB control 
office can be found at www.cdc.gov/tb/links/tboffices.htm.
For additional information about TB guidelines and recommendations, contact  
the following sources:
 • CDC DTBE website: www.cdc.gov/tb
 • TB Regional Training and Medical Consultation Centers (RTMCCs):  
http://www.cdc.gov/tb/education/rtmc/default.htm
 • American Lung Association: www.lungusa.org/
 • American Thoracic Society: www.thoracic.org
Additional Education and Training Resources
 • Find TB Resources website: www.findtbresources.org
 • TB Regional Training and Medical Consultation Centers product list:  
https://sntc.medicine.ufl.edu/rtmccproducts.aspx
Content Experts
Content experts included staff from the Centers for Disease Control and Prevention, Division of 
Tuberculosis Elimination. 
For Additional Information 
For additional information on TB, visit the CDC DTBE website at www.cdc.gov/tb. If you have 
questions on state-specific TB guidelines, please contact your state TB control office. A list of state 
TB control offices can be found on the CDC DTBE website at www.cdc.gov/tb/links/tboffices.htm
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Chapter 1  
Overview of Tuberculosis Epidemiology  
in the United States
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Chapter Objectives
After working through this chapter, you should be able to 
 • Discuss progress toward tuberculosis (TB) elimination in the United States; 
 • Identify TB disease trends in the United States; and
 • List the racial and ethnic groups that are disproportionately affected by TB disease in the 
United States.
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Progress Toward TB Elimination in the United States
In 1989, the Centers for Disease Control and Prevention (CDC) announced the goal of eliminating 
TB from the United States by the year 2010. A Strategic Plan for the Elimination of Tuberculosis in 
the United States was published in 1989 and reassessed in 1999 to identify the actions necessary to 
achieve elimination. The achievement of this goal was thwarted by the TB resurgence that occurred 
in the late 1980s and early 1990s. This resurgence was fueled by the following factors:
 • The onset of the human immunodeficiency virus (HIV) epidemic;
 • Increases in immigration of persons from countries where TB disease was common;
 • TB transmission in congregate settings; and
 • The development of multidrug-resistant (MDR) TB.
These factors occurred at a time when decades of cuts in funding had resulted in inadequate support 
for TB control and other public health efforts, and in the deterioration of TB control programs. As 
a result, federal, state, and local TB control officials had very few resources for TB control activities. 
Subsequently, the United States renewed its commitment to TB control in the 1990s and mobilized 
new resources. In 1993, the upward trend of new TB cases reversed, and the number of new cases 
has continued its decline up to and through 2011. This can be attributed to the increase in funds 
and resources which enabled TB programs to improve their control efforts to
 • Promptly identify persons with TB disease;
 • Start appropriate treatment for persons with TB disease; and
 • Ensure patients complete treatment.
Despite unprecedented low rates of TB disease, elimination of TB faces some major barriers 
including 
 • TB disease in high-risk populations where it is difficult to detect, diagnose, and treat;
 • Persistence and growth of the global TB epidemic; and
 • Limitations of current control measures and the need for new tests and treatments, including 
an effective vaccine.
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TB Disease Trends in the United States, 1982– 2011
The resurgence of TB disease, which began in the mid-1980s, was marked by several years of 
increasing case counts until its peak in 1992. Case counts began decreasing in 1993, and 2011 
marked the 19th year of decline in the total number of TB cases reported in the United States 
since the peak of the resurgence (Figure 1.1). From 1993 until 2002, the total number of TB cases 
decreased 5%– 7% annually. Although rates continued to decline from 2003 through 2008, it was at 
a much slower rate. However, an unprecedented decline occurred in 2009, when the total number of 
TB cases decreased by more than 10% from 2008 to 2009. In 2011, a total of 10,528 TB cases were 
reported. This represents a decline of 5.8% from 2010 (Table 1.1).
Fig 1.1 
Reported TB Cases* 
United States, 1982– 2011
*Updated as of June 25, 2012.
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Table 1.1 
TB Morbidity 
United States, 2006– 2011
Year No. Rate*
2006 13,727 4.6
2007 13,278 4.4
2008 12,895 4.2
2009 11,528 3.8
2010 11,171 3.6
2011 10,528 3.4
*Cases per 100,000, updated as of June 25, 2012
While national trends indicate that there has been a decline in the overall number of cases since 1993, 
cases continue to be reported. It is important to focus on local epidemiology to identify trends in 
individual states or regions.
While national trends indicate that there has been a decline in the 
overall number of cases since 1993, cases continue to be reported.
In 2011, a total of 38 states reported a rate less than or equal to 3.4 TB cases per 100,000, the 2011 
national average. Twelve states and D.C. reported a rate above 3.4 TB cases per 100,000; these 
areas accounted for 67% of the national total in 2011 and have also experienced substantial overall 
decreases in cases and rates from 1992 through 2011 (Figure 1.2).
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Figure 1.2 
TB Case Rates*  
United States, 2011
*Cases per 100,000.
>3.4 (2011 national average)
< 3.4
D.C.
TB Case Rates by Origin
During 1993 to 2003, rates declined in both the U.S.-born and the foreign-born populations; 
however, the decline was substantially less among foreign-born populations. In 2002, for the first 
time, TB cases among foreign-born persons accounted for the majority (51.2%) of TB cases in the 
United States. Overall, the number of cases in foreign-born persons has remained virtually level with 
approximately 7,000– 8,000 cases each year, until 2009 when the number dropped to 6,854. That 
decreasing trend continued in 2011 with the number of cases in foreign-born persons dropping to 
6,510. The number of cases in U.S.-born persons decreased from more than 17,000 in 1993 to 3,981 
in 2011.
In 2002, for the first time, TB cases among foreign-born persons 
accounted for the majority (51.2%) of TB cases in the United States. 
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Percentage of TB Cases among Foreign-Born Persons  
in the United States, 2001– 2011
The percentage range of the total number of TB cases that occurred in foreign-born persons in each 
state is high¬lighted for 2001 and 2011 in side-by-side maps (Figure 1.3). The number of states with 
less than 25% of their TB cases among foreign-born persons decreased from 13 states in 2001 to 6 
states in 2011. The number of states with 25%-49% of cases among foreign-born persons decreased 
from 14 states in 2001 to 11 states in 2011. However, the number of states that had 50% or more of 
their cases among foreign-born persons increased from 23 states in 2001 to 34 states in 2011.  
Figure 1.3 
Percentage of TB Cases Among Foreign-Born Persons 
United States, 2001– 2011*
*Updated as of June 25, 2012.
2001
DC
2011
DC
>50%
25%–49%
<25%
The countries of birth of foreign-born persons reported with TB disease in the United States have 
remained relatively constant since 1986. Seven countries accounted for 61% of the total cases in 
foreign-born persons in 2011 (Table 1.2 and Figure 1.4). 
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Table 1.2 
Countries of Birth of Foreign-Born Persons  
Reported with TB in the United States, 2011
Country
Percent of Total 
Foreign-Born Cases 
in the United States
Mexico 22%
Philippines 11%
Vietnam 8%
India 8%
China 6%
Guatemala 3%
Haiti 3%
Other Countries  (135) 39%
Figure 1.4 
Countries of Birth of Foreign-Born Persons Reported with TB 
United States, 2011
Mexico
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Race and Ethnicity
Figure 1.5 shows the declining trend in TB rates by race/ethnicity during the years 2003– 2011. 
Asians had the highest TB rates, which declined from 29.9 per 100,000 in 2003 to 20.9 in 2011, 
and had a percent decline over the time period of 30%. Rates also declined in the following racial/
ethnic groups: among non-Hispanic blacks or African-Americans, from 11.7 in 2003 to 6.3 in 2011 
(-46%); among Hispanics, from 10.3 to 5.8 (-44%); among American Indians and Alaska Natives, 
from 8.2 to 5.6 (-32%); and among non-Hispanic whites, from 1.4 to 0.8 (-43%). Rates decreased 
among Native Hawaiian or Other Pacific Islanders after two years of increase since 2008, from 16.2 
in 2003 to 15.9 in 2011(-2%). 
Figure 1.5 
TB Case Rates by Race/Ethnicity* 
United States, 2003– 2011**
*All races are non-Hispanic
**Updated as of June 25, 2012.
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Several important factors likely contribute to the disproportionate burden of TB in minorities, 
including the following:
 • Infection acquired in the country of origin in foreign-born minorities;
 • Unequal distribution of TB risk factors contributing to
 » An increased exposure to TB 
 » An increased risk of developing TB disease once infected with M. tuberculosis  
(e.g., HIV infection); 
 • Lower socioeconomic status and the effects of crowding
Chapter 1: Overview of Tuberculosis Epidemiology in the United States
10
HIV-Infected Persons
HIV-infected persons are at high risk for developing TB disease after infection with M. tuberculosis. In 
the age group of 25– 44 among persons reported with TB disease, the percentage of HIV coinfection 
declined from a high of 29% in 1993 to 10% in 2011. In all ages, the percentage of HIV coinfection 
decreased from 15% in 1993 to 6% in 2011. 
Figure 1.6 provides minimum estimates of HIV coinfection among persons reported with TB from 
1993 through 2011. Since the addition of the request for HIV status to the individual TB case report 
in 1993, incomplete reporting has provided a challenge to calculating reliable estimates. Results from 
the cross-matching of TB and AIDS registries have been used to supplement reported HIV test results. 
Figure 1.6 
Estimated HIV Coinfection in Persons Reported with TB 
United States, 1993– 2011*
*Updated as of June 25, 2012
Note: Minimum estimates based on reported HIV-positive status among all TB cases in the age group. 
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HIV-infected persons are at high risk for developing TB 
disease after infection with M. tuberculosis.
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Multidrug-Resistant TB
Multidrug-resistant TB (MDR TB) is caused by an organism that is resistant to at least isoniazid and 
rifampin, the two most potent TB drugs; it is a serious public health concern. Both U.S.-born and 
foreign-born persons had decreases in the number and percentage of cases of MDR TB, although the 
decline in U.S.-born persons has been greater (Figure 1.7). As a result, the percentage of all primary 
MDR TB cases reported and associated with being foreign born increased from approximately 25% 
of all MDR TB cases in 1993 to 83% in 2011.
Figure 1.7 
Primary MDR TB in U.S.-Born vs. Foreign-Born Persons 
United States, 1993– 2011*
*Updated as of June 25, 2012.
Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid 
and rifampin. 
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Year of Diagnosis
Primary MDR TB cases reported in foreign-born persons increased 
from approximately 25% of all MDR cases in 1993 to 83% in 2011.
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Extensively Drug-Resistant TB 
Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid 
and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., 
amikacin, kanamycin, or capreomycin). For 1993– 2011, the annual numbers of reported XDR 
TB cases, as determined by the initial drug-susceptibility test (DST), are shown below (Figure 1.8). 
There is no apparent trend in the number of XDR TB cases over time in the United States. The 
greatest number of cases reported in a single year that met the XDR TB case definition was 10 in 
1993. There were no cases reported in 2003 or 2009. One case of XDR TB was reported in 2010 
and six cases in 2011. 
There is no apparent trend in the number of XDR TB 
cases over time in the United States. 
Figure 1.8 
XDR TB Case Count Defined on Initial DST* by Year  
1993– 2011**
* Drug susceptibility test
** Updated as of June 25, 2012.
Note: Extensively drug-resistant TB (XDR TB) is defined as resistance to isoniazid and rifampin, plus resistance to any 
fluoroquinolone and at least one of three injectable second-line anti-TB drugs.  
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Identifying Groups at High Risk for TB
The decrease in TB cases and MDR TB is encouraging; however, the earlier resurgence of TB 
provides a valuable lesson. Every TB case is a potential outbreak. Health departments must be 
prepared to identify promptly and treat persons who have active TB disease, as well as identify 
and treat close contacts who may have become infected from persons with active TB disease. By 
understanding which groups are at higher risk for becoming infected with M. tuberculosis, health 
departments can better focus TB prevention and control efforts (Table 1.3).
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Table 1.3 
Persons at Higher Risk for Exposure to  
and/or Infection with M. tuberculosis
Description
 • Close contacts of persons known or suspected to have TB disease
 • Foreign-born persons from areas that have a high incidence of TB disease  
(e.g., Africa, Asia, Eastern Europe, Latin America, and Russia)
 • Persons who visit areas with a high prevalence of TB disease, especially if  
visits are frequent or prolonged
 • Residents and employees of high-risk congregate settings  
(e.g., correctional facilities, long-term care facilities, and homeless shelters)
 • Health-care workers who serve clients who are at increased risk for TB disease
 • Populations defined locally as having an increased incidence of latent M. tuberculosis 
infection or TB disease, possibly including medically underserved, low-income 
populations, or persons who abuse drugs or alcohol
 • Infants, children, and adolescents exposed to adults who are at increased risk for 
latent tuberculosis infection or TB disease
Study Questions
1.1 In 2011, how many TB cases were reported from the 50 states and D.C.?  
(circle the one best answer)
A. 5,466
B. 10,528
C. 21,553
1.2 Which of the following statements is true about TB case rates between 1993 and 2011? 
(circle the one best answer)
A. Rates increased in both foreign-born populations and U.S.-born populations.
B. Rates decreased in both foreign-born populations and U.S.-born populations.
C. Rates remained level in both foreign-born populations and U.S.-born populations.
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The following countries of birth of foreign-born persons accounted for 61% of the total number 
of TB cases in the United States in 2011. Match the country of birth with its percentage of total 
TB cases among foreign-born persons. (Choose the one best answer and write the letter for the 
correct answer on the line next to the question number.) 
Country of Birth
Percent of Total TB Cases in  
Foreign-Born Persons in the 
United States, 2011  
(Answers may be used more than once)
____  1.3 China
____  1.4 Guatemala
____  1.5 Haiti
____  1.6 India
____  1.7 Mexico
____  1.8 Philippines
____  1.9 Vietnam
A. 3%
B. 6%
C. 8%
D. 11%
E. 22%
1.10 Which of the following statements about trends in TB rates by race/ethnicity in the 
United States, from 2003 to 2011, are true? (circle the one best answer)
A. Rates declined among Asians and Pacific Islanders from 29.9 per 100,000 in 2003 to  
20.9 in 2011.
B. Rates declined by at least 22% among non-Hispanic blacks or African Americans, 
Hispanics, American Indians and Alaska Natives, and non-Hispanic whites from  
2003 to 2011.
C. Rates increased among Hispanics, from 8.1 per 100,000 in 2003 to 19.9 in 2011.
D. A, B, and C are all correct.
E. Only A and B are correct.
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1.11 Which of the following factors contribute to the disproportionate burden of TB disease in 
minorities? (circle the one best answer)
A. Infection acquired in the country of origin in foreign-born minorities.
B. Unequal distribution of TB risk factors (e.g., HIV), contributing to increased  
exposure to TB disease or to an increased risk of developing TB disease once  
infected with M. tuberculosis.
C. Lower socioeconomic status and the effects of crowding.
D. A, B, and C are all correct.
E. Only A and B are correct.
1.12 Which of the following statements about MDR TB and XDR TB in the United States are 
true? (circle the one best answer)
A. Primary MDR TB cases reported in foreign-born persons increased from approximately 
25% among all MDR TB cases in 1993 to 83% in 2011.
B. There is no apparent trend in the number of XDR TB cases over time in the United States. 
C. The annual number of cases of counted XDR TB cases during 1993– 2011 was 160. 
D. A, B, and C are correct.
E. Only A and B are correct.
1.13 Of the following persons, who is LEAST likely to be exposed to TB disease? 
(circle the one best answer)
A. Trang was born in Vietnam and recently immigrated to the United States.
B. Frank lives in a homeless shelter.
C. Joshua attends high school in Canton, Ohio.
D. Ellen is a nurse at the Texas State Penitentiary at Huntsville.
Chapter 1: Overview of Tuberculosis Epidemiology in the United States
16
Chapter Summary
The resurgence of TB disease, which began in the mid-1980s, was marked by several years of 
increasing case counts until its peak in 1992. Case counts began decreasing in 1993, and 2011 
marked the 19th year of decline in the total number of TB cases reported in the United States since 
the peak of the resurgence. From 1993 until 2002, the total number of TB cases decreased 5%– 7% 
annually. Although rates continued to decline from 2003 through 2008, it was at a much slower rate. 
However, an unprecedented decline occurred in 2009, when the total number of TB cases decreased 
by more than 10% from 2008 to 2009. In 2011, a total of 10,528 TB cases were reported. This 
represents a decline of 5.8% from 2010.
HIV-infected persons are at high risk for developing TB disease after infection with M. tuberculosis. 
In the age group of 25– 44 among persons reported with TB disease, the percentage of HIV 
coinfection declined from a high of 29% in 1993 to 10% in 2011. In all ages, the percentage of HIV 
coinfection decreased from 15% in 1993 to 6% in 2011. 
MDR TB is caused by an organism that is resistant to at least isoniazid and rifampin, the two most 
potent TB drugs; it is a serious public health concern. Both U.S.-born and foreign-born persons had 
decreases in the number and percentage of cases of MDR TB, although the decline in U.S.-born 
persons has been greater. As a result, the percentage of all primary MDR TB cases reported and 
associated with being foreign-born increased from approximately 25% of all MDR TB cases in 1993 
to 83% in 2011. 
There is no apparent trend in the number of XDR TB cases over time in the United States. The 
greatest number of cases reported in a single year that met XDR TB case definition was 10 in 1993. 
There were no cases reported in 2003 or 2009. One case of XDR TB was reported in 2010 and six 
cases in 2011.
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Chapter Objectives
After working through this chapter, you should be able to 
 • Identify ways in which tuberculosis (TB) is spread;
 • Describe the pathogenesis of TB;
 • Identify conditions that increase the risk of TB infection progressing to TB disease;
 • Define drug resistance; and
 • Describe the TB classification system.
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Introduction
TB is an airborne disease caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis) 
(Figure 2.1). M. tuberculosis and seven very closely related mycobacterial species (M. bovis,  
M. africanum, M. microti, M. caprae, M. pinnipedii, M. canetti and M. mungi) together comprise 
what is known as the M. tuberculosis complex. Most, but not all, of these species have been found to 
cause disease in humans. In the United States, the majority of TB cases are caused by M. tuberculosis. 
M. tuberculosis organisms are also called tubercle bacilli. 
Figure 2.1 
Mycobacterium tuberculosis
Transmission of TB
M. tuberculosis is carried in airborne particles, called droplet nuclei, of 1– 5 microns in diameter. 
Infectious droplet nuclei are generated when persons who have pulmonary or laryngeal TB disease 
cough, sneeze, shout, or sing. Depending on the environment, these tiny particles can remain 
suspended in the air for several hours. M. tuberculosis is transmitted through the air, not by surface 
contact. Transmission occurs when a person inhales droplet nuclei containing M. tuberculosis, and 
the droplet nuclei traverse the mouth or nasal passages, upper respiratory tract, and bronchi to reach 
the alveoli of the lungs (Figure 2.2). 
M. tuberculosis is carried in airborne particles, called droplet nuclei, of 1– 5 
microns in diameter. Infectious droplet nuclei are generated when persons 
who have pulmonary or laryngeal TB disease cough, sneeze, shout, or sing.
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Figure 2.2  
Transmission of TB 
TB is spread from person to person through the air. The dots in the air  
represent droplet nuclei containing tubercle bacilli.
Factors that Determine the Probability of M. tuberculosis Transmission 
There are four factors that determine the probability of transmission of M. tuberculosis (Table 2.1). 
Table 2.1 
Factors that Determine the 
Probability of Transmission of M. tuberculosis 
Factor Description
Susceptibility Susceptibility (immune status) of the exposed individual
Infectiousness Infectiousness of the person with TB disease is directly related to the 
number of tubercle bacilli that he or she expels into the air. Persons who 
expel many tubercle bacilli are more infectious than patients who expel few 
or no bacilli (Table 2.2) (see Chapter 7, TB Infection Control)
Environment Environmental factors that affect the concentration of M. tuberculosis 
organisms (Table 2.3)
Exposure Proximity, frequency, and duration of exposure (Table 2.4)
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Table 2.2 
Characteristics of a Patient with TB Disease that 
Are Associated with Infectiousness
Factor Description
Clinical  • Presence of cough, especially lasting 3 weeks or longer
 • Respiratory tract disease, especially with involvement of the 
larynx (highly infectious)
 • Failure to cover the mouth and nose when coughing
 • Inappropriate or inadequate treatment (drugs, duration)
Procedure  • Undergoing cough-inducing or aerosol-generating 
procedures (e.g., bronchoscopy, sputum induction, 
administration of aerosolized medications)
Radiographic and laboratory  • Cavitation on chest radiograph
 • Positive culture for M. tuberculosis
 • Positive AFB sputum smear result
The infectiousness of a person with TB disease is directly related to the number 
of tubercle bacilli that he or she expels into the air. Persons who expel many 
tubercle bacilli are more infectious than patients who expel few or no bacilli.
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Table 2.3 
Environmental Factors that Enhance the Probability that 
M. tuberculosis Will Be Transmitted
Factor Description
Concentration of infectious 
droplet nuclei
The more droplet nuclei in the air, the more probable that  
M. tuberculosis will be transmitted
Space Exposure in small, enclosed spaces
Ventilation Inadequate local or general ventilation that results in insufficient 
dilution or removal of infectious droplet nuclei
Air circulation Recirculation of air containing infectious droplet nuclei
Specimen handling Improper specimen handling procedures that generate 
infectious droplet nuclei
Air Pressure Positive air pressure in infectious patient’s room that causes  
M. tuberculosis organisms to flow to other areas
Table 2.4 
Proximity and Length of Exposure Factors that Can Affect 
Transmission of M. tuberculosis
Factor Description
Duration of exposure to a person with 
infectious TB
The longer the duration of exposure, the higher 
the risk for transmission
Frequency of exposure to infectious person The more frequent the exposure, the higher the 
risk for transmission
Physical proximity to infectious person The closer the proximity, the higher the risk for 
transmission
Young children with pulmonary and laryngeal TB disease are less likely than adults to be infectious. 
This is because children generally do not produce sputum when they cough. However, transmission 
from children can occur. Therefore, children and adolescents with TB disease should be evaluated 
for infectiousness using the same criteria as adults. These criteria include presence of cough lasting 
3 weeks or longer; cavitation on chest radiograph; or respiratory tract disease with involvement of 
lungs, airways, or larynx (see Chapter 3, Testing for Tuberculosis Infection and Disease).
Young children with pulmonary and laryngeal TB disease 
are less likely than adults to be infectious.
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Study Questions
2.1 How is TB spread? (circle the one best answer)
A. From sharing eating utensils with an infected person.
B. From person to person through the air.
C. From insect bites. 
D. From touching surfaces that are contaminated with M. tuberculosis.
2.2 The probability that M. tuberculosis will be transmitted depends on… 
(circle the one best answer)
A. Susceptibility (immune status) of the exposed individual.
B. Infectiousness of the person with TB.
C. Proximity, frequency, and duration of exposure.
D. Environmental factors that affect the concentration of M. tuberculosis organisms.
E. A, B, C, and D are correct.
Are the following statements about infectiousness true or false? (Choose the one best answer and 
write the letter for the correct answer on the line next to the question number.) 
Statement about Infectiousness True or False
____  2.3 The infectiousness of a person with TB disease is 
directly related to the number of tubercle bacilli 
that he or she expels into the air.
____  2.4 Persons who expel few or no tubercle bacilli are 
just as infectious as those who expel many bacilli.
A. True
B.  False
2.5 Which of the following environmental factors do NOT increase the probability that  
M. tuberculosis will be transmitted? (circle the one best answer)
A. Exposure in small enclosed spaces.
B. Inadequate local or general ventilation that results in insufficient dilution or removal of 
infectious droplet nuclei.
C. Recirculation of air containing infectious droplet nuclei.
D. Improper specimen handling procedures that generate infectious droplet nuclei.
E. Negative pressure in an infectious TB patient’s room.
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Pathogenesis of TB
Infection occurs when a person inhales droplet nuclei containing tubercle bacilli that reach the 
alveoli of the lungs. These tubercle bacilli are ingested by alveolar macrophages; the majority of these 
bacilli are destroyed or inhibited. A small number may multiply intracellularly and are released when 
the macrophages die. If alive, these bacilli may spread by way of lymphatic channels or through the 
bloodstream to more distant tissues and organs (including areas of the body in which TB disease 
is most likely to develop: regional lymph nodes, apex of the lung, kidneys, brain, and bone). This 
process of dissemination primes the immune system for a systemic response. Further details about 
pathogenesis of latent tuberculosis infection (LTBI) and TB disease are described in Figure 2.3.
Figure 2.3 
Pathogenesis of LTBI and TB Disease
1.
Area of 
detail for 
boxes 2, 4, 
and 5 
Droplet nuclei containing 
tubercle bacilli are 
inhaled, enter the lungs, 
and travel to the alveoli.
2.
Bronchiole
Tubercle bacilli
Alveoli
Tubercle bacilli multiply in 
the alveoli.
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3.
Brain
Bone Larynx
Lymph node
Lung
Spine
Kidney
A small number of 
tubercle bacilli enter the 
bloodstream and spread 
throughout the body. 
The tubercle bacilli may 
reach any part of the 
body, including areas 
where TB disease is more 
likely to develop (such as 
the brain, larynx, lymph 
node, lung, spine, bone, 
or kidney).
4.
Special 
immune cells 
form a barrier 
shell (in this 
example, 
bacilli are in 
the lungs)
Within 2 to 8 weeks, 
special immune cells 
called macrophages 
ingest and surround the 
tubercle bacilli. The cells 
form a barrier shell, called 
a granuloma, that keeps 
the bacilli contained and 
under control (LTBI).
5.
Shell breaks 
down and 
tubercle 
bacilli escape 
and multiply
If the immune system 
cannot keep the tubercle 
bacilli under control, the 
bacilli begin to multiply 
rapidly (TB disease). 
This process can occur 
in different areas in the 
body, such as the lungs, 
kidneys, brain, or bone 
(see diagram in box 3).
Infection occurs when a person inhales droplet nuclei containing 
tubercle bacilli that reach the alveoli of the lungs.
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Latent Tuberculosis Infection (LTBI)
Persons with LTBI have M. tuberculosis in their bodies, but do not have TB disease and cannot 
spread the infection to other people. A person with LTBI is not regarded as having a case of TB. The 
process of LTBI begins when extracellular bacilli are ingested by macrophages and presented to other 
white blood cells. This triggers the immune response in which white blood cells kill or encapsulate 
most of the bacilli, leading to the formation of a granuloma. At this point, LTBI has been 
established. LTBI may be detected by using the tuberculin skin test (TST) or an interferon-gamma 
release assay (IGRA) (see Chapter 3, Testing for Tuberculosis Disease and Infection). It can take 2 to 
8 weeks after the initial TB infection for the body’s immune system to be able to react to tuberculin 
and for the infection to be detected by the TST or IGRA. Within weeks after infection, the immune 
system is usually able to halt the multiplication of the tubercle bacilli, preventing further progression. 
Persons with LTBI have M. tuberculosis in their bodies, but do not 
have TB disease and cannot spread the infection to other people.
TB Disease
In some people, the tubercle bacilli overcome the immune system and multiply, resulting in 
progression from LTBI to TB disease (Figure 2.4). Persons who have TB disease are usually infectious 
and may spread the bacteria to other people. The progression from LTBI to TB disease may occur at 
any time, from soon to many years later. Body fluid or tissue from the disease site should be collected 
for AFB smear and culture (see Chapter 5, Treatment for Latent Tuberculosis Infection). Positive 
culture for M. tuberculosis confirms the diagnosis of TB disease. Table 2.5 indicates the differences 
between LTBI and TB disease. 
Persons who have TB disease may spread the bacteria to other people.
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Figure 2.4 
Progression of TB 
People who are exposed to M. tuberculosis may or may not develop LTBI. 
People with LTBI may or may not develop TB disease.
People Exposed to M. tuberculosis
Infected 
with 
M. tuberculosis?
Negative 
TST or IGRA result
Positive
TST or IGRA result
Does not develop 
LTBI or 
TB disease
Not Infectious
No Yes
Abnormal 
chest radiograph
Symptoms
May have
positive culture
Normal 
chest radiograph
May develop 
symptoms
later in life
No Symptoms
Has LBTI
Not Infectious
Has TB Disease
May be infectious
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Table 2.5 
LTBI vs. TB Disease
Person with  
LTBI (Infected)
Person with 
TB Disease (Infectious)
Has a small amount of TB bacteria in his/her 
body that are alive, but inactive
Has a large amount of active TB bacteria in  
his/her body
Cannot spread TB bacteria to others May spread TB bacteria to others
Does not feel sick, but may become sick if the 
bacteria become active in his/her body
May feel sick and may have symptoms  
such as a cough, fever, and/or weight loss
Usually has a TB skin test or TB blood test 
reaction indicating TB infection
Usually has a TB skin test or TB blood test 
reaction indicating TB infection
Radiograph is typically normal Radiograph may be abnormal
Sputum smears and cultures are negative Sputum smears and cultures may be positive
Should consider treatment for LTBI to prevent 
TB disease
Needs treatment for TB disease
Does not require respiratory isolation May require respiratory isolation
Not a TB case A TB case
Risk of Developing TB Disease over a Lifetime 
Without treatment, approximately 5% of persons who have been infected with M. tuberculosis will 
develop disease in the first year or 2 after infection, and another 5% will develop disease sometime 
later in life. Thus, without treatment, approximately 10% of persons with normal immune systems 
who are infected with M. tuberculosis will develop TB disease at some point in their lives.
Sites of TB Disease
TB disease can occur in pulmonary and extrapulmonary sites.
Pulmonary
TB disease most commonly affects the lungs; this is referred to as pulmonary TB. In 2011, 67% of 
TB cases in the United States were exclusively pulmonary. Patients with pulmonary TB usually have 
a cough and an abnormal chest radiograph, and may be infectious. Although the majority of TB 
cases are pulmonary, TB can occur in almost any anatomical site or as disseminated disease. 
Extrapulmonary
Extrapulmonary TB disease occurs in places other than the lungs, including the larynx, the lymph 
nodes, the pleura, the brain, the kidneys, or the bones and joints. In HIV-infected persons, 
extrapulmonary TB disease is often accompanied by pulmonary TB. Persons with extrapulmonary 
TB disease usually are not infectious unless they have 1) pulmonary disease in addition to 
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extrapulmonary disease; 2) extrapulmonary disease located in the oral cavity or the larynx; or 
3) extrapulmonary disease that includes an open abscess or lesion in which the concentration of 
organisms is high, especially if drainage from the abscess or lesion is extensive, or if drainage fluid is 
aerosolized. Persons with TB pleural effusions may have underlying pulmonary TB that is masked on 
chest radiograph because the effusion fluid compresses the lung. These patients should be considered 
infectious until pulmonary TB disease is excluded. 
Miliary TB
Miliary TB occurs when tubercle bacilli enter the bloodstream and disseminate to all parts of 
the body, where they grow and cause disease in multiple sites. This condition is rare but serious. 
“Miliary” refers to the radiograph appearance of millet seeds scattered throughout the lung. It is most 
common in infants and children younger than 5 years of age, and in severely immunocompromised 
persons. Miliary TB may be detected in an individual organ, including the brain; in several organs; 
or throughout the whole body. The condition is characterized by a large amount of TB bacilli, 
although it may easily be missed, and is fatal if untreated. Up to 25% of patients with miliary TB 
may have meningeal involvement. 
Central Nervous System 
When TB occurs in the tissue surrounding the brain or spinal cord, it is called tuberculous 
meningitis. Tuberculous meningitis is often seen at the base of the brain on imaging studies. 
Symptoms include headache, decreased level of consciousness, and neck stiffness. The duration 
of illness before diagnosis is variable and relates in part to the presence or absence of other sites of 
involvement. In many cases, patients with meningitis have abnormalities on a chest radiograph 
consistent with old or current TB, and often have miliary TB.
Risk of LTBI Progressing to TB Disease
Anyone who has LTBI can develop TB disease, but some people are at higher risk than others (Table 
2.6). HIV infection is the greatest risk factor for the development of TB disease in persons with 
LTBI, due to a weakened immune system. The risk of developing TB disease is 7% to 10% each year 
for persons who are infected with both M. tuberculosis and HIV and who are not receiving highly 
active treatment for HIV; it is 10% over a lifetime for persons infected only with M. tuberculosis 
(Figure 2.5). Children younger than 5 years of age are also at increased risk for progression of LTBI 
to TB disease.
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Table 2.6 
Persons at Increased Risk for Progression of LTBI to TB Disease
Persons at Increased Risk
 • Persons infected with HIV;
 • Children younger than 5 years of age;
 • Persons who were recently infected with M. tuberculosis (within the past 2 years);
 • Persons with a history of untreated or inadequately treated TB disease, including persons with 
fibrotic changes on chest radiograph consistent with prior TB disease;
 • Persons who are receiving immunosuppressive therapy such as tumor necrosis factor-alpha 
(TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per 
day, or immunosuppressive drug therapy following organ transplantation;
 • Persons with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, 
neck, or lung;
 • Persons who have had a gastrectomy or jejunoileal bypass;
 • Persons who weigh less than 90% of their ideal body weight;
 • Cigarette smokers and persons who abuse drugs and/or alcohol; and
 • Populations defined locally as having an increased incidence of disease due to  
M. tuberculosis, including medically underserved, low-income populations.
Figure 2.5 
Risk of Developing TB Disease 
Risk Factor Risk of Developing TB Description
TB infection and 
no risk factors
About 10% over a lifetime
For people with TB infection, no risk 
factors, and no treatment, the risk is about 
5% in the first 2 years after infection and 
about 10% over a lifetime.
TB infection and 
diabetes
About 30% over a lifetime
For people with TB infection and diabetes, 
and with no treatment, the risk is three 
times as high, or about 30% over a lifetime.
TB infection and 
HIV infection
About 7% to 10% PER YEAR
For people with TB infection and 
untreated HIV infection and with no LTBI 
treatment, the risk is about 7% to 10% PER 
YEAR, a very high risk over a lifetime.
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Anyone who has LTBI can develop TB disease, but some people are at higher 
risk than others. HIV infection is the highest risk factor for development of 
TB disease in persons with LTBI owing to weakening of the immune system.
Study Questions
2.6 Which statement about the difference between LTBI and TB disease is true? 
(circle the one best answer)
A. Tubercle bacilli are in the body only with TB disease.
B. Persons with LTBI cannot spread TB bacteria to others.
C. Sputum smears and cultures are positive with LTBI but NOT with TB disease.
Which of the following patient characteristics indicate LTBI, TB disease, or both? 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Patient Characteristics
Type of TB 
(Answers May Be Used 
More Than Once)
____  2.7 Has a positive TB skin test or TB 
blood test reaction.
____  2.8 May spread TB bacteria to others.
____  2.9 Has TB bacteria in his/her body.
____  2.10 May require respiratory isolation.
____  2.11 Is NOT a case of TB.
A. LTBI
B. TB disease
C. Both LTBI and  
TB disease
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2.12 TB disease most commonly affects which part of the body? 
(choose the one best answer)
A. Bone
B. Lungs
C. Kidneys
D. Brain
E. None of the above
The following persons have LTBI. Which persons have factors that put them either at an 
increased risk or NOT at an increased risk of progressing to TB disease?  
(Choose the one best answer, and write the letter for the correct answer on the line next to the 
question number.) 
Persons with LTBI Risk of Progressing to TB Disease
____  2.13 Susan has osteopenia.
____  2.14 Andy has diabetes.
____  2.15 Cindy is 3 years old.
A. Increased risk
B. Not an increased risk
Case Study– Daniel 
Daniel, a 30-year-old male, visits the Jackson County Health Department for a 
tuberculosis test because he is required to have one before he starts his new job at the 
Brice Nursing Home. He has a positive reaction to the test. He has no symptoms of TB 
and his chest x-ray findings are normal. 
2.16 Should Daniel be considered a case of TB? 
(circle the one best answer)
A. Yes, because he had a positive reaction to the tuberculosis test.
B. No, because he has TB infection, but no evidence of TB disease.
2.17 Should Daniel be considered infectious? 
 (circle the one best answer)
A. Yes, the test indicates that he has TB infection. Therefore he is infectious.
B. No, because he has TB infection, but not TB disease. Therefore he is not infectious.
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Case Study– Lorena 
Lorena, a 45-year-old female, is referred to the Galion County Health Department by 
her private physician because she was diagnosed with LTBI. She is obese, has high blood 
pressure, and has heart problems. She reports that she has injected illegal drugs in the 
past and also tested positive for HIV infection. 
What conditions does Lorena have that increase the risk that she will develop TB disease? 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Conditions of Persons with LTBI Risk of Progressing toTB Disease
____  2.18 Obesity
____  2.19 High blood pressure
____  2.20 Heart problems
____  2.21 Injection of illegal drugs
____  2.22 HIV
A. Increased risk
B. Not an increased risk
Drug-Resistant TB (MDR and XDR)
Drug-resistant TB is caused by M. tuberculosis organisms that are resistant to the drugs normally used 
to treat the disease (Figure 2.6). Drug-resistant TB is transmitted in the same way as drug-susceptible 
TB, and is no more infectious than drug-susceptible TB. However, delay in the recognition of drug 
resistance or prolonged periods of infectiousness may facilitate increased transmission and further 
development of drug resistance.
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Figure 2.6 
Drug-Resistant Tuberculosis
TB
with any 
drug
resistance
MDR TB* 
with drug 
resistance to at least 
the first-line drugs 
isoniazid and 
rifampin
XDR TB**
with drug resistance
to the first-line drugs 
isoniazid and rifampin 
and to specific 
second-line drugs
All 
TB  
  * Often resistant to additional drugs
** Resistant to any fluoroquinolone and at least one of three injectable second-line drugs  
(i.e., amikacin, kanamycin, or capreomycin)
Drug-resistant TB is caused by M. tuberculosis organisms that  
are resistant to the drugs normally used to treat the disease.  
Drug-resistant TB is transmitted in the same way as drug-susceptible 
TB, and is no more infectious than drug-susceptible TB.
Multidrug-Resistant TB
Multidrug-resistant TB (MDR TB) is caused by organisms resistant to the most effective anti-TB 
drugs, isoniazid and rifampin. These drugs are considered first-line drugs and are used to treat most 
persons with TB disease (see Chapter 6, Treatment of Tuberculosis Disease).
Multidrug-resistant TB (MDR TB) is caused by organisms resistant 
to the most effective anti-TB drugs, isoniazid and rifampin.
Extensively Drug-Resistant TB 
Extensively drug-resistant TB (XDR TB) is a relatively rare type of drug-resistant TB. XDR TB is 
resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable 
second-line drugs (i.e., amikacin, kanamycin, or capreomycin). Because XDR TB is resistant to 
first-line and second-line drugs, patients are left with treatment options that are more toxic, more 
expensive, and much less effective. 
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Types of Drug-Resistant TB Disease
Drug-resistant TB disease can develop in two different ways, called primary and secondary 
resistance (Table 2.7). Primary resistance occurs in persons who are initially infected with resistant 
organisms. Secondary resistance, or acquired resistance, develops during TB therapy, either 
because the patient was treated with an inadequate regimen, did not take the prescribed regimen 
appropriately, or because of other conditions such as drug malabsorption or drug-drug interactions 
that led to low serum levels.
Circumstances in which an exposed person is at an increased risk of infection with drug-resistant TB 
include the following:
 • Exposure to a person who has known drug-resistant TB disease;
 • Exposure to a person with TB disease who has had prior treatment for TB (treatment failure or 
relapse) and whose susceptibility test results are not known;
 • Exposure to a person with TB disease from an area in which there is a high prevalence of drug 
resistance, or travel to one of these areas (see the World Health Organization’s “Tuberculosis: 
MDR-TB & XDR-TB: The 2008 Report” for a list countries with highest prevalence of drug 
resistance at www.who.int/tb/features_archive/drs_factsheet.pdf); or
 • Exposure to a person who continue to have positive smear and cultures after 2 months of 
combination chemotherapy.
Table 2.7 
Primary and Secondary MDR TB
Primary MDR TB
(Infected with Drug-Resistant Organisms)
Secondary MDR TB
(Acquired or Developed Drug Resistance)
Caused by person-to-person transmission of 
drug-resistant organisms
Develops during TB treatment
 • Exposure to a person who 
 » Has known drug-resistant TB
 » Had prior treatment for TB (treatment 
failure or relapse and whose 
susceptibility test results are not known)
 » Is from an area in which there is a high 
prevalence of drug resistance
 » Continues to have positive smears and 
cultures after 2 months of combination 
chemotherapy
 • Travel in areas with a high prevalence of 
drug-resistant TB disease
Develops because the patient
 • Was not treated with the appropriate 
treatment regimen
 Or
 • Did not follow the treatment regimen as 
prescribed 
 » Took the drugs incorrectly
 » Took the drugs irregularly
 • Malabsorption 
 • Drug-drug interactions causing low serum 
levels
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Study Questions
2.23 Which of the following statements is true about drug-resistant TB disease? 
(choose the one best answer)
A. Drug-resistant TB disease is transmitted in the same way as drug-susceptible TB disease.
B. Drug-resistant TB disease is NO more infectious than drug-susceptible TB disease.
C. Drug-resistant TB disease is easily treated with standard drug regimens.
D. A, B, and C are all correct.
E. Only A and B are correct.
2.24 Which of the following types of TB disease is caused by the organism M. tuberculosis? 
(choose the one best answer.) 
A. Drug-susceptible TB
B. MDR TB
C. XDR TB
D. A, B, and C are all correct.
E. Only A and B are correct.
What are the characteristics for each type of TB disease?  
(Choose the one best answer, and write the letter for the correct answer on the line next to the 
question number.) 
Characteristic Type of TB
____  2.25 Resistant to isoniazid and rifampin, plus 
any fluoroquinolone, and at least one of 
three injectable second-line drugs.
____  2.26 Resistant to at least the two first-line drugs, 
isoniazid and rifampin.
A. MDR TB 
B. XDR TB
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What type of drug-resistant TB does each patient have?  
(Choose the one best answer, and write the letter for the correct answer on the line next to the 
question number.) 
Patient Type of Drug-Resistant TB
____  2.27 Sally is diagnosed with and treated for 
TB by her family physician. She is not 
placed on directly observed therapy DOT; 
thus she often forgets to take her anti-
TB medicine and takes only part of her 
prescribed regimen. Because of inadequate 
treatment, she now has MDR TB.
____  2.28 Li, a 13-year-old boy, immigrates from 
China with his family. He gets MDR TB 
from his older brother.
A. Primary resistance 
B. Secondary  
“acquired” resistance
TB Classification System
The current clinical classification system for TB used in the United States is based on the 
pathogenesis of the disease (Table 2.8). It is intended mainly as an operational framework for 
public health programs. This classification system provides clinicians the opportunity to track the 
development of TB in their patients. Health-care providers should comply with state and local laws 
and regulations requiring the reporting of TB disease. All persons with Class 3 (clinically active) or 
Class 5 (TB suspected) TB should be reported promptly to the local or state health department. A 
patient should not have a Class 5 classification for more than 3 months.
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Table 2.8 
TB Classification System
Class Type Description
0 No TB exposure 
Not infected
 • No history of TB exposure and no evidence of  
M. tuberculosis infection or disease
 • Negative reaction to TST or IGRA
1 TB exposure 
No evidence of infection
 • History of exposure to M. tuberculosis
 • Negative reaction to TST or IGRA  
(given at least 8 to 10 weeks after exposure)
2 TB infection 
No TB disease
 • Positive reaction to TST or IGRA 
 • Negative bacteriological studies  
(smear and cultures) 
 • No bacteriological or radiographic evidence of  
active TB disease
3 TB clinically active  • Positive culture for M. tuberculosis OR 
 • Positive reaction to TST or IGRA, plus clinical, bacteriological, 
or radiographic evidence of current active TB
4 Previous TB disease 
(not clinically active)
 • May have past medical history of TB disease
 • Abnormal but stable radiographic findings
 • Positive reaction to the TST or IGRA 
 • Negative bacteriologic studies  
(smear and cultures) 
 • No clinical or radiographic evidence of current  
active TB disease
5 TB suspected  • Signs and symptoms of active TB disease, but medical 
evaluation not complete
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Study Questions
What is the TB classification for each of the following patients? 
(Choose the one best answer, and write the letter for the correct answer on the line next to the 
question number.) 
Patient TB Classification
____  2.29 Sonya has a positive reaction to a TST. There is 
no bacteriological or radiographic evidence of 
TB disease.
____  2.30 Luke has signs and symptoms of TB disease, 
but his medical evaluation is not complete.
____  2.31 Sergei has a past medical history of TB disease. 
His radiographic findings are abnormal, but 
stable. He has a positive reaction to an IGRA. 
Both smear and culture results are negative and 
there is no clinical or radiographic evidence of 
current TB disease.
____  2.32 Joseph has a history of exposure to  
M. tuberculosis and a negative TST result. 
____  2.33 Louisa has no history of TB exposure and no 
evidence of M. tuberculosis infection or disease. 
She had a negative IGRA result.
____  2.34 Rosella has a positive culture for  
M. tuberculosis.
A. 0 No exposure 
 Not infected
B. 1 TB exposure 
 No evidence of infection
C. 2 TB infection 
 No TB disease
D. 3 TB, clinically active
E. 4 Previous TB disease 
 (not clinically active)
F. 5 TB disease suspected
Chapter Summary
TB is an airborne disease caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis).  
M. tuberculosis and seven very closely related mycobacterial species (M. bovis, M. africanum,  
M. microti, M. caprae, M. pinnipedii, M. canetti and M. mungi) together comprise what is known as 
the M. tuberculosis complex. Most, but not all, of these species have been found to cause disease in 
humans. In the United States, the majority of TB cases are caused by M. tuberculosis. M. tuberculosis 
organisms are also called tubercle bacilli.
M. tuberculosis is carried in airborne particles, called droplet nuclei, of 1– 5 microns in diameter. 
Infectious droplet nuclei are generated when persons who have pulmonary or laryngeal TB disease 
cough, sneeze, shout, or sing. Depending on the environment, these tiny particles can remain 
suspended in the air for several hours. M. tuberculosis is transmitted through the air, not by surface 
contact. Transmission occurs when a person inhales droplet nuclei containing M. tuberculosis, and 
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the droplet nuclei traverse the mouth or nasal passages, upper respiratory tract, and bronchi to reach 
the alveoli of the lungs.
TB disease most commonly affects the lungs; this is referred to as pulmonary TB disease. In 2009, 
71% of TB cases in the United States were exclusively pulmonary. Patients with pulmonary TB disease 
usually have a cough and an abnormal chest radiograph, and may be infectious. Although the majority 
of TB cases are pulmonary, TB can occur in almost any anatomical site or as disseminated disease. 
Persons with LTBI have M. tuberculosis in their bodies, but do not have TB disease and cannot spread 
the infection to other people. A person with LTBI is not regarded as a case of TB disease. The process 
of LTBI begins when extracellular bacilli are ingested by macrophages and presented to other white 
blood cells. This triggers the immune response in which white blood cells kill or encapsulate most of 
the bacilli, leading to the formation of a granuloma. At this point, LTBI has been established. LTBI 
may be detected by using the TST or IGRA. It can take 2 to 8 weeks after the initial TB infection 
for the body’s immune system to be able to react to tuberculin and for the infection to be detected 
by the TST or IGRA. Within weeks after infection, the immune system is usually able to halt the 
multiplication of the tubercle bacilli, preventing further progression. 
In some people, the tubercle bacilli overcome the immune system and multiply, resulting in 
progression from LTBI to TB disease. Persons who have TB disease are usually infectious and may 
spread the bacteria to other people. The progression from LTBI to TB disease may occur soon or  
many years after infection. Body fluid or tissue from the disease site should be collected for AFB  
smear and culture. Positive culture for M. tuberculosis confirms the diagnosis of TB disease. 
Drug-resistant TB disease can develop in two different ways, called primary and secondary resistance. 
Primary resistance occurs in persons who are initially exposed to and infected with resistant organisms. 
Secondary resistance, or acquired resistance, develops during TB therapy, either because the patient 
was treated with an inadequate regimen or did not take the prescribed regimen appropriately, or 
because of other conditions such as drug malabsorption or drug-drug interactions that led to low 
serum levels.
MDR TB is caused by organisms resistant to both isoniazid and rifampin, which are the two most 
effective anti-TB drugs. These drugs are considered first-line drugs and are used to treat most persons 
with TB disease.
XDR TB is a relatively rare type of drug-resistant TB. XDR TB is resistant to both isoniazid  
and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs  
(i.e., amikacin, kanamycin, or capreomycin). Because XDR TB disease is resistant to first-line and 
second-line drugs, patients are left with treatment options that are more toxic, more expensive,  
and much less effective.
The current clinical classification system for TB used in the United States is based on the pathogenesis 
of the disease. It is intended mainly as an operational framework for public health programs. This 
classification system provides clinicians the opportunity to track the development of TB in their 
patients. Health-care providers should comply with state and local laws and regulations requiring 
the reporting of TB disease. All persons with Class 3 (clinically active) or Class 5 (TB suspected) TB 
should be reported promptly to the local or state health department. A patient should not have a  
Class 5 classification for more than 3 months.
Chapter 2:  Transmission and Pathogenesis of Tuberculosis
43
References
American Thoracic Society and CDC. Diagnostic standards and classification of tuberculosis in 
adults and children. Am J Respir Crit Care Med 2000; 161 (4): 1376– 1395.  
http://ajrccm.atsjournals.org/cgi/reprint/161/4/1376
American Thoracic Society and Infectious Diseases Society of America. Diagnosis, treatment, 
and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 
367– 416. www.thoracic.org/statements/resources/mtpi/nontuberculous-mycobacterial-diseases.pdf
CDC. A strategic plan for the elimination of tuberculosis from the United States. MMWR 1989; 38 
(Suppl No. S-3). www.cdc.gov/mmwr/preview/mmwrhtml/00001375.htm
CDC. Controlling tuberculosis in the United States: Recommendations from the American Thoracic 
Society, CDC, and the Infectious Diseases Society of America. MMWR 2005; 54 (No. RR-12). 
www.cdc.gov/mmwr/PDF/rr/rr5412.pdf
CDC. Essential components of a tuberculosis prevention and control program: Recommendations of 
the Advisory Council for the Elimination of Tuberculosis. MMWR 1995; 44 (No. RR-11). 
www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm
CDC. Extensively drug-resistant tuberculosis— United States, 1993– 2006. MMWR 2007; 56 (11): 
250– 3. www.cdc.gov/mmwr/preview/mmwrhtml/mm5611a3.htm
CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care 
settings, 2005. MMWR 2005; 54 (No. RR-17).  
www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e
CDC. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults 
and adolescents. MMWR 2009; 58 (No. RR-4).  
www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm?s_cid=rr58e324a1_e
CDC. Management of persons exposed to multidrug-resistant tuberculosis. MMWR 1992; 41  
(No. RR-11): 59– 71. www.cdc.gov/mmwr/preview/mmwrhtml/00031296.htm 
CDC. National action plan to combat multidrug-resistant tuberculosis. MMWR 1992; 41  
(No. RR-11): 1– 48. www.cdc.gov/mmwr/preview/mmwrhtml/00031159.htm 
CDC. Recommendations for prevention and control of tuberculosis among foreign-born persons: 
Report of the Working Group on Tuberculosis among Foreign-born Persons. MMWR 1998; 47  
(No. RR-16). www.cdc.gov/mmwr/preview/mmwrhtml/00054855.htm
CDC. Reported Tuberculosis in the United States, 2011. Atlanta, Ga: U.S. Department of Health 
and Human Services, CDC; September 2012. www.cdc.gov/tb/statistics/reports/2011/default.htm
CDC. Screening for tuberculosis and tuberculosis infection in high-risk populations: 
Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995; 44 
(No. RR-11): 18– 34. www.cdc.gov/mmwr/preview/mmwrhtml/00038873.htm 
Chapter 2:  Transmission and Pathogenesis of Tuberculosis
44
CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49 
(No. RR-6). www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm
Updates: 
Adverse event data and revised American Thoracic Society/CDC recommendations against the 
use of rifampin and pyrazinamide for treatment of latent tuberculosis infection— United States, 
2003. MMWR 2003; 52 (31):735– 9. 
www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm
Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis 
infection, and revisions in American Thoracic Society/CDC recommendations— United States, 
2001. MMWR 2001; 50 (34):733– 5 
www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent 
tuberculosis infection— New York and Georgia, 2000. MMWR 2001; 50 (15): 289– 91.  
www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm
CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat 
latent Mycobacterium tuberculosis infection recommendations— United States, 2011. MMWR 2011; 
60 (48): 1650– 1653. 
 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w
Errata (February 3, 2012) 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a7.htm
CDC. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society 
of America. MMWR 2003; 52 (No. RR-11).  
www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm
Errata (January 7, 2005) 
www.cdc.gov/mmwr/preview/mmwrhtml/mm5351a5.htm
CDC. Tuberculosis elimination revisited: Obstacles, opportunities, and a renewed commitment. 
MMWR 1999; 48 (No. RR-9). www.cdc.gov/mmwr/preview/mmwrhtml/rr4809a1.htm
CDC. Updated guidelines for using interferon gamma release assays to detect Mycobacterium 
tuberculosis infection—  United States, 2010. MMWR 2010; 59 (No. RR-05).  
www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e
Chapter 3: Testing for Tuberculosis Infection and Disease
45
Chapter 3  
Testing for Tuberculosis Infection  
and Disease
Table of Contents
Chapter Objectives  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 45
Introduction  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 47
Identifying High-Risk Groups for M. tuberculosis Testing   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 47
Testing Methods for TB Infection  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 49
BCG Vaccination  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 67
Chapter Summary  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 71
References   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 72
Chapter Objectives
After working through this chapter, you should be able to 
 • Describe why high-risk groups should be tested for M. tuberculosis infection;
 • Identify appropriate testing methods for M. tuberculosis infection; 
 • Identify special considerations when using tuberculin skin tests (TSTs); and
 • Discuss general recommendations for the use of interferon-gamma release assays (IGRAs).
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Introduction
Targeted testing is a TB control strategy that is used to identify, evaluate, and treat persons who are 
at high risk for latent tuberculosis infection (LTBI) or at high risk for developing TB disease once 
infected with M. tuberculosis. Identifying persons with LTBI is important to the goal of TB control 
and elimination because treatment of LTBI can prevent infected persons from developing TB 
disease and stop the further spread of TB. All testing activities should be accompanied by a plan for 
appropriate follow-up medical evaluation and treatment. Necessary medical evaluation and treatment 
resources need to be identified before testing activities begin. 
Targeted testing is a TB control strategy that is used to identify, evaluate, and 
treat persons who are at high risk for latent tuberculosis infection (LTBI) or 
at high risk for developing TB disease once infected with M. tuberculosis.
Study Question
3.1 Why is targeted testing conducted? (circle the one best answer)
G. To identify, evaluate, and treat persons who are at high risk for latent tuberculosis 
infection.
H. To identify, evaluate, and treat persons who are at high risk for developing TB disease  
once infected with M. tuberculosis.
I. To identify the strain of TB bacteria that a patient may have so the correct treatment 
regimen can be provided.
J. A, B, and C are all correct.
K. Only A and B are correct.
Identifying High-Risk Groups for M. tuberculosis Testing
As part of their routine evaluation, health-care providers should identify and test persons who are 
at high risk for acquiring TB infection or at high risk of progressing to TB disease if infected. In 
some select settings, active case finding may be more appropriate than testing for M. tuberculosis 
infection. Flexibility is needed in defining high-risk groups for testing. The changing epidemiology 
of TB indicates that the risk for TB disease or LTBI among groups currently considered high risk 
may decrease over time, and groups currently not identified as being at risk may subsequently be 
considered high risk (see Chapter 1, Overview of Tuberculosis Epidemiology in the United States).
Evaluation of Persons with Positive TB Test Results
Health-care or other (e.g., correctional) facilities should consult with their local health department 
before starting a testing program, to ensure resources are available for the evaluation and treatment of 
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persons whose test results for LTBI or TB disease are positive. Persons with a positive test result for 
TB infection should be evaluated for TB disease and, if disease is ruled out, considered for treatment 
of LTBI (see Chapter 5, Treatment of Latent Tuberculosis Infection).
Health-care or other (e.g., correctional) facilities should consult with 
their local health department before starting a testing program to 
ensure there are resources available for the evaluation and treatment 
of persons whose test results for LTBI or TB disease are positive.
Follow-up TSTs or IGRAs and serial chest radiographs are unnecessary for persons who have a 
positive test result for TB infection and who have had TB disease ruled out or for persons who refuse 
or are unable to receive treatment for LTBI. These persons should be educated about the signs and 
symptoms of TB disease (Figure 3.1). 
Figure 3.1 
Evaluation of Persons with Positive TB Test Results
Person has a positive test 
for TB infection
TB disease ruled out 
Consider for LTBI treatment
Person accepts and is able to 
receive treatment for LTBI 
If person refuses or is unable 
to receive treatment for LTBI, 
follow-up TST or IGRA and serial 
chest radiographs are unnecessary 
Develop a plan of 
treatment with patient to 
ensure adherence Educate patient about signs and 
symptoms of TB disease
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Study Question
3.2 Which of the following statements about evaluating persons with a positive TB test is 
true? (circle the one best answer)
A. Persons with a positive test for TB infection should be evaluated for TB disease and, if 
disease is ruled out, considered for treatment of LTBI.
B. If a person refuses or is unable to receive treatment for LTBI, follow-up TST or IGRA 
tests and serial chest radiographs are unnecessary. 
C. All persons who have a positive test result for TB infection should receive LTBI treatment.
D. A, B, and C are all correct.
E. Only A and B are correct.
Testing Methods for TB Infection
Selection of the most suitable test(s) for detection of M. tuberculosis infection should be based on 
the reasons and the context for testing, test availability, and overall cost effectiveness of testing. 
Currently, there are two methods available for the detection of M. tuberculosis infection in the United 
States. The tests are:
 • Mantoux tuberculin skin test (TST)
 • Interferon-gamma release assays (IGRAs)
 » QuantiFERON-TB Gold In-Tube test (QFT-GIT)
 » T-SPOT.TB test
Currently, there are two methods available for the detection of  
M. tuberculosis infection in the United States. The tests are: 
• Mantoux tuberculin skin test (TST) 
• Interferon-gamma release assays (IGRAs)
These tests help clinicians differentiate infected from uninfected people. However, a negative reaction 
to any of the tests does not exclude the diagnosis of LTBI or TB disease. The decisions about 
medical or public health management should include epidemiological, historical, and other clinical 
information when using IGRA or TST results. Decisions should not be based on TST or IGRA 
results alone. Additional tests are needed to diagnose TB disease. A comparison of the TST and the 
IGRA is included in Table 3.1.
A negative reaction to a TST or IGRA does not exclude 
the diagnosis of LTBI or TB disease.
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The decisions about medical or public health management should include 
epidemiological, historical, and other clinical information when using IGRA 
or TST results. Decisions should not be based on TST or IGRA results alone.
Table 3.1 
TST vs IGRAs
TST IGRA
Tuberculin is injected under the 
skin and produces a delayed-type 
hypersensitivity reaction if the person 
has been infected with M. tuberculosis 
Blood is drawn for testing; test measures 
the immune response to the TB bacteria in 
whole blood 
Requires two or more patient visits to 
conduct the test 
Requires one patient visit to conduct the test
Results are available 48 to 72 hours later Results can be available in 24 hours 
(depending on the batching of specimens  
by the laboratory and transport)
Can cause booster phenomenon Does not cause booster phenomenon
Reading by HCW may be subjective Laboratory test not affected by HCW 
perception or bias
BCG vaccination can cause false-
positive result
BCG vaccination does not cause false-
positive result and infection with most 
nontuberculous mycobacteria does not 
cause false-positive result
A negative reaction to the test  
does not exclude the diagnosis of  
LTBI or TB disease
A negative reaction to the test does not 
exclude the diagnosis of LTBI or TB disease
Mantoux Tuberculin Skin Test (TST)
The TST is used to determine if a person is infected with M. tuberculosis. In this test, a substance 
called purified protein derivative (PPD), which is derived from tuberculin, is injected under the skin. 
Typically PPD produces a T-cell mediated delayed-type hypersensitivity reaction if the person has 
been infected with M. tuberculosis. In most people who have TB infection, the immune system will 
recognize the PPD because it is extracted from the tubercle bacilli that caused the infection. It takes 
2 to 8 weeks after initial infection with M. tuberculosis for the immune system to be able to react to 
PPD and for the infection to be detected by the TST.
The TST is used to determine if a person is infected with M. tuberculosis. 
In this test, a substance called PPD is injected under the skin.
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It takes 2 to 8 weeks after initial infection with M. tuberculosis 
for the body’s immune system to be able to react to PPD 
and for the infection to be detected by the TST.
In some people who are infected with M. tuberculosis, the ability to react to PPD may wane over the 
years. When these people receive a TST many years after infection, they may have an initial negative 
reaction. Subsequent TSTs may produce a positive reaction (see Boosted Reaction in this chapter).
Administering the TST
The TST is performed by intradermal injection of 0.1 ml of PPD containing 5 tuberculin units into 
the volar surface of the forearm. The injection should be made with a disposable 27-gauge tuberculin 
syringe, intradermally (just beneath the surface of the skin), with the needle bevel facing upward. 
This should produce a discrete, pale elevation of the skin (a wheal) 6 mm to 10 mm in diameter 
(Figure 3.2). Institutional guidelines regarding universal precautions for infection control (e.g., the 
use of gloves) should be followed (see Chapter 7, TB Infection Control).
The TST is performed by intradermal injection of 0.1 ml of PPD 
containing 5 tuberculin units into the volar surface of the forearm.
Reading the TST 
The reaction to the TST should be assessed 48 to 72 hours after the injection by a health-care worker 
trained to read TST results. Reactions to PPD usually begin 5 to 6 hours after injection, reach a 
maximum at 48 to 72 hours, and subside over a period of a few days. However, positive reactions 
often persist for up to 1 week or longer. Health-care workers should not ask patients to read their 
own skin test.
The reaction to the TST should be assessed 48 to 72 hours after the 
injection by a health-care worker trained to read TST results.
The TST is read by palpating the site of injection to find an area of induration (firm swelling). 
The diameter of the indurated area should be measured across the forearm (Figure 3.3). Erythema 
(redness) should not be measured (Figure 3.4). Induration should be recorded in millimeters, even 
those classified as negative. If no induration is found, “0 mm” should be recorded.
The TST is read by palpating the site of injection to find an area of induration 
(firm swelling). The diameter of the indurated area should be measured across 
the forearm (Figure 3.3). Erythema (redness) should not be measured.
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Figure 3.2
Administering the Mantoux TST
Figure 3.3 
Reading the TST Correctly
Only the induration is being measured. 
This is CORRECT. 
The correct example below measures 10 mm.
Figure 3.4 
Reading the TST Incorrectly
The erythema is being measured. 
This is INCORRECT.
The incorrect example below measures 30 mm. 
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Interpreting TST Reactions
Interpretation of TST reactions depends on the measurement (in millimeters) of induration and the 
person’s risk of acquiring TB infection or the risk of progression to TB disease if infected (Table 3.2). 
Induration of 5 or more millimeters is interpreted as a positive result in the following groups: 
 • HIV-infected persons;
 • Recent contacts of persons with infectious TB disease;
 • Persons with fibrotic changes on a chest radiograph consistent with prior TB; and
 • Patients with organ transplants and other immunosuppressed patients (including patients 
receiving the equivalent of ≥ 15 mg/day of prednisone for ≥ 1 month).
Induration of 10 millimeters or more is interpreted as a positive result in persons who do not meet 
the preceding criteria, but who have other risk factors for TB. These include the following: 
 • Recent arrivals to the United States (< 5 years) from high-prevalence areas (e.g., Africa, Asia, 
Eastern Europe, Latin America, and Russia);
 • Injection drug users; 
 • Residents and employees of high-risk congregate settings (e.g., correctional facilities, long-term 
care facilities, homeless shelters, and hospitals);
 • Mycobacteriology laboratory personnel;
 • Persons with medical conditions that increase the risk for progression to TB disease, including 
silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (e.g., leukemia and 
lymphomas, or cancer of the head, neck, or lung), gastrectomy or jejunoileal bypass, and 
weight loss of at least 10% below ideal body weight;
 • Children younger than 5 years of age; and 
 • Infants, children, and adolescents exposed to adults in high-risk categories.
An induration of 15 millimeters or greater is interpreted as a positive result in persons with 
no known risk factors for TB who, except for certain testing programs required by local law or 
regulation, would otherwise not be tested. Targeted testing programs should only be conducted 
among higher risk groups.
Interpretation of TST reactions depends on the measurement (in 
millimeters) of the induration and the person’s risk of acquiring TB 
infection or the risk of progression to TB disease if infected.
Chapter 3: Testing for Tuberculosis Infection and Disease
54
Table 3.2 
Interpreting the TST Reaction
5 or more millimeters 10 or more millimeters 15 or more millimeters
An induration of 5 or more 
millimeters is considered 
positive for
 • HIV-infected persons
 • Recent contacts of persons 
with infectious TB
 • People who have fibrotic 
changes on a chest 
radiograph
 • Patients with organ 
transplants and other 
immunosuppressed 
patients (including patients 
taking a prolonged course 
of oral or intravenous 
corticosteroids or TNF-α 
antagonists)
An induration of 10 or more 
millimeters is considered 
positive for
 • People who have come to 
the United States within 
the last 5 years from areas 
of the world where TB is 
common (for example, 
Asia, Africa, Eastern Europe, 
Russia, or Latin America)
 • Injection drug users 
 • Mycobacteriology lab 
workers
 • People who live or work 
in high-risk congregate 
settings
 • People with certain 
medical conditions that 
place them at high risk 
for TB (silicosis, diabetes 
mellitus, severe kidney 
disease, certain types 
of cancer, and certain 
intestinal conditions)
 • Children younger than  
5 years of age
 • Infants, children, and 
adolescents exposed 
to adults in high-risk 
categories
An induration of 15 or more 
millimeters is considered 
positive for
 • People with no known risk 
factors for TB
TST False-Positive Reactions 
The TST is a valuable tool, but it is not perfect. Several factors can lead to false-positive or false-
negative skin test reactions (Table 3.3). Infection with nontuberculous mycobacteria can sometimes 
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cause a false-positive reaction to the TST. Another cause of a false-positive reaction is BCG (bacille 
Calmette-Guérin), a vaccine for TB disease that is rarely used in the United States. People who have 
been vaccinated with BCG may have a positive reaction to the TST even if they do not have TB 
infection (see BCG Vaccination in this chapter).
A false-positive reaction may also occur if an incorrect antigen is used or when the results are not 
measured or interpreted properly.
People who have been vaccinated with BCG may have a positive 
reaction to the TST even if they do not have TB infection.
TST False-Negative Reactions 
Some people have a negative reaction to the TST even though they have been infected with  
M. tuberculosis. A false-negative reaction can be caused by many things (Table 3.3).
Some people have a negative reaction to the TST even 
though they have been infected with M. tuberculosis. 
Anergy
A common cause of false-negative reactions is anergy. Anergy is the inability to react to a TST 
because of a weakened immune system. The absence of a reaction to a TST does not exclude a 
diagnosis of TB disease or infection with M. tuberculosis. Anergy may be caused by many factors, 
including advanced HIV infection, other acute or chronic bacterial, viral or fungal infections, 
sarcoidosis, poor nutrition, certain medications (e.g., TNF-alpha blockers or oral steroids), 
live virus vaccinations, TB disease itself, and other factors. HIV-infected persons may have a 
compromised ability to react to TST because of cutaneous anergy associated with progressive HIV 
immunosuppression; however, the usefulness of anergy testing in tuberculin-negative, HIV-infected 
persons who might benefit from treatment of LTBI has not been demonstrated.
Factors causing false-negative reactions may include, but are not limited to, the following:
 • Concurrent viral infection (e.g., measles, mumps, chicken pox, HIV);
 • Concurrent bacterial infection (e.g., typhoid fever, brucellosis, typhus, leprosy, pertussis);
 • Concurrent fungal infection;
 • Chronic renal failure;
 • Low protein states (e.g., severe protein depletion, afibrinogenemia);
 • Diseases affecting lymphoid organs (e.g., Hodgkin’s disease, lymphoma, chronic leukemia, 
sarcoidosis);
 • Immunosuppressive drugs (e.g., medical steroids);
 • Children aged 6 months or less or elderly patients (i.e., immature or waning immunity);
 • Stress (e.g., surgery, burns, mental illness, graft-versus-host reactions);
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 • Incorrect storage or handling of antigen or results that are not measured or interpreted 
properly;
 • Vaccinations using live virus; or
 • Recent TB infection.
Vaccinations
Vaccination with live viruses may interfere with TST reactivity and cause false-negative reactions; 
this includes measles, mumps, rubella, oral polio, varicella, yellow fever, BCG, and oral typhoid. For 
persons scheduled to receive TST and live virus vaccines, the testing should be done either on the 
same day as vaccination or at least 1 month after vaccination to minimize the potential for a false-
negative TST reaction.
Infection occurs within 8 weeks of skin testing 
False-negative TST reactions may occur if the TB infection occurred within 8 weeks of skin testing. 
For this reason, it is recommended that contacts of a person with infectious TB disease who have a 
negative reaction to the initial TST be retested at least 8 weeks after the last time they were in contact 
with the person who has infectious TB disease.
False-negative TST reactions may occur if the TB infection 
occurred within 8 weeks of skin testing.
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Table 3.3 
False-Positive and False-Negative Reactions to the TST
Type of Reaction Possible Cause People at Risk
False-positive Nontuberculous mycobacteria 
(NTM)
People infected with NTM
BCG vaccination People vaccinated with BCG
Administering of incorrect antigen Any person being tested
Incorrect interpretation of TST result Any person being tested
False-negative Anergy HIV-infected people, other people 
with weakened immune systems, 
severe TB disease, and some viral 
illness (e.g., measles, mumps, and 
chicken pox) or bacterial infection 
(e.g., typhoid, etc.)
Recent TB infection People infected with M. tuberculosis 
within the past 8 weeks
Concurrent viral infection People injected with a live-virus 
vaccination
Concurrent bacterial infection People with typhoid fever, 
brucellosis, typhus, leprosy, 
pertussis
Concurrent fungal infection People with fungal infection
Chronic renal failure People with renal failure
Low protein states People with severe protein 
depletion or afibrinogenemia
Diseases affecting lymphoid organs People with Hodgkin’s disease, 
lymphoma, chronic leukemia, 
sarcoidosis
Immunosuppressive drugs People taking medical steroids, TNF-
alpha blockers or comparable drugs
Very young or elderly persons Newborns or elderly patients with 
immature or waning immunity
Stress People who have had surgery, 
burns, mental illness, graft-versus-
host reactions
Incorrect storage or handling of 
antigen, administering the TST, or 
results that are not measured or 
interpreted properly
Any person being tested
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Special Considerations When Using TST
Boosted Reaction
The booster phenomenon occurs mainly in previously infected, older adults whose ability to react 
to tuberculin has waned over time (Figure 3.5). When these people are skin tested many years after 
they were infected with M. tuberculosis, they may have an initial negative reaction. However, if they 
are tested again within a year of the first test, they may have a positive reaction. This is because the 
first TST “triggered the memory” of the immune system, boosting its ability to react to the second 
TST. It may appear that these people were infected between the first and second tests (recent TB 
infection). The second, positive test reaction is actually a boosted reaction due to TB infection that 
occurred a long time ago. These people may still be considered for LTBI treatment if they fit into a 
high-risk category for progression to TB disease.
The booster phenomenon occurs mainly in previously infected,  
older adults whose ability to react to tuberculin has waned over time.
Figure 3.5 
The TST Booster Phenomenon
The person is skin tested.
The person has a negative reaction.  This is 
because over time, the person’s ability to react to 
tuberculin lessens. However, this skin test 
“triggers the memory” of the immune system to 
recognize and react to tuberculin.
The person is skin tested again, up to 1 year 
later. For this example, we assume that the 
person was NOT exposed to TB during this time.
A person is infected
with M. tuberculosis.
The person has 
a positive reaction. This is a boosted 
reaction due to TB infection that occurred a long 
time ago, not during the time between the 
two skin tests.
As the years pass, the 
person’s ability to react to 
tuberculin lessens.
Occurs mainly in previously 
infected, older adults 
whose ability to react to 
tuberculin has decreased 
over time.
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Two-step TST Testing
Two-step testing is a strategy used to reduce the likelihood that a boosted reaction will be 
misinterpreted as a recent infection (Figure 3.6). Two-step testing should be used for the initial skin 
testing of persons who will be retested periodically, such as health-care workers. 
Two-step testing is a strategy used to reduce the likelihood that a 
boosted reaction will be misinterpreted as a recent infection.
If the reaction to the first test is classified as negative, a second test should be repeated 1 to 3 weeks 
later. A positive reaction to the second test probably represents a boosted reaction. On the basis 
of this second test result, the person should be classified as previously infected. This would not be 
considered a skin test conversion or a new TB infection; however, the patient may still be a candidate 
for LTBI treatment. If the second test result is also negative, the person should be classified as having 
a negative baseline TST result. 
Figure 3.6 
Two-Step TST Testing
What is 
the 
Reaction?
Retest 
1-3 weeks later
Person probably 
has TB infection
The reaction is considered a boosted reaction 
(due to TB infection that occurred a long time ago). 
Note: The person does have LTBI; a decision must be 
made whether to treat or not.
Person probably 
does NOT have
 TB infection
Repeat TST at 
regular intervals; 
a positive reaction 
could be due to a 
recent TB infection.
Negative Positive
Baseline skin test
Follow-up for 
positive TST and evaluate 
for LTBI treatment
What is 
the 
Reaction?
Negative Positive
Follow-up for 
positive TST and evaluate 
for LTBI treatment
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Pregnant Women
TST is both safe and reliable throughout the course of pregnancy. Pregnant women should receive a 
TST if they have a specific risk factor for acquiring LTBI or for progression of LTBI to TB disease. 
No documented episodes of TST-related fetal harm have been reported since the test was developed, 
and no evidence exists that the TST has adverse effects on the pregnant mother.
TST is both safe and reliable throughout the course of pregnancy.
Occupational Exposure 
Guidelines for interpreting TST reactions should also be applied to persons who may have 
occupational exposure to TB (e.g., health-care workers; staff of nursing homes, drug treatment 
centers, or correctional facilities). Thus, the appropriate cutoff for defining a positive reaction 
depends on the employee’s individual risk factors for TB, including recent TB exposure and the 
prevalence of TB in the facility (based on facility risk assessment). In facilities where the risk of 
exposure is very low, 15 mm or greater induration may be an appropriate cut-off for employees with 
no other known risk factors. 
Residents and employees of high-risk congregate facilities should be tested for TB with the two-step 
method upon employment or entry into the facility, and thereafter at intervals determined by the 
annual risk assessment in that facility (see Chapter 7, TB Infection Control).
Residents and employees of high-risk congregate facilities should be tested for 
TB with the two-step method upon employment or entry into the facility and 
thereafter at intervals determined by the annual risk assessment in that facility.
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Study Questions
3.3 A negative reaction to a TST or IGRA does not exclude the diagnosis of LTBI or TB 
disease. (circle the one best answer)
A. True
B. False
3.4 After TB has been transmitted, how long does it take for the body’s immune system to be 
able to react to tuberculin? 
(circle the one best answer)
A. 48 to 72 hours
B. 7 to 10 days
C. 2 to 8 weeks
D. 6 months or more
What induration size is considered a positive TST reaction for the following people?  
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Persons Who Received a TST Size of Induration
____  3.5 Prieta lives in a homeless shelter in El Paso 
and has poor access to health care.
____  3.6 Gloria has no known risk factors for TB.
____  3.7 Elwood has HIV infection.
A. 5 or more millimeters
B. 10 or more millimeters
C. 15 or more millimeters
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Match the factors associated with TST with the appropriate term.  
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Factors Associated with TST Terms
____  3.8 Mainly occurs in previously infected, older 
adults whose ability to react to tuberculin 
has lessened over time.
____  3.9 May occur in people who have been 
vaccinated with BCG.
____  3.10 Should be used for initial skin testing of 
persons who will be retested periodically.
____  3.11 May occur in people who were recently 
infected with M. tuberculosis.
____  3.12 Is the inability to react to a TST because of 
a weakened immune system.
A. False-positive skin test 
reaction
B. False-negative skin test 
reaction
C. Anergy
D. Boosted reaction
E. Two-step testing
3.13 Is it safe for a pregnant woman to have a TST? 
(choose the one best answer)
A. Yes
B. No
Case Study– Bret 
Bret comes to the county health department for a TST. He believes that he has been 
exposed to TB, and he knows he is at high risk for TB disease because he is HIV infected. 
He is given a TST, and his reaction is read 48 hours later as 0 millimeters of induration.
3.14 Which of the following reasons is a possible interpretation for this result?  
(circle the one best answer)
A. He may not have TB infection.
B. It may be less than 8 weeks since he was exposed to TB. 
C. He may be anergic.
D. A, B, and C are all correct.
E. Only A and B are correct.
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Interferon-Gamma Release Assays (IGRAs)
IGRAs detect the presence of M. tuberculosis infection by measuring the immune response to TB 
proteins in whole blood. IGRAs cannot differentiate between LTBI and active TB disease. As with 
the TST, additional tests are needed to diagnose or rule out TB disease. IGRAs may be used for 
surveillance purposes or to identify people who are likely to benefit from treatment, including people 
who are or will be at increased risk of progression to TB disease if infected with M. tuberculosis.
Two IGRAs are commercially available and approved by the U.S. Food and Drug Administration 
(FDA) as aids in diagnosing M. tuberculosis infection:
 • QuantiFERON®-TB Gold In-Tube test (QFT-GIT); and
 • T-Spot®.TB test. 
IGRAs identify the presence of M. tuberculosis infection by measuring 
the immune response to the TB proteins in whole blood. IGRAs cannot 
differentiate between LTBI and active TB disease. As with the TST, 
additional tests are needed to diagnose or rule out TB disease.
IGRAs may be used for surveillance purposes or to identify people who 
are likely to benefit from treatment, including people who are or will be at 
increased risk of progression to TB disease if infected with M. tuberculosis.
General Recommendations for the Use of IGRAs
An IGRA may be used in place of (but not in addition to) a TST in all situations in which  
CDC recommends a TST as an aid in diagnosing M. tuberculosis infection, with the preferences  
and specific considerations noted below (Table 3.4).
 • Preferred for testing persons from groups that historically have poor rates of return for  
TST reading.
 • Preferred for testing persons who have received BCG (as a vaccine or for cancer therapy)  
(see BCG Vaccination in this chapter).
 • Generally should not be used for testing children younger than 5 years of age unless used  
in conjunction with TST.
 • May be used in place of TST to test recent contacts of persons with infectious TB disease  
with special considerations for follow-up testing:
 » IGRAs offer the possibility of detecting M. tuberculosis infection with greater specificity 
than with a TST;
 » Data on the ability of IGRAs to predict subsequent TB are limited;
 » If IGRAs are to be used in contact investigations, negative results obtained prior to 8 weeks 
typically should be confirmed by repeating the test 8 to 10 weeks after the end of exposure;
 » Use of the same test for repeat testing will minimize misclassification errors that occur due 
to test discordance.
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 • May be used in place of a TST for periodic screening that addresses occupational exposure to 
TB disease (e.g., surveillance programs for health-care workers).
 • IGRAs do not boost subsequent test results and can be completed following a single patient 
visit.
 • Routine testing with both a TST and an IGRA is not recommended; however, results from 
both tests may be useful in the following situations when the initial test is negative:
 » When the risk of infection, the risk of progression from infection to disease, and the risk 
of a poor outcome are high (e.g., HIV infection, children under 5 years of age who are 
exposed to persons with infectious TB); or
 » When there is clinical suspicion for TB disease (e.g., signs, symptoms, and/or radiographic 
evidence suggestive of TB disease) and confirmation of M. tuberculosis infection is desired.
 • Routine testing with both a TST and an IGRA is not recommended; however, results from 
both tests may be useful in the following situations when the initial test is positive:
 » Additional evidence of infection is required to encourage compliance (e.g., foreign-born 
health-care workers who believe their positive TST is due to BCG); and
 » In healthy persons who have a low risk of both infection and progression from infection to 
TB disease.
 • Repeating an IGRA or performing a TST may be useful when the initial IGRA result is 
indeterminate, borderline, or invalid, and a reason for testing persists.
 • Each institution and TB control program should evaluate the availability, overall cost 
effectiveness, and benefits of the use of IGRAs.
An IGRA may be used in place of (but not in addition to) TST in all situations in 
which CDC recommends TST as an aid in diagnosing M. tuberculosis infection.
As with the TST, IGRAs generally should not be used for testing persons who have a low risk for 
both infection and disease attributable to M. tuberculosis (with exception of those who are likely to 
be at increased risk in the future) because screening such persons diverts resources from TB control 
activities of higher priority and increases the number of false-positive results.
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Table 3.4 
Recommendations for the Use of IGRAs
Category Recommended Not Recommended
Groups  
for use
 • Preferred for groups that historically have poor 
rates of return for TST reading
 • Preferred for persons who have received BCG (as 
a vaccine or for cancer therapy)
 • Children younger than 5 
years of age unless it is used 
in conjunction with TST
 • Persons at low risk of 
infection
 • Persons at low risk of disease 
due to M. tuberculosis (except 
those who are likely to be at 
increased risk in the future)
In place  
of TST
 • Recent contacts of persons with TB disease with 
special considerations for follow-up testing
 » If IGRAs are used in contact investigations, 
negative results obtained prior to 8 weeks 
typically should be confirmed by repeating 
the test 8 to 10 weeks after the end of 
exposure
 » Use of the same test for repeat testing will 
minimize misclassification errors that occur 
due to test discordance
 • Periodic screening that addresses occupational 
exposure to TB disease (e.g., surveillance 
programs for health workers)
Testing 
with 
both 
TST and 
IGRA 
Results from both tests may be useful when the 
initial test is negative 
 • When the following risks are high
 » Risk of infection
 » Risk of progression from infection to disease
 » Risk of a poor outcome
 • When there is clinical suspicion for active TB 
and confirmation of M. tuberculosis infection is 
desired 
Routine testing with both TST 
and IGRA
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Category Recommended Not Recommended
Testing 
with 
both 
TST and 
IGRA
Results from both tests may be useful in the 
following situations when the initial test is 
positive:
 • Additional evidence of infection is required to 
encourage compliance (e.g., foreign-born health-
care workers who believe their positive TST is due 
to BCG); and
 • In healthy persons who have a low risk of both 
infection and progression from infection to TB 
disease.
Routine testing with both TST 
and IGRA
Study Questions
Match the characteristic with the type of TB test.  
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Characteristic Type of TB Test
____  3.15 Used to detect TB infection.
____  3.16 Blood is drawn for the test.
____  3.17 PPD is injected for the test.
____  3.18 Requires two or more patient visits to 
conduct test.
____  3.19 Requires one patient visit to conduct test.
____  3.20 Results need to be read in 48– 72 hours.
____  3.21 Results can be available in 24 hours.
____  3.22 BCG vaccination can cause false-positive 
result.
____  3.23 BCG vaccination does not cause false-
positive result.
A. TST
B. IGRA
C. Both TST and IGRA
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BCG Vaccination
The bacille Calmette-Guérin (BCG) vaccine is a live, attenuated (weakened) vaccine derived from a 
strain of Mycobacterium bovis that was developed over several years by Calmette and Guérin at the 
Pasteur Institute in Lille, France. An early version of BCG was first administered to humans in 1921. 
Since that time, many different strains have been derived and used throughout the world. BCG 
vaccination is not generally recommended in the United States because of the low risk of infection 
with M. tuberculosis, the variable efficacy of the BCG vaccine against pulmonary TB, the low risk of 
severe disseminated TB disease in young children in the United States, and the vaccine’s interference 
with the ability to determine TST reactivity. Many highly TB-prevalent countries vaccinate infants 
with BCG as part of their TB control effort to prevent children from contracting severe disseminated 
TB or TB meningitis.
BCG vaccination is not generally recommended in the United States 
because of the low risk of infection with M. tuberculosis, the variable 
efficacy of the BCG vaccine against pulmonary TB, the low risk of severe 
disseminated TB disease in young children in the United States and the 
vaccine’s interference with the ability to determine TST reactivity.
Recommendations for the Use of BCG Vaccination in the United States 
The BCG vaccine may be considered in limited circumstances for selected persons who meet specific 
criteria. The use of the BCG vaccine should be undertaken only after consultation with local health 
departments and experts in the management of TB. 
Recent BCG vaccination may cause a subsequent false positive reaction to the TST. Thus, it may 
complicate decisions to prescribe treatment for LTBI for BCG-vaccinated persons who have a 
positive TST result. In such cases, an IGRA would be the test of choice for LTBI diagnosis.
Recent BCG vaccination may cause a subsequent false positive reaction 
to the TST. Thus, it may complicate decisions to prescribe treatment 
for LTBI for BCG-vaccinated persons who have a positive TST result.
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Infants and Children
In the United States, BCG vaccination should only be considered for those children who have a 
negative TST or IGRA result and who are continually exposed to, and cannot be separated from, 
adults who:
 • Are  untreated or ineffectively treated for TB disease (if the child cannot be given long-term 
treatment for infection); or
 • Have TB disease caused by strains resistant to isoniazid and rifampin.
The BCG vaccination is contraindicated in children infected with HIV.
BCG vaccination is contraindicated in children infected with HIV.
Health-Care Workers
BCG vaccination of health-care workers should be considered on an individual basis in  
settings in which:
 • A high percentage of TB patients are infected with M. tuberculosis strains resistant to  
both isoniazid and rifampin;
 • Transmission of such drug-resistant M. tuberculosis strains to health-care workers and 
subsequent infection are likely; and
 • Comprehensive TB infection control precautions have been implemented and have  
not been successful.
BCG vaccination should not be required for employment or for assignment of health-care workers 
in specific work areas. Health-care workers considered for BCG vaccination should be counseled 
regarding the risks and benefits associated with both BCG vaccination and treatment of LTBI. BCG 
vaccination is contraindicated in health-care workers who are infected with HIV.
Contraindications to BCG Vaccination
BCG is contraindicated in persons who have an impaired immune system from the following:
 • HIV infection;
 • Congenital immunodeficiency;
 • Leukemia;
 • Lymphoma;
 • Generalized malignancy;
 • High-dose steroid therapy;
 • Alkylation agents;
 • Antimetabolites; or
 • Radiation therapy.
It is also prudent to avoid giving BCG vaccination to pregnant women, although no harmful effects 
of BCG on the fetus have been observed.
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BCG vaccination should not be given to pregnant women. 
Interpretation of TB Testing Results in BCG-Vaccinated Persons
The TST or IGRA is not contraindicated for persons who have been vaccinated with BCG.  
The TST or IGRA results are used to support decisions about the diagnosis of infection with  
M. tuberculosis. TST in persons vaccinated with BCG should be interpreted using the same criteria 
for those not BCG vaccinated. The booster phenomenon may occur among persons who have had  
a prior BCG vaccination. 
The TST or IGRA is not contraindicated for persons who have been 
vaccinated with BCG. The TST or IGRA results are used to support 
decisions about the diagnosis of infection with M. tuberculosis.
TST in persons vaccinated with BCG should be interpreted using the 
same criteria for those not BCG vaccinated. The booster phenomenon 
may occur among persons who have had a prior BCG vaccination.
Study Questions
3.24 Which of the following statements about recommendations for using BCG in the United 
States is true?  
(choose the one best answer)
A. Should NOT be given to pregnant women.
B. Should be used for children infected with HIV.
C. Should be required for employment of all health-care workers.
D. A, B, and C are all correct.
E. Only A and B are correct.
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Case Study– Anshuman 
Anshuman recently immigrated from India. He is given a TST that results in an 
induration of 14 millimeters. He reports that he was vaccinated with BCG as a child. He 
also says that his wife was treated for pulmonary TB disease last year. 
Are the following statements about how to interpret Anshuman’s results true or false?  
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Statement True or False
____  3.25 He has a positive reaction to the TST.
____  3.26 He is a contact of a person with pulmonary TB. 
____  3.27 There is no reliable way to distinguish a positive TST 
reaction caused by BCG or from a true TB infection. 
____  3.28 Because he was vaccinated with BCG there is no need 
to evaluate him further. 
____  3.29 He should be further evaluated for LTBI or TB 
disease.
A. True
B. False
Which of the following factors make it more likely that Anshuman’s positive reaction is due to 
TB infection? (Choose the one best answer and write the letter for the correct answer on the line 
next to the question number.) 
Factor Yes or No
____  3.30 He is from an area of the world where TB is common, 
so he was probably exposed to TB in  
his native country.
____  3.31 His wife has had pulmonary TB, which further 
increases the probability that he has been exposed  
to TB.  
____  3.32 He had BCG as a child, not as an adult. 
A. Yes, a factor
B. No, not a 
factor
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Chapter Summary
Targeted testing is a TB control strategy that is used to identify, evaluate, and treat persons who are 
at high risk for LTBI or at high risk for developing TB disease once infected with M. tuberculosis. 
Identifying persons with LTBI is important to the goal of TB control and elimination because 
treatment of LTBI can prevent infected persons from developing TB disease and stop the further 
spread of TB. All testing activities should be accompanied by a plan for appropriate follow-up 
medical evaluation and treatment. Necessary medical evaluation and treatment resources need to be 
identified before testing activities begin. 
As part of their routine evaluation, health-care providers should identify and test persons who are 
at high risk for acquiring TB infection or at high risk for progressing to TB disease if infected. In 
some select settings, active case finding may be more appropriate than testing for M. tuberculosis 
infection. Flexibility is needed in defining high-risk groups for testing. The changing epidemiology 
of TB indicates that the risk for TB disease or LTBI among groups currently considered high risk 
may decrease over time, and groups currently not identified as being at risk may subsequently be 
considered high risk. 
Selection of the most suitable test(s) for detection of M. tuberculosis infection should be based on 
the reasons and the context for testing, test availability, and overall cost effectiveness of testing. 
Currently, there are two methods available for the detection of M. tuberculosis infection in the United 
States. The tests are:
 • Mantoux tuberculin skin test (TST)
 • Interferon-gamma release assays (IGRAs)
 » QuantiFERON-TB Gold In-Tube test (QFT-GIT)
 » T-Spot®.TB test
The TST is used to determine if a person is infected with M. tuberculosis. In this test, a substance 
called purified protein derivative (PPD), which is derived from tuberculin, is injected under the skin. 
Typically PPD produces a T-cell mediated delayed-type hypersensitivity reaction if the person has 
been infected with M. tuberculosis. In most people who have TB infection, the immune system will 
recognize the PPD because it is extracted from the tubercle bacilli that caused the infection. It takes 
2 to 8 weeks after initial infection with M. tuberculosis for the body’s immune system to be able to 
react to PPD and for the infection to be detected by the TST.
The booster phenomenon occurs mainly in previously infected, older adults whose ability to react 
to tuberculin has waned over time. When these people are skin tested many years after they were 
infected with M. tuberculosis, they may have an initial negative reaction. However, if they are tested 
again within a year of the first test, they may have a positive reaction. This is because the first TST 
“triggered the memory” of the immune system, boosting its ability to react to the second TST. It may 
appear that these people were infected between the first and second tests (recent TB infection).  The 
second, positive test reaction is actually a boosted reaction due to TB infection that occurred a long 
time ago. These people may still be considered for LTBI treatment if they fit into a high-risk category 
for progression to TB disease.
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IGRAs identify the presence of M. tuberculosis infection by measuring the immune response to the 
TB proteins in whole blood. These tests cannot differentiate between LTBI and active TB disease. As 
with the TST, additional tests are needed to diagnose or rule out TB disease. IGRAs may be used for 
surveillance purposes or to identify people who are likely to benefit from treatment, including people 
who are or will be at increased risk of progression to TB disease if infected with M. tuberculosis.
The bacille Calmette-Guérin (BCG) vaccine is a live, attenuated (weakened) vaccine derived from a 
strain of Mycobacterium bovis that was developed by Calmette and Guérin at the Pasteur Institute in 
Lille, France. An early version of BCG was first administered to humans in 1921. Since that time, 
many different strains have been derived and used throughout the world. BCG vaccination is not 
generally recommended in the United States because of the low risk of infection with M. tuberculosis, 
the variable efficacy of the BCG vaccine against pulmonary TB, the low risk of severe disseminated 
TB disease in young children in the United States, and the vaccine’s interference with the ability 
to determine TST reactivity. Many highly TB-prevalent countries vaccinate infants with BCG as 
part of their TB control effort to prevent children from contracting severe disseminated TB or TB 
meningitis.
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Chapter Objectives
After working through this chapter, you should be able to 
 • Describe the five components of a TB medical evaluation;
 • Identify the major components of TB diagnostic microbiology;
 • List at least five symptoms of pulmonary TB disease;
 • Explain the purpose and significance of acid-fast bacilli (AFB);
 • Explain the purpose and significance of the culture; and 
 • Explain the purpose and significance of genotyping.
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Introduction
Tuberculosis (TB) is not as common as it was many years ago in the United States; consequently, 
clinicians do not always consider the possibility of TB disease when evaluating patients who have 
symptoms. As a result, the diagnosis of TB disease may be delayed or even overlooked, and the 
patient may remain ill and possibly infectious for a prolonged period. 
Not all persons with TB disease have symptoms; however, most persons with TB disease have one or 
more symptoms that lead them to seek medical care. All persons with symptoms of TB disease, or 
either a positive tuberculin skin test (TST) or an interferon-gamma release assay (IGRA) indicative 
of M. tuberculosis infection, should be medically evaluated to exclude TB disease.
Not all persons with TB disease have symptoms; however, most persons with 
TB disease have one or more symptoms that lead them to seek medical care.
All persons with symptoms of TB disease, or either a positive 
TST or IGRA indicative of M. tuberculosis infection, should 
be medically evaluated to exclude TB disease.
Study Question
4.1 All persons with symptoms of TB disease, or a positive TST or IGRA result indicating  
M. tuberculosis infection, should be medically evaluated to exclude TB disease. 
(choose the one best answer)
C. True
D. False
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Medical Evaluation
A complete medical evaluation for TB disease includes the following five components:
1. Medical history
2. Physical examination
3. Test for M. tuberculosis infection
4. Chest radiograph
5. Bacteriologic examination of clinical specimens.
1. Medical History
When conducting a medical history, the clinician should ask if any symptoms of TB disease are 
present; if so, for how long, and if there has been known exposure to a person with infectious 
TB disease. Equally important is obtaining information on whether or not the person has been 
diagnosed in the past with latent tuberculosis infection (LTBI) or TB disease. Clinicians may also 
contact the local health department for information on whether a patient has a past history of TB 
infection or disease. If the previous treatment regimen for TB disease was inadequate or if the patient 
did not adhere to therapy, TB disease may recur and possibly be drug-resistant. It is important to 
consider demographic factors (e.g., country of origin, age, ethnicity, occupation, or racial group) 
that may increase the patient’s risk for being exposed to TB infection (see Chapter 2, Transmission 
and Pathogenesis of Tuberculosis). Clinicians should determine if the patient has underlying medical 
conditions, especially human immunodeficiency virus (HIV) infection or diabetes, that increase the 
risk for progression to TB disease in those latently infected with M. tuberculosis. 
Clinicians should determine if the patient has underlying medical 
conditions, especially HIV infection and diabetes, that increase the risk for 
progression to TB disease in those latently infected with M. tuberculosis.
As discussed in Chapter 2, Transmission and Pathogenesis of Tuberculosis, TB disease most 
commonly affects the lungs and is referred to as pulmonary TB disease. Pulmonary TB disease 
usually causes one or more of the symptoms indicated in Table 4.1.
TB disease most commonly affects the lungs and 
is referred to as pulmonary TB disease.
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Extrapulmonary TB disease may cause symptoms related to the part of the body that is affected 
(Table 4.1). For example, TB of the spine may cause back pain; TB of the kidney may cause blood 
in the urine; TB meningitis may cause headache or confusion. Extrapulmonary TB disease should 
be considered in the differential diagnosis of ill persons who have systemic symptoms and who are at 
high risk for TB disease.
Both pulmonary and extrapulmonary TB disease symptoms can be caused by other diseases; 
however, they should prompt the clinician to consider TB disease.
Both pulmonary and extrapulmonary TB disease symptoms 
can be caused by other diseases; however, they should 
prompt the clinician to consider TB disease.
Table 4.1 
Symptoms of Pulmonary and Extrapulmonary TB Disease
Symptoms of 
Pulmonary TB Disease
(TB disease usually causes 
one or more of the symptoms)
Symptoms of 
Possible Extrapulmonary TB Disease
(Depends on the part of the body 
that is affected by the disease) 
 • Cough (especially if lasting for 3 weeks or 
longer) with or without sputum production
 • Coughing up blood (hemoptysis)
 • Chest pain 
 • Loss of appetite
 • Unexplained weight loss
 • Night sweats
 • Fever
 • Fatigue
 • TB of the kidney may cause blood in the urine
 • TB meningitis may cause headache or 
confusion
 • TB of the spine may cause back pain
 • TB of the larynx can cause hoarseness
 • Loss of appetite
 • Unexplained weight loss
 • Night sweats
 • Fever
 • Fatigue
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Study Questions
Match the patient symptoms with the type of TB. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Patient Symptoms Type of TB
____  4.2 Regina has back pain and blood in her 
urine, unexplained weight loss, fever, 
fatigue, loss of appetite.
____  4.3 Maria has a cough, loss of appetite, and 
unexplained weight loss. She has also been 
coughing up blood.
A. Pulmonary TB
B. Extrapulmonary TB
2. Physical Examination
A physical examination is an essential part of the evaluation of any patient. It cannot be used to 
confirm or rule out TB disease, but it can provide valuable information about the patient’s overall 
condition, inform the method of diagnosis, and reveal other factors that may affect TB disease 
treatment, if diagnosed.
A physical examination is an essential part of the evaluation of 
any patient. It cannot be used to confirm or rule out TB disease, 
but it can provide valuable information about the patient’s overall 
condition, inform the method of diagnosis, and reveal other 
factors that may affect TB disease treatment, if diagnosed.
Study Question
4.4 A physical examination can be used to confirm and rule out TB disease. 
(circle the one best answer)
A. True
B. False
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3. Test for M. tuberculosis Infection
Selection of the most suitable tests for detection of M. tuberculosis infection should be based on 
the reasons and the context for testing, test availability, and overall cost effectiveness of testing. 
Currently, there are two methods available for the detection of M. tuberculosis infection in the United 
States. The tests are:
 • Mantoux tuberculin skin test (TST) (Figure 4.1); and 
 • Interferon-gamma release assays (IGRAs)*
 » QuantiFERON-TB Gold In-Tube test (QFT-GIT) (Figure 4.2);
 » T-SPOT®.TB test (Figure 4.3).
*See Chapter 3, Testing for Tuberculosis Infection and Control
  
Figure 4.1 
Mantoux Tuberculin 
Skin Test 
Figure 4.2 
QuantiFERON-TB Gold  
In-Tube Test (QFT-GIT)
Figure 4.3 
T-SPOT®.TB Test
These tests help clinicians differentiate people infected with M. tuberculosis from those uninfected. 
However, a negative reaction to any of the tests does not exclude the diagnosis of TB disease or LTBI 
(see Chapter 3, Testing for Tuberculosis Infection and Disease).
TST and QFT tests help clinicians differentiate people infected with  
M. tuberculosis from those uninfected. However, a negative reaction to 
any of the tests does NOT exclude the diagnosis of TB disease or LTBI.
Study Question
4.5 A negative reaction for a TST or IGRA test excludes a person from having TB disease.
(choose the one best answer)
A. True
B. False
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4. Chest Radiograph
With pulmonary TB being the most common form of disease, the chest radiograph is useful for 
diagnosis of TB disease. Chest abnormalities can suggest pulmonary TB disease (Figure 4.4). A 
posterior-anterior radiograph of the chest is the standard view used for the detection of TB-related 
chest abnormalities. In some cases, especially in children, a lateral view may be helpful.
Figure 4.4  
Chest Radiograph with Lower Lobe Cavity
In some instances, a computerized tomography (CT) scan may provide additional information. A 
CT scan provides more detailed images of parts of the body that cannot easily be seen on a standard 
chest radiograph; however, CT scans can be substantially more expensive. 
In pulmonary TB disease, radiographic abnormalities are often seen in the apical and posterior 
segments of the upper lobe or in the superior segments of the lower lobe. However, lesions may 
appear anywhere in the lungs and may differ in size, shape, density, and cavitation, especially in HIV-
infected and other immunosuppressed persons. Radiographic abnormalities in children tend to be 
minimal with a greater likelihood of lymphadenopathy, more easily diagnosed on the lateral film.
Mixed nodular and fibrotic lesions may contain slowly multiplying tubercle bacilli and have the 
potential for progression to TB disease. Persons who have lesions consistent with findings of “old” 
TB disease on a chest radiograph and have a positive TST reaction or positive IGRA result should 
be considered high-priority candidates for treatment of LTBI (see Chapter 5, Treatment for Latent 
Tuberculosis Infection), but only after TB disease is excluded by obtaining three specimens for 
AFB smear and culture because “old” TB cannot be differentiated from active TB disease based on 
radiographic appearance alone. Conversely, fully calcified, discrete, nodular lesions without fibrosis 
likely represent granulomas and pose a lower risk for future progression to TB disease. 
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In HIV-infected persons, pulmonary TB disease may present with atypical findings or with no 
lesions seen on the chest radiograph. The radiographic appearance of pulmonary TB disease in 
persons infected with HIV might be typical; however, cavitary disease is less common among such 
patients. More common chest radiograph findings for HIV-infected persons include infiltrates in 
any lung zone, mediastinal or hilar adenopathy, or, occasionally, a normal chest radiograph. Typical 
cavitary lesions are usually observed in patients with higher CD4 counts, and more atypical patterns 
are observed in patients with lower CD4 counts because cavitation is thought to occur as a result of 
the immune response to TB organisms. In HIV-infected persons, almost any abnormality on a chest 
radiograph may be indicative of TB disease. In patients with symptoms and signs of TB disease, a 
negative chest radiograph result does not exclude TB disease. 
Abnormalities seen on chest radiographs may be suggestive of, but are never diagnostic of, TB 
disease. Chest radiographs may be used to exclude pulmonary TB disease in an HIV-negative person 
who has a positive TST reaction or IGRA and who has no symptoms or signs of TB disease.
Abnormalities seen on chest radiographs may be suggestive of, but are 
never diagnostic of, TB disease. Chest radiographs may be used to exclude 
pulmonary TB disease in a person with a normal immune system who has a 
positive TST reaction or IGRA and who has no symptoms or signs of TB disease.
Study Question
4.6 Chest radiographs may be used to exclude pulmonary TB disease in an HIV-negative 
person who has a positive TST reaction or IGRA and who has no symptoms or signs of 
TB disease. (choose the one best answer)
A. True
B. False
5. Bacteriologic Examination of Clinical Specimens
Examinations of clinical specimens (e.g., sputum, urine, or cerebrospinal fluid) are of critical 
diagnostic importance. The specimens should be examined and cultured in a laboratory that 
specializes in testing for M. tuberculosis. The bacteriologic examination has five parts:
 • Specimen collection, processing, and review
 • AFB smear classification and results
 • Direct detection of M. tuberculosis in clinical specimen using nucleic acid amplification (NAA)
 • Specimen culturing and identification
 • Drug-susceptibility testing
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Specimen Collection, Processing, and Review
For diagnostic purposes, all persons suspected of having TB disease at any site should have sputum 
specimens collected for an AFB smear and culture, even those without respiratory symptoms. At least 
three consecutive sputum specimens are needed, each collected in 8- to 24-hour intervals, with at 
least one being an early morning specimen. If possible, specimens should be obtained in an airborne 
infection isolation (AII) room or other isolated, well-ventilated area (e.g., outdoors) (Figure 4.5).
For diagnostic purposes, all persons suspected of having TB disease 
at any site should have sputum collected for TB culture. At least three 
consecutive sputum specimens are needed, each collected in 8- to 24-
hour intervals, with at least one being an early morning specimen.
Figure 4.5 
TB Patient Coughing Up Sputum
A TB patient has coughed up sputum and is spitting it into a sterile 
container. The patient is sitting in a special sputum collection booth 
that, if properly ventilated, prevents the spread of tubercle bacilli.
For diagnostic purposes, all persons suspected of having TB disease 
should have sputum collected for AFB smear and culture.
During specimen collection, patients produce an aerosol that may be hazardous to health-care 
workers or other patients in close proximity. For this reason, precautionary measures for infection 
control must be followed during sputum induction, bronchoscopy, and other common diagnostic 
procedures (see Chapter 7, TB Infection Control).
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During specimen collection, patients produce an aerosol that may be 
hazardous to health-care workers or other patients in close proximity.
Specimen Collection Methods for Pulmonary TB Disease
There are four specimen collection methods for pulmonary TB disease (Table 4.2):
 • Coughing
 • Induced sputum
 • Bronchoscopy
 • Gastric aspiration
Coughing– Coughing is the most commonly used method of sputum collection. Coughing 
should be supervised to ensure that sputum is collected correctly. A health-care worker wearing the 
recommended personal protective equipment should coach and directly supervise the patient when 
sputum is collected (Figure 4.6). Patients should be informed that sputum is the material brought 
up from the lungs, and that mucus from the nose or throat and saliva are not good specimens. 
Unsupervised patients are less likely to provide an adequate specimen, especially the first time.
Patients should be informed that sputum is the material 
brought up from the lungs, and that mucus from the nose 
or throat and saliva are not good specimens.
Figure 4.6
Patient Coughing Up Sputum
Sputum Induction– For patients unable to cough up sputum, deep sputum-producing coughing 
may be induced by inhalation of an aerosol of warm, sterile, hypertonic saline (3%– 5%). Because 
induced sputum is very watery and resembles saliva, it should be labeled “induced” to ensure that the 
laboratory staff workers do not discard it.
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Bronchoscopy– A bronchoscopy is a medical procedure that allows visualization of the inside of 
a person’s airways. The airways are called the bronchial tubes or bronchi. Bronchoscopy might be 
needed for specimen collection, especially if previous results have been nondiagnostic and doubt 
exists as to the diagnosis. At other times, bronchoscopy is considered because TB is among several 
other diagnoses being considered. If possible, examine three spontaneous or induced sputum to 
exclude a diagnosis of TB disease before bronchoscopy. If possible, avoid bronchoscopy on patients 
with suspected or confirmed TB disease or postpone the procedure until the patient is determined 
to be noninfectious, by confirmation of the three negative AFB sputum smear results (Figure 
4.7). Bronchial washings, brushings, and biopsy specimens may be obtained, depending on the 
bronchoscopy findings. Sputum collected after a bronchoscopy may also be useful for a diagnosis. 
A bronchoscopy should never be substituted for sputum collection, but rather used as an additional 
diagnostic procedure. 
Figure 4.7 
Performing a Bronchoscopy
Whenever feasible, bronchoscopy should be performed in a room that meets the ventilation 
requirements for an airborne infection isolation (AII) room. Health-care workers should wear N95 
respirators while present during a bronchoscopy procedure on a patient with suspected or confirmed 
infectious TB disease (see Chapter 7, TB Infection Control).
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Gastric Aspiration– Gastric aspiration is a procedure sometimes used to obtain a specimen for 
culture when a patient cannot cough up adequate sputum. A tube is inserted through the mouth 
or nose and into the stomach to recover sputum that was coughed into the throat and then 
swallowed. This procedure is particularly useful for diagnosis in children, who are often unable 
to cough up sputum (Figure 4.8). Gastric aspiration often requires hospitalization and should be 
done in the morning before the patient gets out of bed or eats, as it is the optimal time to collect 
swallowed respiratory secretions from the stomach. Specimens obtained by gastric aspiration should 
be transported to the lab immediately for neutralization or neutralized immediately at the site of 
collection.
Figure 4.8 
Performing a Gastric Aspiration
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Table 4.2 
Methods of Obtaining a Sputum Specimen
Method Description Advantage Disadvantage
Spontaneous 
sputum sample
Patient coughs up 
sputum into a sterile 
container
 • Inexpensive
 • Easy to do
 • Patient may not be able to 
cough up sputum without 
assistance or may spit up 
saliva instead of sputum
 • Health-care worker has to 
coach and supervise the 
patient when collecting 
sputum
Sputum induction Patient inhales a 
saline mist which 
can cause a deep 
cough
 • Easy to do
 • Use to obtain 
sputum when 
coughing sputum 
is not productive
 • Specimens may be watery 
and may be confused with 
saliva (should be labeled 
“induced specimen”)
 • Requires special 
equipment
 • May cause bronchospasm
Bronchoscopy Bronchoscope is 
passed through 
the mouth or nose 
directly into the 
diseased portion 
of the lung, and 
sputum or lung 
tissue is removed
Use to obtain 
sputum when 
coughing or 
inducing sputum is 
not productive or 
other diagnoses are 
being considered
 • Most expensive and 
invasive procedure
 • Requires special 
equipment
 • Must be done by a 
specialist in a hospital or 
clinic
 • Requires anesthesia
Gastric washing Tube is inserted 
through the 
patient’s mouth or 
nose and passed 
into the stomach 
to get a sample of 
gastric secretions 
that contain sputum 
that has been 
coughed into the 
throat and then 
swallowed
Use to obtain 
samples in children, 
who do not 
produce sputum 
when they cough
 • Must be done as soon as 
patient wakes up in the 
morning; patient may be 
required to stay in hospital
 • Can be uncomfortable for 
the patient
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Specimen Collection Methods for Extrapulmonary TB
TB disease can occur in almost any anatomical site; thus, a variety of clinical specimens other than 
sputum (e.g., urine, cerebrospinal fluid, pleural fluid, pus, or biopsy specimens) may be submitted 
for examination when extrapulmonary TB disease is suspected (Figures 4.9 and 4.10). Procedures 
for the expeditious and recommended handling of the specimen must be in place or assured before 
the specialist performs an invasive procedure to obtain the specimen. Especially important is rapid 
transportation to the laboratory according to the laboratory’s instructions. It is important to note 
that the portion of the specimen placed in formalin for histologic examination cannot be used for 
culture.
TB disease can occur in almost any anatomical site; thus, a variety 
of clinical specimens other than sputum (e.g., urine, cerebrospinal 
fluid, pleural fluid, pus, or biopsy specimens) may be submitted for 
examination when extrapulmonary TB disease is suspected.
Figure 4.9 
Clinical Specimen Used for  
Examination When Extrapulmonary 
TB Disease Is Suspected
Figure 4.10 
Collection Bottles Used for Collecting 
Specimens When Extrapulmonary  
TB Disease Is Suspected
AFB Smear Classification and Results
Detection of acid-fast bacilli in stained and acid-washed smears examined microscopically may 
provide the initial bacteriologic evidence of the presence of mycobacteria in a clinical specimen 
(Figure 4.11). Smear microscopy is the quickest and easiest procedure that can be performed. 
Detection of acid-fast bacilli in stained and acid-washed smears 
examined microscopically may provide the first bacteriologic 
evidence of the presence of mycobacteria in a clinical specimen.
Chapter 4: Diagnosis of TB Disease
90
Figure 4.11 
Acid-Fast Bacilli Stained in Smear  
Tubercle bacilli are shown in red
There are two procedures commonly used for acid-fast staining: 
 • Carbolfuchsin methods which include the Ziehl-Neelsen and Kinyoun methods  
(direct microscopy)
 • Fluorochrome procedure using auramine-O or auramine-rhodamine dyes  
(fluorescent microscopy).
Studies have shown that there must be 5,000 to 10,000 bacilli per milliliter of specimen to allow the 
detection of bacteria in stained smears. In contrast, 10 to 100 bacilli are needed for a positive culture. 
Smear examination is a quick procedure; results should be available within 24 hours of specimen 
collection when specimens are delivered to the laboratory promptly. However, smear examination 
permits only the presumptive diagnosis of TB disease because the acid-fast bacilli in a smear may be 
acid-fast organisms other than M. tuberculosis. Also, many TB patients have negative AFB smears 
with a subsequent positive culture. Negative smears do not exclude TB disease (Table 4.3).
Many TB patients have negative AFB smears with a subsequent 
positive culture. Negative smears do not exclude TB disease.
When acid-fast bacilli are seen in a smear, they are counted. There is a system for reporting the 
number of acid-fast bacilli that are seen at a certain magnification. According to the number of 
acid-fast bacilli seen, the smears are classified as 4+, 3+, 2+, or 1+. The greater the number, the more 
infectious the patient (Table 4.3). 
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Table 4.3 
Smear Classification Results
Smear Result
(Number of AFB observed 
at 1000X magnification)
Smear Interpretation Infectiousness of Patient
4+ (>9/field) Strongly positive Probably very infectious
3+ (1-9/field) Strongly positive Probably very infectious
2+ (1-9/10 fields) Moderately positive Probably infectious
1+ (1-9/100 fields) Moderately positive Probably infectious
+/- (1-2/300 fields)* Weakly positive† Probably infectious
No acid-fast bacilli seen Negative Probably not infectious**
* There are variations on labeling for this result, and include listing the number of AFB counted.  
† Laboratories may report these smear results as “doubtful” or “inconclusive” based on CDC guidelines.
** The criteria for determining whether a patient may be considered noninfectious are discussed in  
Chapter 7 on TB Infection Control.
Direct Detection of M. tuberculosis in Clinical Specimen Using Nucleic Acid  
Amplification (NAA)
NAA tests are used to amplify DNA and RNA segments to rapidly identify the microorganisms in a 
specimen. NAA testing can reliably detect M. tuberculosis bacteria in specimens in hours as compared 
to 1 week or more for culture (Figure 4.12). Possible benefits of using NAA tests include
 • Earlier laboratory confirmation of TB disease;
 • Earlier treatment initiation;
 • Improved patient outcomes;
 • Interruption of transmission by early diagnosis, respiratory isolation and appropriate treatment; 
 • Earlier, more efficient use of respiratory isolation; 
 • Earlier initiation of contact investigation; and
 • More effective public health interventions. 
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NAA tests are used to amplify DNA and RNA segments to 
rapidly identify the microorganisms in a specimen. 
CDC recommends that NAA testing be performed on at least one respiratory specimen from each 
patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered 
but has not yet been established, and for whom the test result would alter case management or TB 
control activities, such as contact investigations.
Figure 4.12 
Nucleic Acid Amplification (NAA) Test
Clinicians should interpret all laboratory results in the context of the clinical situation. A single 
negative NAA test result should not be used as a definitive result to exclude TB disease, especially 
when the clinical suspicion of TB disease is moderate to high. Rather, the negative NAA test result 
should be used as additional information in making clinical decisions, to expedite testing for an 
alternative diagnosis, or to prevent unnecessary TB disease treatment.
Culture remains the gold standard for laboratory confirmation of TB disease, and growing bacteria 
are required to perform drug-susceptibility testing and genotyping. In accordance with current 
recommendations, sufficient numbers and portions of specimens should always be reserved for 
culture. Nonetheless, NAA testing should become standard practice for patients suspected of having 
TB, and all clinicians and public health TB programs should have access to NAA testing for TB to 
shorten the time to diagnosis.
Culture remains the gold standard for laboratory confirmation 
of TB disease, and growing bacteria are required to perform 
drug-susceptibility testing and genotyping.
Chapter 4: Diagnosis of TB Disease
93
Specimen Culture and Identification
Positive cultures for M. tuberculosis confirm the diagnosis of TB disease; however, in the absence 
of a positive culture, TB disease may also be diagnosed on the basis of clinical signs and symptoms 
alone. Culture examinations should be done on all diagnostic specimens, regardless of AFB smear or 
NAA results. The commercially available broth culture systems (e.g., BACTEC, MGIT, VersaTREK, 
MBBACT) allow detection of most mycobacterial growth in 4 to 14 days compared to 3 to 6 weeks 
for solid media (Figure 4.13). Laboratories performing TB cultures should routinely use a broth-
based system (Table 4.4). 
Positive cultures for M. tuberculosis confirm the diagnosis of TB disease; 
however, in the absence of a positive culture, TB disease may also be 
diagnosed on the basis of clinical signs and symptoms alone.
Culture examinations should be done on all diagnostic 
specimens, regardless of AFB smear or NAA results.
Figure 4.13 
Colonies of M. tuberculosis Grown in Culture
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Table 4.4 
Differences Between Sputum Smears and Cultures
Feature Smears Cultures
Equipment needed  • Microscope
 • Glass slides
 • Special dyes
 • Incubators
 • Safety cabinet
 • Culture plates or tubes
 • Culture media, biochemicals for tests
Time needed to 
make report
 • 1 day  • 4 days to 12 weeks (depending on 
method used and how quickly the 
organism grows)
Basis of procedure  • Looking for acid-fast bacilli 
on slide under microscope
 • Growth and identification of tubercle 
bacilli or other mycobacteria on culture 
media in incubator
Significance of a 
negative report
 • Patient is probably not 
infectious
 • Does not rule out TB disease 
(culture may be positive)
 • No live tubercle bacilli found in 
specimen
 • Does not rule out TB disease (live 
tubercle bacilli may be in other 
specimens and/or body sites)
Significance of a 
positive report
 • Patient is more likely to be 
infectious (if acid-fast bacilli 
are tubercle bacilli)
 • Acid-fast bacilli could 
be nontuberculous 
mycobacteria
 • Confirms diagnosis of TB disease
Follow-up Bacteriologic Examination
Follow-up bacteriologic examinations are important for assessing the patient’s infectiousness  
and response to therapy. Specimens should be obtained at monthly intervals until two consecutive 
specimens sent for culture are reported as negative. Culture conversion is the most important 
objective measure of response to treatment. Conversion is documented by the first negative  
culture in a series of previously positive cultures. In addition, all subsequent culture results must 
remain negative.
Specimens should be obtained at monthly intervals until 
two consecutive specimens sent for culture are reported as negative.
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Reporting Results
Laboratories should report initial positive smears, positive M. tuberculosis cultures, and positive 
NAA results within 24 hours by telephone or fax to the primary health-care provider and health 
department. Out-of-state laboratories who receive referral specimens must contact the health-care 
provider and health department in the patient’s state of origin. Follow-up results may be reported  
by mail. It is the responsibility of the primary health-care provider to report all suspected or 
confirmed cases of TB disease promptly to the state or local health department unless state laws 
indicate otherwise. Prompt reporting to health authorities ensures that the person with TB disease 
can be adequately treated, interrupting the potential for ongoing transmission. It also ensures that 
contact investigations can be initiated quickly to find contacts of the patient who may have LTBI  
or TB disease.
Laboratories should report initial positive smears, positive M. tuberculosis 
cultures, and positive NAA results within 24 hours by telephone or 
fax to the primary health-care provider and health department.
Drug-Susceptibility Testing
For all patients, the initial M. tuberculosis isolate should be tested for resistance to the first-line  
anti-TB drugs: isoniazid, rifampin, ethambutol, and pyrazinamide (Figure 4.14). The results of  
drug-susceptibility tests should direct clinicians to choose the appropriate drugs for treating each 
patient. Patients with TB disease who are treated with drugs to which their strain of TB is resistant 
may not be successfully cured. In fact, their strain of TB may become resistant to additional drugs.
For all patients, the initial M. tuberculosis isolate should 
be tested for resistance to the first-line anti-TB drugs: 
isoniazid, rifampin, ethambutol, and pyrazinamide.
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Figure 4.14 
Drug-Susceptibility Testing
Rapid, broth-based systems should be used to identify drug resistance as early as possible in order to 
ensure appropriate treatment. Susceptibility results from laboratories should be promptly forwarded 
to the physician and health department. Drug-susceptibility tests should be repeated for patients 
who do not respond as expected or who have positive culture results despite 3 months of adequate 
treatment. 
Second-line drug susceptibility testing should be done only in reference laboratories and generally be 
limited to specimens from patients who have the following characteristics:
 • Prior TB disease treatment;
 • Contact with a patient with known anti-TB drug resistance; 
 • Demonstrated resistance to first-line anti-TB drugs; or
 • Positive cultures after more than 3 months of treatment. 
A patient is diagnosed with multidrug-resistant TB (MDR TB) disease if the organisms are 
resistant to at least isoniazid and rifampin, the two most potent first-line anti-TB drugs. A patient 
is diagnosed with extensively drug-resistant TB (XDR TB) disease if the TB isolate is resistant to 
isoniazid and rifampin, any fluoroquinolone, and at least one of three injectable second-line drugs 
(i.e., amikacin, kanamycin, or capreomycin).
A patient is diagnosed with multidrug-resistant TB (MDR TB) 
disease if the organisms are resistant to at least isoniazid and 
rifampin, the two most potent first-line anti-TB drugs.
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A patient is diagnosed with extensively drug-resistant TB (XDR TB)  
disease if the isolate is resistant to isoniazid and rifampin,  
any fluoroquinolone, and at least one of three injectable  
second-line drugs (i.e., amikacin, kanamycin, or capreomycin).
Molecular Detection of Drug Resistance
The drug resistance of clinical isolates as determined by conventional methods (e.g, broth-based 
and agar proportion) is due to the presence of mutations in specific M. tuberculosis genes. These 
mutations often are single base pair changes in the DNA sequence of the bacteria. There are a variety 
of commercial assays and laboratory developed tests that can detect mutations associated with drug 
resistance. The assays are done on patient specimens or isolates from patient specimens. 
 • Line-probe assays use polymerase chain reaction (PCR) to amplify the region of a gene known 
to be associated with resistance. The amplified product is labeled and specifically joins to 
probes on a nitrocellulose strip. Mutations are detected by the lack of binding to probes with 
the normal sequence or by binding to probes specific for commonly occurring mutations.
 • PCR amplification of genes known to be associated with drug resistance can be followed by 
DNA sequencing that can detect mutations.
 • Real-time PCR with fluorescing probes that specifically join to the target can do so in one step, 
a technique sometimes called “molecular beacons.” 
All of these assays allow rapid detection of drug resistance through the identification of genetic 
mutations associated with resistance and provide preliminary guidance on effective therapy. 
Molecular detection of drug resistance should be considered for patients with the following 
characteristics:
 • High risk of rifampin resistance, including MDR TB (e.g., previously treated TB, contact with 
someone with MDR TB, or being foreign born from a high-risk country);
 • First-line drug susceptibility results are available and show resistance to rifampin;
 • Infectiousness poses a risk to vulnerable contacts (e.g., daycare workers, nurses, and infants); and
 • Contraindications to essential first-line medications (e.g., rifampin allergy). 
A limitation of molecular testing for drug resistance is that the clinical relevance of some mutations 
remains unknown. Further, not all biological mechanisms of resistance are known. As a result, 
if no mutations are detected by the molecular assay, resistance cannot be ruled out. Therefore, 
it is essential that conventional growth-based drug-susceptibility tests are done and used in 
conjunction with molecular results.
It is essential that conventional growth-based drug-susceptibility 
tests are done and used in conjunction with molecular results.
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Study Questions
Indicate which of the following activities is a component of a complete medical evaluation for 
TB. (Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Activity Yes or No
____  4.7 Medical history 
____  4.8 Physical examination 
____  4.9 Test for M. tuberculosis infection
____  4.10 Chest radiograph
____  4.11 Bone density testing
____  4.12 Bacteriological examination of  
clinical specimens
A. Yes, is a component 
of a complete medical 
evaluation for TB
B. No, is not a component 
of a complete medical 
evaluation for TB 
Match the specimen collection method with how to use it. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Use of Specimen Collection Method Method
____  4.13 Use only if there is a suspicion of TB disease 
and there are three negative sputum smears 
or induced sputum AFB results. 
____  4.14 Best way to obtain specimens from children 
who cannot produce sputum.
____  4.15 Use for extrapulmonary TB disease.
____  4.16 Use for patients unable to cough up sputum 
to encourage deep coughing.
____  4.17 Most common method for collecting 
sputum. 
A. Coughing
B. Sputum induction
C. Bronchoscopy
D. Gastric aspiration
E. Biopsy
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4.18 What do laboratory personnel look for in a sputum smear? 
(choose the one best answer)
A. White-blood cells
B. Fast-moving bacilli
C. Drug-resistant bacilli
D. Acid-fast bacilli
Case Study– Chin 
Chin has symptoms of TB disease and a cavity on his chest radiograph, but all of his 
sputum smears are negative for acid-fast bacilli.
4.19 Does this rule out the diagnosis of pulmonary TB disease for Chin?  
(circle the one best answer)
A. Yes, because his sputum smears are negative for acid-fast bacilli. Even though he has 
symptoms of TB disease and a cavity on his chest radiograph, his sputum smears have to 
be positive for acid-fast bacilli to indicate a diagnosis of pulmonary TB disease.
B. No, because he has symptoms of TB disease and his abnormal chest x-ray suggest that 
he does have pulmonary TB disease. Also, M. tuberculosis may grow in the cultures even 
though there are no acid-fast bacilli on the smear.
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Which of the following statements about nucleic acid amplification (NAA) tests and cultures 
are true or false? (Choose the one best answer and write the letter for the correct answer on the line 
next to the question number.) 
Statements about NAA and Cultures True or False
____  4.20 NAA tests are used to amplify DNA and RNA 
segments to rapidly identify the microorganisms in a 
specimen. 
____  4.21 Culture is required for growing bacteria for drug-
susceptibility testing and genotyping.
____  4.22 Culture is the gold standard for laboratory 
confirmation of TB disease.
____  4.23 A single negative NAA test result should be used as a 
definitive result to exclude TB disease.
____  4.24 Cultures should be done on all diagnostic specimens, 
regardless of AFB smear or NAA results.
A. True
B. False
4.25 During patient follow-up, how often should specimens be obtained? 
(circle the one best answer)
A. At monthly intervals until one specimen sent for culture is reported as negative.
B. At monthly intervals until three consecutive specimens sent for culture are  
reported as negative.
C. At monthly intervals until two consecutive specimens sent for culture are  
reported as negative.
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Are the following statements about drug-susceptibility testing true or false? 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Statements about Drug-Susceptibility Testing True or False
____  4.26 For all patients, the initial M. tuberculosis isolate 
should be tested for resistance to the first-line anti-TB 
drugs.
____  4.27 For all patients, the initial M. tuberculosis isolate 
should be tested for resistance to the second-line anti-
TB drugs.
____  4.28 Drug-susceptibility tests should be repeated for 
patients who do not respond as expected.
____  4.29 Drug-susceptibility tests should be repeated for 
patients who have positive culture results despite 3 
months of adequate therapy.
A. True
B. False
Case Study– Lea 
Lea gave three sputum specimens, which were sent to the laboratory for smear 
examination and culture. The smear results were reported as 4+, 3+, and 4+.
4.30 What do these results tell you about Lea’s diagnosis and her infectiousness?  
(circle the one best answer)
A. Because the smears are positive, clinicians should suspect that Lea has TB disease. 
B. She is probably very infectious.
C. It is possible that the acid-fast bacilli are mycobacteria other than tubercle bacilli. 
Therefore, diagnosis of TB disease cannot be proven until further results are available. 
D. A, B, and C are all correct.
E. Only A and B are correct.
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Case Study– Francis 
In the health clinic you see Francis, a new patient. She complains of weight loss, fever, 
and a cough of 4 weeks’ duration. When questioned, she reports that she has been treated 
for TB disease in the past and that she occasionally injects heroin. 
4.31 What parts of Francis’ medical history lead you to suspect TB disease?  
(circle the one best answer)
A. Her symptoms of TB disease (weight loss, fever, and a persistent cough). 
B. The fact that she has been treated for TB disease in the past. 
C. Her history of injecting illegal drugs (heroin).
D. A, B, and C are all correct.
E. Only A and C are correct.
4.32 What diagnostic tests should be done on Francis?  
(circle the one best answer)
A. Sputum specimen collection for smear and culture.
B. Drug-susceptibility testing if culture is positive.
C. Chest radiograph because she has symptoms of pulmonary TB disease. 
D. A, B, and C are all correct.
E. Only A and B are correct.
Genotyping
TB genotyping is a laboratory-based approach used to analyze the genetic material (i.e., DNA)  
of M. tuberculosis. The total genetic content is referred to as the genome. Specific sections of  
the M. tuberculosis genome form distinct genetic patterns that help distinguish different strains of  
M. tuberculosis. M. tuberculosis genotyping is based on polymorphisms in the number and genomic 
location of mycobacterial repetitive elements. M. tuberculosis isolates with identical genotypes suggest 
that there may have been recent TB transmission among the persons from whom they were isolated. 
The main purpose of genotyping is to add to TB controllers’ understanding of TB transmission in 
their community.
TB genotyping is a laboratory-based approach used to analyze 
the genetic material (i.e., DNA) of M. tuberculosis.
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M. tuberculosis isolates with identical genotypes are often indicative of 
recent TB transmission among the persons from whom they were isolated.
When coupled with traditional epidemiologic investigations, analyses of the genotype of  
M. tuberculosis strains have confirmed suspected transmission and detected unsuspected transmission 
of M. tuberculosis. These analyses have also identified risk factors for recent infection with rapid 
progression to disease, demonstrated re-infection with different strains, identified weaknesses in 
conventional contact investigations, documented the existence of laboratory cross-contamination, 
and identified outbreaks of TB that were not previously recognized (Table 4.5). Genotyping has 
become an increasingly useful tool for studying the pathogenesis, epidemiology, and transmission of 
TB infection and disease.
Table 4.5 
Use of Genotyping Analyses
How Genotyping Has Been Used
 • Confirmed suspected transmission and detected unsuspected transmission of 
M. tuberculosis, when coupled with traditional epidemiologic investigations 
 • Identified risk factors for recent infection with rapid progression to disease
 • Demonstrated re-infection with different strains
 • Identified weaknesses in conventional contact investigations
 • Documented the existence of laboratory cross-contamination
 • Identified outbreaks of TB that were not previously recognized
Study Question
4.33 What is the main purpose of genotyping?  
(choose the one best answer)
A. To amplify DNA and RNA segments to rapidly identify the microorganisms  
in a specimen. 
B. To add to TB controllers’ understanding of TB transmission in their community.
C. To determine drug susceptibility of TB strains.
D. A, B, and C are all correct.
E. Only A and B are correct.
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Chapter Summary
TB is not as common as it was many years ago in the United States; consequently, clinicians do not 
always consider the possibility of TB disease when evaluating patients who have symptoms. As a 
result, the diagnosis of TB disease may be delayed or even overlooked, and the patient may remain ill 
and possibly infectious for a prolonged period. 
Not all persons with TB disease have symptoms; however, most persons with TB disease have one or 
more symptoms that lead them to seek medical care. All persons with symptoms of TB disease, and 
either a positive TST or IGRA indicative of M. tuberculosis infection, should be medically evaluated.   
A complete medical evaluation for TB disease includes the following five components:
1. Medical history
2. Physical examination
3. Test for M. tuberculosis infection
4. Chest radiograph
5. Bacteriologic examination of clinical specimens
1. Medical History
When conducting a medical history, the clinician should ask if any symptoms of TB disease are 
present; if so, for how long, and if there has been known exposure to a person with infectious 
TB disease. Equally important is obtaining information on whether or not the person has been 
diagnosed in the past with LTBI or TB disease. 
TB disease most commonly affects the lungs and is referred to as pulmonary TB disease.  
Symptoms include:
 • Cough (especially if lasting for 3 weeks or longer) with or without sputum collection
 • Coughing up blood (hemoptysis)
 • Chest pain 
 • Loss of appetite
 • Unexplained weight loss
 • Night sweats
 • Fever
 • Fatigue
Extrapulmonary TB disease may cause symptoms related to the part of the body that is affected.  
For example, TB of the spine may cause back pain; TB of the kidney may cause blood in the urine; 
TB meningitis may cause headache or confusion. Extrapulmonary TB disease should be considered 
in the differential diagnosis of ill persons who have systemic symptoms and who are at high risk for 
TB disease.
Both pulmonary and extrapulmonary TB disease symptoms can be caused by other diseases; 
however, they should prompt the clinician to consider TB disease.
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2. Physical Examination 
A physical examination is an essential part of the evaluation of any patient. It cannot be used to 
confirm or rule out TB disease, but it can provide valuable information about the patient’s overall 
condition, inform the method of diagnosis, and reveal other factors that may affect TB disease 
treatment, if diagnosed. 
3. Test for M. tuberculosis Infection 
Selection of the most suitable tests for detection of M. tuberculosis infection should be based on 
the reasons and the context for testing, test availability, and overall cost effectiveness of testing. 
Currently, there are two methods available for the detection of M. tuberculosis infection in the United 
States. The tests are:
 • Mantoux tuberculin skin test (TST); and 
 • Interferon-gamma release assays (IGRAs)
 » QuantiFERON-TB Gold In-Tube test (QFT-GIT)
 » T-SPOT®.TB test.
These tests may help clinicians differentiate people infected with M. tuberculosis from those 
uninfected. However, a negative reaction to any of the tests does not exclude the diagnosis of TB 
disease or LTBI.
4. Chest Radiograph
With pulmonary TB being the most common form of disease, the chest radiograph is useful for 
diagnosis of TB disease. Chest abnormalities can suggest pulmonary TB disease. A posterior-anterior 
radiograph of the chest is the standard view used for the detection of chest abnormalities. In some 
cases, especially in children, a lateral view may be helpful.
Abnormalities seen on chest radiographs may be suggestive of, but are never diagnostic of, TB 
disease. Chest radiographs may be used to exclude TB disease in an HIV-negative person who has a 
positive TST reaction or IGRA and who has no symptoms or signs of TB disease.
5. Bacteriologic Examination of Clinical Specimens 
Examinations of clinical specimens (for example, sputum or urine) are of critical diagnostic 
importance. The specimens should be examined and cultured in a laboratory that specializes in 
testing for M. tuberculosis. The bacteriologic examination has five parts:
 • Specimen collection, processing, and review;
 • AFB smear classification and results;
 • Direct detection of M. tuberculosis in clinical specimen (NAA);
 • Specimen culturing and identification; and
 • Drug-susceptibility testing.
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Chapter Objectives
After working through this chapter, you should be able to 
 • List the high-risk groups who should be given priority for latent tuberculosis infection (LTBI) 
treatment;
 • Describe LTBI treatment regimens;
 • Describe LTBI treatment regimens for specific situations; and
 • Identify components of patient monitoring at baseline and during the treatment of LTBI.
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Introduction
It is currently estimated that more than 11 million people in the United States have latent 
tuberculosis (TB) infection, which is about 4 percent of the total population. While not everyone 
with latent TB infection (LTBI) will develop TB disease, about 5 to 10 percent of infected people 
will develop TB disease if not treated. This equates to approximately 550,000 to 1,100,000 people 
who will develop TB at some point in their life, unless they receive adequate treatment for LTBI.
Treatment of LTBI is essential to controlling and eliminating TB disease in the United States. It 
substantially reduces the risk that persons infected with M. tuberculosis will progress to TB disease. 
Certain groups are at high risk of developing TB disease once infected. Targeted testing programs 
should be designed to identify persons who are at high risk for TB disease and who would benefit 
from treatment of LTBI. Targeted testing should be undertaken only if resources are identified  
and available to ensure full evaluation and treatment. There are two methods available for the 
detection of M. tuberculosis infection in the United States, the Mantoux tuberculin skin test (TST) 
and interferon-gamma release assays (IGRAs) (see Chapter 3, Testing for Tuberculosis Infection  
and Disease).
Targeted testing programs should be designed to identify persons who are 
at high risk for TB disease and who would benefit from treatment of LTBI.
Study Question
5.1 Which statement about the purpose of LTBI treatment is true? 
(choose the one best answer)
F. It is given to people who have LTBI to prevent them from testing positive on a  
subsequent TST.
G. It is given to people who have LTBI to prevent the progression to TB disease.
H. It is given to people who have TB disease to prevent the disease from getting worse.
I. It is given to people who have TB disease to prevent them from becoming infectious.
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Candidates for the Treatment of LTBI
Persons with Positive IGRA Result, or TST Reaction ≥5 mm
Persons in the following high-risk groups should be given treatment for LTBI if they have either a 
positive IGRA result or if their reaction to the TST is ≥5 mm (Table 5.1):
 • HIV-infected persons;
 • Recent contacts of persons with infectious TB disease;
 • Persons with fibrotic changes on chest radiograph consistent with prior TB disease  
(once TB disease is excluded); and
 • Patients with organ transplants, and other immunosuppressed patients (including patients 
receiving the equivalent of 15 mg/day of prednisone for >1 month).
Persons with Positive IGRA Result, or TST Reaction ≥10 mm 
Persons in the following high-risk groups should be considered for treatment of LTBI if they have 
either a positive IGRA result or if their reaction to the TST is ≥10 mm (Table 5.1):
 • Recent arrivals to the United States (<5 years) from high-prevalence areas (e.g., Africa, Asia, 
Eastern Europe, Latin America, and Russia);
 • Injection drug users;
 • Residents and employees of high-risk congregate settings (e.g., correctional facilities, nursing 
homes, homeless shelters, and hospitals);
 • Mycobacteriology laboratory personnel;
 • Persons with medical conditions that increase the risk for progression to TB disease, i.e., 
silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (e.g., leukemia and 
lymphomas, or cancer of the head, neck, or lung), gastrectomy or jejunoileal bypass, and 
weight loss of at least 10% from ideal body weight;
 • Children younger than 5 years of age; and 
 • Infants, children, and adolescents exposed to adults in high-risk categories (see Chapter 3, 
Testing for Tuberculosis Disease and Infection).
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Table 5.1 
High-Priority Candidates for LTBI Treatment Using IGRA or TST*
Groups Who Should Be Given 
High Priority for LTBI Treatment
People who have a positive 
IGRA result or a
TST reaction of
5 or more millimeters
People who have a positive 
IGRA result or a
TST reaction of
10 or more millimeters
 • HIV-infected persons**
 • Recent contacts of persons with infectious  
TB disease**
 • Persons with fibrotic changes on chest 
radiograph consistent with prior TB disease
 • Patients with organ transplants and other 
immunosuppressed patients (including 
patients receiving the equivalent of  
15 mg/day of prednisone for ≥1 month)
 • Recent arrivals to the United States (<5 years) 
from high-prevalence areas (e.g., Asia, Africa, 
Eastern Europe, Russia, or Latin America)
 • Injection drug users 
 • Residents and employees of high-risk 
congregate settings (e.g., correctional 
facilities, nursing homes, homeless shelters, 
hospitals, or other health-care facilities)
 • Mycobacteriology laboratory personnel
 • Persons with medical conditions that 
increase the risk for progression to TB 
disease, including silicosis, diabetes mellitus, 
chronic renal failure, certain types of cancer 
(e.g., leukemia and lymphomas, or cancer 
of the head, neck or lung), gastrectomy or 
jejunoileal bypass, and weight loss of at least 
10% below body weight;
 • Children younger than 5 years of age; or 
children and adolescents exposed to adults 
in high-risk categories
  * See Chapter 3, Testing for Tuberculosis Infection and Disease for information on interpreting a TST or IGRA 
result
** In certain circumstances, people in these categories may be given LTBI treatment even if they do not have a 
positive TST or IGRA result (see the Special Considerations for LTBI Treatment section in this Chapter).
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Persons with No Known Risk Factors Who Have Positive IGRA Result,  
or TST Reaction ≥15 mm 
People without any risk factors generally should not be tested for TB infection. Testing should be 
targeted to groups at high risk for LTBI and TB disease (see Chapter 3, Testing for Tuberculosis 
Infection and Disease). However, if a person without any risk factors is tested and has a positive 
IGRA result or TST reaction that is ≥15 mm, he or she should be evaluated for LTBI treatment once 
TB disease is excluded. 
People without any risk factors generally should not be tested for TB infection.
Close Contacts Who Have a Negative IGRA or TST Result
Some contacts who have a negative IGRA or TST result should be evaluated for treatment of LTBI 
after TB disease has been ruled out. These contacts include: 
 • Children less than 5 years of age
 • Immunosuppressed persons
 • Those at risk for rapid progression to TB disease once infected (see Chapter 3, Testing for 
Tuberculosis Infection and Disease)
Any contact who is to be treated for LTBI should have a chest radiograph to exclude pulmonary TB 
disease before starting treatment.
Any contact who is to be treated for LTBI should have a chest radiograph 
to exclude pulmonary TB disease before starting treatment.
Close contacts who have a negative IGRA or TST result should be retested 8 to 10 weeks after  
they were last exposed to infectious TB disease. This is due to the fact that it can take 2 to 8 weeks 
after TB infection for the body’s immune system to react to tuberculin and for the infection to  
be detected.
Close contacts who have a negative IGRA or TST result should be retested 
8 to 10 weeks after they were last exposed to infectious TB disease.
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HIV-Infected Contacts
Contacts known or suspected to be HIV infected or who have other serious immunocompromising 
conditions should be started on treatment for LTBI regardless of their IGRA or TST result after  
TB disease has been excluded. Treatment of LTBI may be discontinued if the TST or IGRA result is 
negative on the second test given 8 to 10 weeks after the last exposure and if the person is no longer 
exposed to infectious TB disease. However, because HIV-infected and other immunocompromised 
persons may be anergic and not be able to manifest a positive TST or IGRA result if infected, in 
some cases medical providers may decide to prescribe a complete course of LTBI treatment even  
if the second TST or IGRA result is negative, particularly if the exposure to TB is substantial  
(e.g., prolonged, frequent exposure to very infectious TB patient).  
Contacts known or suspected to be HIV infected or who have other serious 
immunocompromising conditions should be started on treatment for LTBI 
regardless of their IGRA or TST result after TB disease has been excluded.
Infants and Young Children
Because of their age, infants and young children with LTBI are known to have been infected recently, 
and thus are at a high risk of their infection progressing to TB disease (Table 5.2). Infants and young 
children are also more likely than older children and adults to develop life-threatening forms of TB 
disease, especially meningeal and disseminated disease, because they do not have fully developed 
immune systems.
Because of their age, infants and young children with LTBI 
are known to have been infected recently, and thus are at a 
high risk of their infection progressing to TB disease.
Infants and young children are more likely than older children 
and adults to develop life-threatening forms of TB disease.
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Window Prophylaxis
Children less than 5 years of age who are close contacts to an adult with infectious TB should receive 
treatment for LTBI even if the TST result is negative and once TB disease is excluded by chest 
radiograph and symptom review; this is called “window” prophylaxis.  Also, infected infants may be 
anergic as late as 6 months of age. A second TST should be administered 8 to 10 weeks after the last 
exposure to infectious TB disease. Window prophylaxis can be discontinued if all of the following 
conditions are met:
 • The infant is at least 6 months of age
 • The second TST result is also negative
 • The second TST was performed at least 8 weeks after the child was last exposed to an adult 
with infectious TB disease
Children less than 5 years of age who are close contacts to an adult with 
infectious TB should receive treatment for LTBI even if the TST result is negative 
once TB disease is excluded by chest radiograph and symptom review.  
Table 5.2 
LTBI in Children
Infants and Young Children 
with LTBI
Treating Children Less than 5 Years of Age 
Who Are Close Contacts
 • Are known to have been infected recently 
(because of their age)
 • Are more likely than older children and 
adults to develop life-threatening forms of TB 
disease (e.g., disseminated TB, TB meningitis)
 • Should provide LTBI treatment even if initial 
TST result is negative once TB disease is 
excluded (infected infants may be anergic as 
late as 6 months of age)
 • Administer a second TST 8 to 10 weeks after 
the last exposure to infectious TB disease
 • Discontinue window prophylaxis if all of the 
following conditions are met:
 » Infant is at least 6 months of age
 » Second TST result is also negative
 » Second TST was performed at least 8 
weeks after the child was last exposed 
to infectious TB disease
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Study Questions
Match the patient with the TST reaction size that makes them a candidate for LTBI. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Patients TST Reaction that Makes Them a Candidate for LTBI
____  5.2 Peter is an injection drug user.
____  5.3 Louis is HIV positive.
____  5.4 Katrina, a 4-year-old, is a recent  
arrival from Mexico.
____  5.5 Edith is a resident at the DeLand  
Nursing Home.
____  5.6 Ann lives with her brother Joel,  
who has infectious TB disease.
____  5.7 Richard is the recipient of a heart 
transplant.
____  5.8 Sherry is a bank teller and has no 
known risk factors for TB.
____  5.9 Ginny is a nurse in the Dade 
County Correctional Facility.
____  5.10 Joe is diabetic.
A. ≥5 mm of induration
B. ≥10 mm of induration 
C. ≥15 mm of induration
5.11 The following close contacts to someone with infectious TB disease have a negative IGRA 
result. Which patient(s) should be evaluated for treatment of LTBI? 
(choose the one best answer)
A. Bernard is being treated for leukemia.
B. Sophia is 6 years old.
C. Kathy works in a bakery.
D. A, B, and C are all correct.
E. Only A and B are correct.
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5.12 When should close contacts who have a negative IGRA or TST result be retested?  
(choose the one best answer)
A. 4 to 6 weeks after they were last exposed to infectious TB disease.
B. 8 to 10 weeks after they were last exposed to infectious TB disease.
C. It is not necessary to retest them.
5.13 Which of the following statements is true about infants and young children with LTBI? 
(choose the one best answer)
A. Because of their age, they are known to have been infected recently.
B. They are at high risk of their infection progressing to TB disease.
C. They are less likely than older children and adults to develop life-threatening  
forms of TB disease.
D. A, B, and C are all correct.
E. Only A and B are correct.
LTBI Treatment Regimens
There are several treatment regimens available for the treatment of LTBI. Providers should choose the 
appropriate regimen based on 
 • Drug-susceptibility results of the presumed source case (if known);
 • Coexisting medical illnesses; and 
 • Potential for drug-drug interactions (Table 5.3). 
For persons who are at especially high risk for TB disease and are either suspected of nonadherence 
or are given an intermittent dosing regimen, directly observed therapy (DOT) for LTBI should 
be considered (for more information on DOT, see Chapter 6, Treatment of Tuberculosis Disease). 
This method of treatment is especially appropriate if the person in need of LTBI treatment lives 
with a household member who is on DOT for TB disease, or lives in an institution or facility where 
treatment for LTBI can be observed by a staff member. It is necessary to exclude TB disease before 
starting LTBI treatment.
For persons who are at especially high risk for TB disease and are either 
suspected of nonadherence or are given an intermittent dosing regimen, 
directly observed therapy (DOT) for LTBI should be considered.
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Isoniazid (INH) Dosage
When INH alone is given to persons with TB disease, drug resistance may develop. For this reason, 
persons suspected of having TB disease should receive the recommended multidrug regimen for 
treatment of TB disease rather than INH monotherapy until the diagnosis is confirmed or excluded. 
There are two options for treatment with INH (Table 5.3):
 • 9-month regimen
 • 6-month regimen
INH is normally used alone for treatment of LTBI in a single daily dose of 300 mg in adults and 
10– 20 mg/kg body weight in children, not to exceed 300 mg per dose. INH can be given two times 
a week at a dosage of 20– 40 mg/kg by DOT for LTBI for children, or 900 mg for adults. 
The 9-month regimen is preferred because it is more efficacious. Treatment for LTBI for 6 months 
rather than 9 months may be more cost-effective and result in greater adherence by patients; 
therefore, local programs may prefer to implement the 6-month regimen rather than the 9-month 
regimen. Every effort should be made to ensure that patients adhere to LTBI treatment for at least 6 
months. 
When INH alone is given to persons with TB disease, drug resistance may 
develop. For this reason, persons suspected of having TB disease should 
receive the recommended multidrug regimen for treatment of disease 
rather than INH monotherapy until the diagnosis is confirmed or excluded.
9-Month INH Regimen
A 9-month INH regimen is considered optimal treatment. In order to be considered adequate 
treatment, the patient must receive a minimum of 270 doses administered within 12 months. The 
preferred regimen for children 2 to 11 years of age is 9 months of daily INH. Patients may be treated 
with a twice-weekly regimen as an alternative as long as they are undergoing DOT. In a twice-weekly 
regimen, 76 doses administered within 12 months is considered adequate therapy.  
6-Month INH Regimen
A 6-month INH regimen also provides substantial protection against developing TB disease, but 
it is less protective than the 9-month regimen. In order to be considered adequate treatment, the 
patient must receive a minimum of 180 doses administered within 9 months. Patients may be 
treated with a twice-weekly regimen given by DOT as an alternative regimen. In the twice-weekly 
regimen, 52 doses administered within 9 months is considered adequate therapy. This regimen is not 
recommended for children, or immunosuppressed persons, or those with evidence of previous TB on 
chest radiograph.
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Isoniazid (INH) and Rifapentine (RPT) Regimen
3-Month INH-RPT Regimen (12-Dose Regimen)
The 12-dose regimen is a combination of INH and RPT given in 12 once-weekly doses under DOT. 
Because missed doses, altered dosing intervals or amounts, or incomplete treatment could jeopardize 
the 12-dose regimen efficacy or safety, DOT is strongly recommended for this regimen. Patients 
using the 12-dose regimen should undergo monthly clinical monitoring, including inquiries about 
side effects and a physical assessment for signs of adverse effects.
The 12-dose regimen 
 • Is recommended as an equal option to 9 months of daily INH, but does not replace other 
recommended treatment options for LTBI (Table 5.3) 
 • Is recommended for treating LTBI in 
 » Otherwise healthy people, 12 years of age or older and who were recently in contact  
with infectious TB, or who had tuberculin skin test or positive blood test for TB  
infection conversions. 
 • Can be considered for specific groups when it offers practical advantages, such as completion  
of treatment within a limited timeframe.
The 12-dose regimen is not recommended for children younger than 2 years, HIV-infected patients 
taking antiretroviral therapy (ART), patients with presumed INH or RIF-resistant M. tuberculosis, 
pregnant women, or women expecting to become pregnant within the treatment period.
The dosage for a combination 12-dose regimen of INH and RPT is: 
Isoniazid (INH)
 • 15 mg/kg rounded up to the nearest 50 or 100 mg with a 900 mg maximum.
Rifapentine (RPT)
 • 10.0– 14.0 kg 300 mg
 • 14.1– 25.0 kg 450 mg
 • 25.1– 32.0 kg 600 mg
 • 32.1– 49.9 kg 750 mg
 • ≥ 50.0 kg 900 mg maximum.
INH is formulated as 100 mg and 300 mg tablets. RPT is formulated as 150 mg tablets packed in 
blister packs that should be kept sealed until usage. New formulations with larger dosage per tablet 
and fixed-dose INH-RPT combinations are in development.
The 12-dose regimen is recommended as an equal option to 9 months of daily 
INH, but does not replace other recommended treatment options for LTBI.
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Table 5.3 
Drug Regimens for the Treatment of LTBI*
Drug Duration Interval Minimum Doses Comments
INH 9 months Daily 270  • The preferred regimen is daily treatment for  
9 months
 • Recommended regimen for people with HIV, for 
children, and for people with chest radiograph 
findings suggestive of previous TB disease
 • DOT must be used with twice-weekly dosing
Twice 
weekly
  76
6 months Daily 180  • Not recommended for people with HIV, for 
children, or for people with chest radiograph 
findings suggestive of previous TB disease
 • DOT must be used with twice-weekly dosing
Twice 
weekly
  52
INH 
and 
RPT
3 months Once 
weekly
12  • Recommended as an equal alternative to 9 
months of daily INH for otherwise healthy 
patients aged ≥12 years who were recently 
in contact with infectious TB, or who had 
tuberculin skin test or a positive blood test for 
TB infection conversions 
 • The 12-dose regimen can be considered 
for other groups when it offers practical 
advantages, such as completion within a limited 
timeframe
 • DOT is strongly recommended 
 • Not recommended for children younger than 
2 years, HIV-infected patients taking ART, 
patients with presumed INH or RIF-resistant 
M. tuberculosis, pregnant women, or women 
expecting to become pregnant within the 
treatment period 
* For more detailed information on LTBI treatment, please refer to Targeted tuberculin testing and treatment of 
latent TB infection. MMWR 2000; 49 (No. RR-6). 
http://www.cdc.gov/tb/publications/reportsarticles/mmwr/mmwr_updates.htm
* Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin 
and pyrazinamide for treatment of latent tuberculosis infection. MMWR 2003; 52 (31). 
http://www.cdc.gov/MMWR/preview/MMWRhtml/mm5231a4.htm
* Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent 
Mycobacterium tuberculosis infection. MMWR 2011; 60 (48).  
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w
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Table 5.4 
Adverse Drug Reactions to INH
Adverse Reaction Comments
Peripheral 
neuropathy
 • Uncommon at doses of 5 mg/kg
 • Those at risk may also be given pyridoxine (vitamin B6) 
 » Persons at high risk for neuropathy (e.g., diabetes, uremia, 
alcoholism, malnutrition, HIV infection)
 » Pregnant women
 » Persons with a seizure disorder
 » Patients who develop signs and symptoms of peripheral 
neuropathy
Fatal hepatitis  • Pregnant women are at increased risk
 • Postpartum women are at increased risk, especially during the initial 
3-month postpartum period 
Elevated liver 
enzymes
 • 10% to 20% of persons taking INH will have some mild elevation of 
liver enzymes. These tend to resolve even if INH is continued. 
 • Discontinue INH if the following occurs:
 » Measurements exceed 3 times the normal limit with  
symptoms present
 » Measurements exceed 5 times the upper limit of normal  
in an asymptomatic individual
 • Provide close clinical and laboratory monitoring if there are any 
signs or symptoms of hepatotoxicity or liver function test elevations 
less than the levels listed above
Rifampin (RIF) Regimen
For persons who cannot tolerate INH or have been exposed to INH-resistant TB, an alternative 
treatment regimen is 4 months of RIF. In order to be considered adequate treatment, the patient 
must receive a minimum of 120 doses administered within 6 months. RIF should not be used in 
HIV-infected persons being treated with some combinations of ART. In some situations where RIF 
cannot be used because of interactions with ART, another drug, rifabutin, may be used.
For persons who cannot tolerate INH or have been exposed to INH-
resistant TB, an alternative treatment regimen is 4 months of RIF.
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RIF should not be used in HIV-infected persons being 
treated with some combinations of ART.
Adverse Drug Reactions
Patients on treatment for LTBI should be instructed to report any signs and symptoms of adverse 
drug reactions to their health care provider, including
 • Unexplained anorexia, nausea or vomiting, dark urine*, or icterus
 • Persistent paresthesia of hands and feet
 • Persistent weakness, fatigue, fever, or abdominal tenderness
 • Easy bruising or bleeding
Peripheral neuropathy is associated with the use of INH, but is uncommon at doses of 5 mg/
kg (Table 5.4). Persons with risk factors for neuropathy (e.g., diabetes, uremia, alcoholism, 
malnutrition, HIV infection), pregnant women, and persons with seizure disorder may be given 
pyridoxine (vitamin B6) 10– 50 mg/day with INH, as this may prevent neuropathy. Patients who 
develop signs and symptoms of peripheral neuropathy may also be started on vitamin B6.
About 10% to 20% of persons taking INH will have some mild, asymptomatic elevation of liver 
enzymes (ALT, AST). These abnormalities tend to resolve even if INH is continued. For this reason, 
routine monitoring of liver enzymes is not recommended for all patients receiving INH. In persons 
who experience symptoms consistent with liver injury, liver enzymes should be measured to evaluate 
for hepatotoxicity. If any of the liver enzymes exceed three times the normal limit with symptoms 
present, it is generally recommended that INH be withheld. For liver enzyme elevations less than 
three times the upper limit of normal in symptomatic patients, at minimum close clinical and 
laboratory monitoring should be instituted if treatment is to be continued. Additional information 
on monitoring patients on LTBI treatment is provided later in this chapter. 
About 10% to 20% of persons taking INH will have some 
mild, asymptomatic elevation of liver enzymes.
Some evidence suggests that pregnant women are at increased risk for fatal hepatitis associated with 
INH. This risk may also increase during the immediate postpartum period. These persons should be 
closely monitored for adverse reactions throughout the course of treatment.
Recommendation Against the Use of RIF/Pyrazinamide (PZA) Treatment Regimen
Recommendations for the use of a daily or a twice-weekly, 2-month regimen of RIF with PZA 
for LTBI treatment have changed due to associated severe liver injury. Based on the high rates of 
hospitalization and death from liver injury in patients treated with RIF and PZA for LTBI treatment, 
the American Thoracic Society (ATS) and CDC now recommend that this regimen not be offered to 
persons with LTBI. Alternative regimens are recommended for the treatment of LTBI (Table 5.1).  
RIF and PZA should continue to be administered in multidrug regimens for the treatment of 
persons with TB disease.
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RIF and PZA should not be offered to persons with LTBI. 
RIF and PZA should continue to be administered in multidrug 
regimens for the treatment of persons with TB disease.
Study Questions
5.14 What should an appropriate LTBI treatment regimen be based on? 
(choose the one best answer)
A. Drug-susceptibility results of the source case (if known).
B. Coexisting medical illnesses.
C. Potential for drug-drug interactions.
D. A, B, and C are all correct.
E. Only A and B are correct.
5.15 Which of the following is a recommended LTBI treatment regimen? 
(choose the one best answer)
A. INH given daily (270 doses) for 9 months.
B. INH and RPT given once weekly (12 doses) for 3 months.
C. INH and RIF given daily (270 doses of each drug) for 9 months.
D. A, B, and C are all correct.
E. Only A and B are correct.
5.16 Which of the following is an adverse reaction to INH? 
(choose the one best answer)
A. Peripheral neuropathy
B. Fatal hepatitis
C. Elevated liver enzymes
D. A, B, and C are all correct.
E. Only A and B are correct.
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5.17 Which of the following statements about the use of the RIF/PZA drug combination  
for treating LTBI is true? (circle the one best answer)
A. Can be used for both HIV-negative and HIV-infected patients who cannot tolerate INH.
B. Not recommended for LTBI treatment based on high rates of hospitalization and death 
from liver injury.
C. Is the recommended drug for treating pregnant women.
D. A, B, and C are all correct.
E. Only A and B are correct.
5.18 What LTBI treatment regimen may be recommended for people with a positive TST or 
IGRA result who have been exposed to INH-resistant TB disease? 
(circle the one best answer)
A. RIF, at a minimum of 120 doses for 4 months.
B. RIF, at a minimum of 180 doses for 6 months.
C. RIF, at a minimum of 270 doses for 9 months.
LTBI Treatment Regimens for Specific Situations
HIV-Infected Persons
LTBI treatment of HIV-infected persons should be provided in consultation with an expert in the 
management of HIV and TB.
LTBI treatment of HIV-infected persons should be done in 
consultation with an expert in the management of HIV and TB.
INH
A 9-month regimen of daily INH is considered the optimal treatment for HIV-infected adults with 
LTBI. To be considered adequate therapy, the patient must receive a minimum of 270 doses of INH 
administered within 12 months. HIV-infected children should receive 9 months of INH treatment 
for LTBI. To be considered adequate therapy for HIV-infected persons, twice-weekly regimens of 
INH must be administered by DOT and consist of at least 76 doses administered within 12 months.
In HIV-infected persons, INH may be administered together with nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitors, or non-nucleoside reverse transcriptase inhibitors (NNRTIs). 
Children and adolescents who are HIV infected and/or have nutritional deficiencies should receive 
pyridoxine (vitamin B6) supplementation.
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INH-RPT (12-dose Regimen)
HIV-infected persons who are receiving ART should not take the 12-dose regimen of INH-RPT 
because the drug interactions have not been studied. However, HIV-infected persons who are 
otherwise healthy and are not receiving ART can be considered for the 12-dose regimen.
RIF
For HIV-infected patients who cannot tolerate INH or have been exposed to INH-resistant TB, an 
alternative treatment regimen is 4 months of RIF. To be considered adequate treatment, the patient 
must receive a minimum of 120 doses of RIF administered within 6 months. RIF should not be  
used in HIV-infected persons being treated with some combinations of ART. In some situations 
where RIF cannot be used because of interactions with ART, another drug, rifabutin, may be used. 
Most protease inhibitors and delavirdine should not be administered together with RIF. Rifabutin 
with appropriate dose adjustments can be used with protease inhibitors and NNRTIs (except 
delavirdine). For more information, please see Managing Drug Interactions in the Treatment of HIV-
Related Tuberculosis www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm.
Persons with Fibrotic Lesions
Persons who have a chest radiograph suggestive of old fibrotic lesions thought to represent previous 
TB disease should be treated for LTBI if they have the following:
 • A positive IGRA result, or TST reaction (induration) of 5 mm or more;
 • No symptoms of infectious TB disease; and
 • No history of treatment for TB disease. 
These persons should be evaluated with three sputum specimens for AFB smear and culture and 
only treated for LTBI once these specimens are negative by culture. Acceptable regimen options are 
described in Table 5.5. 
Persons with evidence suggestive of healed, primary TB disease (i.e., calcified solitary pulmonary 
nodules, calcified hilar lymph nodes, and apical pleural capping) are not at increased risk for 
TB disease. Their risk for developing TB disease and the need for treatment of LTBI should be 
determined by consideration of other risk factors. 
Persons with evidence suggestive of healed, primary TB disease  
(i.e., calcified solitary pulmonary nodules, calcified hilar lymph nodes, 
and apical pleural capping) are not at increased risk for TB disease.
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Table 5.5 
Drug Regimens for the Treatment of LTBI for Persons with Fibrotic Lesions
Drug Duration Interval Minimum Doses Comments
INH* 9 months Daily 270 Provide LTBI treatment for patients who have 
a chest radiograph suggestive of old fibrotic 
lesions thought to represent previous TB 
disease and
 • A positive IGRA result or a TST reaction 
(induration of 5 mm or more)
 • No symptoms of infectious TB disease
 • No history of treatment for TB disease
 • Three negative sputum smears and cultures
Twice 
weekly
  76
RIF 4 months Daily 120
* Preferred.
Contacts of Persons with Multidrug-Resistant TB
If a person is a contact of a patient with multidrug-resistant (MDR) TB, the risk of progressing to 
MDR TB disease should be considered before recommending treatment for LTBI. For persons likely 
to have been infected with a strain of M. tuberculosis resistant to both INH and RIF, alternative LTBI 
treatment regimens should be considered. The treatment of drug-resistant LTBI should be prescribed 
in consultation with an MDR TB expert.
If a person is a contact of a patient with multidrug-resistant 
(MDR) TB, the risk of progressing to MDR TB disease should be 
considered before recommending treatment for LTBI.
Pregnancy and Breast-feeding
INH administered either daily or twice weekly is the preferred regimen for the treatment of 
LTBI in pregnant women. Pregnant women taking INH should also take pyridoxine (vitamin 
B6) supplementation to ameliorate the side effects of the drug (Table 5.6). For pregnant women 
who are intolerant of INH or likely to be infected with an INH-resistant strain of M. tuberculosis, 
consultation with a TB expert is recommended.
The 12-dose regimen of INH-RPT is not recommended for pregnant women or women expecting 
to become pregnant during the treatment period because its safety in pregnancy has not yet been 
studied. 
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The 12-dose regimen of INH-RPT is not recommended for pregnant 
women or women expecting to become pregnant during the treatment 
period because its safety in pregnancy has not yet been studied.
For women who are at high risk for progression from LTBI to TB disease, especially those who are 
HIV infected or diabetic, LTBI treatment should not be delayed on the basis of pregnancy alone, 
even during the first trimester. TB disease must be excluded through symptom review (to see an 
example, go to: http://health.state.ga.us/pdfs/tb/TB.Symp.Screen.09.Eng.pdf) and chest radiograph 
prior to initiation of LTBI treatment. For these women, careful clinical monitoring and/or lab 
monitoring should be conducted.
For women who are at high risk for the progression of LTBI to TB disease, 
especially those who are HIV infected or diabetic, LTBI treatment should not 
be delayed on the basis of pregnancy alone, even during the first trimester.
Breast-feeding is not contraindicated when a mother is being treated for LTBI. The amount of INH 
in the mother’s breast milk is inadequate to either harm or benefit an infant. Breast-fed infants of 
mothers who take INH should receive supplemental pyridoxine (vitamin B6). 
Table 5.6 
Drug Regimens for the Treatment of LTBI 
for Pregnancy and Breast-Feeding
Drug Duration Interval Minimum Doses Comments
INH 9 months Daily 270  • Do not delay initiation of therapy based 
on pregnancy alone, even during the first 
trimester for women who are at high risk 
for progression from LTBI to TB disease, 
especially those who are HIV infected or 
diabetic
 • Breast-feeding is not contraindicated when 
a mother is being treated for LTBI
 • The amount of INH provided in the mother’s 
breast milk is inadequate to either harm or 
benefit an infant. 
 • Breast-feeding infants whose  mothers are 
taking INH should receive supplemental 
pyridoxine (vitamin B6)
Twice 
weekly
  76
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Study Questions
Case Study– Jesse 
Jesse has fibrotic lesions representative of previous TB disease, a TST reaction of 5 mm, 
and no history of treatment for TB disease. 
5.19 How should Jesse be evaluated? 
(choose the one best answer)
A. With a CT scan to determine the extent of lesions
B. With three sputum specimens for AFB smear and culture
C. With a bronchoscopy to obtain specimen samples
D. A, B, and C are all correct.
E. Only A and B are correct.
5.20 Once TB disease is ruled out, what should Jesse’s LTBI treatment regimen include? 
(choose the one best answer)
A. 3 months of INH or 1 month of RIF 
B. 6 months of INH or 2 months of RIF 
C. 9 months of INH or 4 months of RIF 
5.21 Which of the following statements about pregnancy and breast-feeding is true? 
(choose the one best answer)
A. The preferred regimen for the treatment of LTBI in pregnant women is INH taken daily 
or twice weekly, with pyridoxine supplement.
B. For pregnant women who are HIV infected, initiation of therapy should not  
be delayed on the basis of pregnancy alone even during the trimester.
C. Breast-feeding is contraindicated when a mother is being treated for LTBI.
D. A, B, and C are all correct.
E. Only A and B are correct.
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Patient Monitoring
Patient Medical Evaluation and Monitoring for LTBI Treatment
The components of patient monitoring for LTBI treatment include:
 • Medical evaluation prior to LTBI treatment
 • Baseline laboratory testing
 • Monthly medical evaluation
 • Routine laboratory monitoring 
 • Treatment follow-up
Medical Evaluation Prior to LTBI Treatment
Before treatment for LTBI is started, clinicians should conduct a medical history to:
 • Exclude the possibility of TB disease, including symptom review;
 • Determine if there is a history of prior treatment for LTBI or TB disease; 
 • Determine if there are any co-existing medical conditions that are a contraindication to LTBI 
treatment or are associated with an increased risk of adverse effects from treatment;
 • Obtain information about current and previous drug therapy, including any previous or 
current adverse reactions to drugs considered for treatment of LTBI; and 
 • Recommend HIV testing for all TB and LTBI patients after the patient is notified that testing 
will be performed, unless the patient declines (opt-out screening).
In addition, conducting a medical history provides an opportunity to establish rapport with the 
patient and to highlight important aspects of treatment, such as:
 • Benefits of treatment;
 • Importance of adherence to the treatment regimen;
 • Possible adverse side effects of the regimen; and
 • Establishment of an optimal follow-up plan.
A chest radiograph should be performed; LTBI treatment should only be prescribed if the radiograph 
is normal, without evidence of any findings consistent with TB disease. If there are any abnormalities 
consistent with TB disease or if the patient is symptomatic, the patient should have three sputum 
specimens collected for AFB smear and culture, and only be given treatment for LTBI once all three 
cultures are negative.
A chest radiograph should be performed; LTBI treatment 
should only be prescribed if the radiograph is normal, without 
evidence of any findings consistent with TB disease.
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Baseline Laboratory Testing
Baseline laboratory testing is not routinely indicated for all patients at the start of treatment for 
LTBI. Baseline hepatic measurements of serum AST (SGOT) or ALT (SGPT) and bilirubin are 
indicated for patients whose initial evaluation suggests a liver disorder. Baseline testing is also 
indicated for
 • Patients with HIV infection;
 • Women who are pregnant or in the immediate postpartum period (within 3 months after 
delivery); or
 • Persons with a history of chronic liver disease (e.g., hepatitis B or C, alcoholic hepatitis or 
cirrhosis), persons who use alcohol regularly, and others who are at risk of chronic liver disease. 
Baseline laboratory testing is not routinely indicated in older persons. However, testing may be 
considered on an individual basis, particularly for patients who are taking other medications for 
chronic medical conditions. Active hepatitis and end-stage liver disease are relative contraindications 
to the use of INH or RIF for treatment of LTBI. Use of these drugs in such patients must be 
undertaken with caution. Patients with baseline abnormal liver function tests should be monitored at 
regular intervals with clinical and laboratory evaluation.
Patients with baseline abnormal liver function tests should be  
monitored at regular intervals with clinical and laboratory evaluation.
Baseline laboratory testing is not routinely indicated in older persons. 
However, testing may be considered on an individual basis, particularly for 
patients who are taking other medications for chronic medical conditions.
Monthly Evaluation
At least once a month, the patient should be evaluated for
 • Adherence to the prescribed regimen;
 • Signs and symptoms of TB disease; and
 • Signs and symptoms of adverse effects, especially hepatitis (i.e., jaundice, loss of appetite, 
fatigue, and/or muscle and joint aches).
Routine Laboratory Monitoring
Routine laboratory monitoring during treatment of LTBI is recommended only for those whose 
baseline liver function tests are abnormal and for other persons with a risk of hepatic disease. 
Clinicians should order laboratory testing, such as liver function studies, for patients with symptoms 
compatible with hepatotoxicity, to evaluate possible adverse reactions that occur during the treatment 
regimen. If any of the liver enzymes exceed three times the normal limit with symptoms present or 
five times the upper limit of normal in an asymptomatic individual, it is generally recommended 
that INH be withheld. For liver enzyme elevations less than three times the upper limit of normal in 
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symptomatic patients, at minimum close clinical and laboratory monitoring should be instituted if 
treatment is to be continued. 
Treatment Follow-Up
Patients should receive documentation of TST or IGRA results, medication taken, treatment 
duration, and treatment completion dates. They should be told to present this documentation 
when they are required to be tested for TB. Patients should also be re-educated about the signs and 
symptoms of TB disease and advised to seek medical attention if these occur. They should be advised 
that treatment greatly reduces the risk of progression to disease, but does not entirely eliminate it.
Patients should be advised that treatment greatly reduces the risk 
of progression to disease but does not entirely eliminate it.
Study Questions
5.22 Why should patients receive a medical evaluation before starting treatment for LTBI? 
(choose the one best answer)
A. To exclude the possibility of TB disease
B. To determine if there is a history of prior treatment for LTBI or TB disease
C. To determine existing medical conditions
D. A, B, and C are all correct.
E. Only A and B are correct.
Case Study– Edgar, Louise, and Samantha 
Edgar was admitted to the hospital last week and diagnosed with infectious TB disease. 
He lives with his wife, Louise, and 1-year-old daughter Samantha. You visit their home 
to give both Louise and Samantha a TST. Neither one has symptoms of TB disease. You 
return 2 days later to read the results. You find that Louise has 14 mm of induration, but 
Samantha has no induration.
5.23 Why should Louise, Edgar’s wife, be evaluated for LTBI treatment?  
(choose the one best answer)
A. She is a close contact of someone with infectious TB disease.
B. She has a positive skin test reaction of greater than 5 mm.
C. She has an infant daughter.
D. A, B, and C are all correct.
E. Only A and B are correct.
Chapter 5: Treatment for Latent Tuberculosis Infection
133
5.24 After Louise is evaluated, when should she receive LTBI treatment? 
(choose the one best answer)
A. After TB disease is ruled out.
B. After it has been determined that she has never been treated for TB infection or disease.
C. After any medical problems that may complicate therapy have been ruled out.
D. A, B, and C are all correct.
E. Only A and B are correct.
5.25 Should Samantha, Edgar’s daughter, receive LTBI treatment? 
(choose the one best answer)
A. Yes, she should start LTBI treatment after TB disease has been excluded because she is a 
close contact of a person with infectious TB disease and she is less than 4 years old.
B. No, because she had a negative TST.
5.26 Baseline laboratory testing is routinely indicated for which of the following patients? 
(choose the one best answer)
A. HIV-infected persons
B. Pregnant women 
C. Teenagers
D. A, B, and C are all correct.
E. Only A and B are correct.
5.27 Loretta is receiving LTBI treatment and is evaluated each month by her public health 
nurse. What should she be evaluated for? 
(choose the one best answer)
A. Adherence to the prescribed regimen
B. Signs and symptoms of TB disease
C. Signs and symptoms of adverse effects, especially hepatitis
D. A, B, and C are all correct.
E. Only A and B are correct.
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5.28 Routine laboratory monitoring is recommended for which of the following patients with 
LTBI? (circle the one best answer)
A. Persons whose baseline liver function tests are abnormal
B. Persons with a risk of hepatic disease
C. All patients receiving LTBI 
D. A, B, and C are all correct.
E. Only A and B are correct.
Chapter Summary
Treatment of LTBI is essential to controlling and eliminating TB disease in the United States. It 
substantially reduces the risk that persons infected with M. tuberculosis will progress to TB disease. 
Certain groups are at high risk of developing TB disease once infected. Targeted testing programs 
should be designed to identify persons who are at high risk for TB disease and who would benefit 
from treatment of LTBI. Targeted testing should be undertaken only if resources are identified and 
available to ensure full evaluation and treatment. There are two methods available for the detection 
of M. tuberculosis infection in the United States, the TST and IGRAs.
Persons in the following high-risk groups should be given treatment for LTBI if they have either a 
positive IGRA result or if their reaction to the tuberculin skin test is ≥5 mm:
 • HIV-infected persons;
 • Recent contacts of persons with infectious TB disease;
 • Persons with fibrotic changes on chest radiograph consistent with prior TB disease  
(once TB disease is excluded); and
 • Patients with organ transplants, and other immunosuppressed patients (including patients 
receiving the equivalent of 15 mg/day of prednisone for ≥1 month).
Persons in the following high-risk groups should be considered for treatment of LTBI if they have 
either a positive IGRA result or if their reaction to the TST is ≥10 mm:
 • Recent arrivals to the United States (<5 years) from high-prevalence areas (e.g. Africa, Asia, 
Eastern Europe, Latin America, and Russia);
 • Injection drug users;
 • Residents and employees of high-risk congregate settings (e.g., correctional facilities, nursing 
homes, homeless shelters, and hospitals);
 • Mycobacteriology laboratory personnel;
 • Persons with medical conditions that increase the risk for progression to TB disease, i.e., 
silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (e.g., leukemia and 
lymphomas, or cancer of the head, neck, or lung), gastrectomy or jejunoileal bypass, and 
weight loss of at least 10% from ideal body weight;
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 • Children younger than 5 years of age; and 
 • Infants, children, and adolescents exposed to adults in high-risk categories.
People without any risk factors generally should not be tested for TB infection. Testing should 
be targeted to groups at high risk for LTBI and TB disease. However, if a person without any risk 
factors is tested and has a positive IGRA result or TST reaction that is ≥15 mm, he or she should be 
evaluated for LTBI treatment once TB disease is excluded.
There are several treatment regimens available for the treatment of LTBI. Providers should choose 
the appropriate regimen based on the susceptibility results of the presumed source case (if known), 
coexisting medical illnesses, and the potential for drug-drug interactions. 
INH Regimens
When INH alone is given to persons with TB disease, resistance may develop. For this reason, 
persons suspected of having TB disease should receive the recommended multidrug regimen for 
treatment of TB disease rather than INH monotherapy until the diagnosis is confirmed or excluded.
There are two options for treatment with INH:
 • 9-month regimen
 • 6-month regimen
INH is normally used alone for treatment of LTBI in a single daily dose of 300 mg in adults and 
10– 20 mg/kg body weight in children, not to exceed 300 mg per dose. INH can be given two times 
a week at a dosage of 20– 40 mg/kg by DOT for LTBI for children, or 900 mg for adults. 
The 9-month regimen is the preferred because it is more efficacious. Treatment for LTBI for 6 
months rather than 9 months may be more cost-effective and result in greater adherence by patients; 
therefore, local programs may prefer to implement the 6-month regimen rather than the 9-month 
regimen. Every effort should be made to ensure that patients adhere to treatment for LTBI infection 
for at least 6 months. 
9-Month INH Regimen
A 9-month INH regimen is considered optimal treatment. In order to be considered adequate 
treatment, the patient must receive a minimum of 270 doses administered within 12 months. The 
preferred regimen for children 2 to 11 years of age is 9 months of daily INH. Patients may be treated 
with a twice-weekly regimen as an alternative as long as they are undergoing DOT. In a twice-weekly 
regimen, 76 doses administered within 12 months is considered adequate therapy. 
6-Month INH Regimen
A 6-month INH regimen also provides substantial protection against developing TB disease, but it is 
less protective than the 9-month regimen. In order to be considered adequate treatment, the patient 
must receive a minimum of 180 doses administered within 9 months.  Patients may be treated 
with a twice-weekly regimen given as DOT as an alternative. In a twice-weekly regimen, 52 doses 
administered within 9 months is considered adequate therapy. This regimen is not recommended for 
children, or immunosuppressed persons, or those with evidence of previous TB on chest radiograph.
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3-Month INH-RPT Regimen (12-Dose Regimen)
The 12-dose regimen is a combination of INH and RPT given in 12 once-weekly doses under DOT. 
Because missed doses, altered dosing intervals or amounts, or incomplete treatment could jeopardize 
the 12-dose regimen efficacy or safety, DOT is strongly recommended for this regimen. Patients 
using the 12-dose regimen should undergo monthly clinical monitoring, including inquiries about 
side effects and a physical assessment for signs of adverse effects.
The 12-dose regimen does not replace other recommended treatment options for LTBI, but can 
be considered an equal option to the standard INH 9-month daily regimen for treating LTBI in 
otherwise healthy people, 12 years of age or older, who were recently in contact with infectious TB, 
or who had tuberculin skin test or blood test for TB infection conversions.
The dosage for a combination 12-dose regimen of INH and RPT is: 
Isoniazid (INH)
 • 15 mg/kg rounded up to the nearest 50 or 100 mg, with a 900 mg maximum.
Rifapentine (RPT)
 • 10.0– 14.0 kg 300 mg
 • 14.1– 25.0 kg 450 mg
 • 25.1– 32.0 kg 600 mg
 • 32.1– 49.9 kg 750 mg
 • ≥ 50.0 kg 900 mg maximum.
INH is formulated as 100 mg and 300 mg tablets. RPT is formulated as 150 mg tablets packaged in 
blister packs that should be kept sealed until usage. New formulations with larger dosage per tablet 
and fixed-dose INH-RPT combinations are in development.
For persons who are at especially high risk for TB disease and are either suspected of nonadherence 
or given an intermittent dosing regimen, DOT for LTBI should be considered. This method of 
treatment is especially appropriate if the person in need of LTBI treatment lives with a household 
member who is on DOT for TB disease, or lives in an institution or facility where treatment for TB 
infection can be observed by a staff member. It is necessary to exclude TB disease before starting 
LTBI treatment. 
Baseline laboratory testing is not routinely indicated for all patients at the start of treatment for 
LTBI. Baseline hepatic measurements of serum AST (SGOT) or ALT (SGPT) and bilirubin are 
indicated for patients whose initial evaluation suggests a liver disorder. Baseline testing is also 
indicated for:
 • Patients with HIV infection;
 • Women who are pregnant or in the immediate postpartum period (within 3 months of 
delivery); or
 •  Persons with a history of chronic liver disease (e.g., hepatitis B or C, alcoholic hepatitis or 
cirrhosis), persons who use alcohol regularly, and others who are at risk of chronic liver disease.
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Chapter Objectives
After working through this chapter, you should be able to 
 • Describe tuberculosis (TB) disease treatment adherence strategies;
 • Identify anti-TB drugs;
 • Describe treatment regimens for TB disease;
 • Describe patient monitoring; and
 • List common adverse drug reactions to TB medications.
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Introduction
The major goals of treatment for TB disease are to
 • Cure the individual patient;
 • Minimize risk of death and disability; and
 • Reduce transmission of M. tuberculosis to other persons. 
To ensure that these goals are met, TB disease must be treated for at least 6 months and in some cases 
even longer. Most of the bacteria are killed during the first 8 weeks of treatment; however, there are 
persistent organisms that require longer treatment. If treatment is not continued for a long enough 
duration, the surviving bacteria may cause the patient to become ill and infectious again, potentially 
with drug-resistant disease.
There are several options for daily and intermittent therapy, but the goal of treatment for TB disease 
should be to provide the safest and most effective therapy in the shortest period of time. Given 
adequate treatment, almost all patients will recover and be cured. 
Regimens for the treatment of TB disease must contain multiple drugs to which the bacteria 
are susceptible. The standard of care for initiating treatment of TB disease is four-drug therapy. 
Treatment with a single drug can lead to the development of a bacterial population resistant to that 
drug. Likewise, the addition of a single drug to a failing anti-TB regimen can lead to additional 
resistance. When two or more drugs to which in vitro susceptibility has been demonstrated are given 
together, each helps prevent the emergence of tubercle bacilli resistant to the others.
The standard of care for initiating treatment of TB disease is 
four-drug therapy. Treatment with a single drug can lead to the 
development of a bacterial population resistant to that drug.
Study Questions
6.1 The major goals for treatment of TB disease include which of the following?
A. Curing the individual patient
B. Minimizing risk of death and disability
C. Reducing transmission of M. tuberculosis to other persons
D. A, B, and C are all correct.
E. Only A and B are correct.
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Are the following statements about TB treatment true or false? 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.)
Statements True or False
____  6.2 Most of the TB bacteria are killed during the first 8 weeks of 
treatment. However, some persistent organisms require longer 
treatment.
____  6.3 Regimens for the treatment of TB disease need to only 
contain one drug to which the bacteria are susceptible.
____  6.4 Treatment that is not continued for a long enough time allows 
the surviving bacteria to cause the patient to become ill and 
infectious again.
____  6.5 Treatment with a single drug cannot lead to the development 
of a bacterial population resistant to that drug.
____  6.6 When two or more drugs to which in vitro susceptibility has 
been demonstrated are given together, each helps prevent the 
emergence of tubercle bacilli resistant to the other drugs(s).
____  6.7 Given adequate treatment, almost all patients will recover and 
be cured.
A. True
B. False
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Treatment and Monitoring Plan
For each patient with newly diagnosed TB disease, a specific treatment and monitoring plan should 
be developed in collaboration with the local TB control program within 1 week of the presumptive 
diagnosis. This plan should include:
 • Description of the TB treatment regimen; 
 • Methods of assessing and ensuring adherence to the TB treatment regimen; 
 • Methods to monitor for adverse reactions; and
 • Methods for evaluating treatment response.
Study Question
6.8 Which of the following should NOT be included in a treatment and monitoring plan? 
(choose the one best answer)
A. Description of the TB treatment regimen
B. Methods of assessing and ensuring adherence to the TB treatment regimen
C. Methods to monitor for adverse reactions
D. Methods to prevent a patient returning to work when noninfectious
E. Methods for evaluating treatment response
Adherence Strategies
To treat TB disease and prevent acquired drug resistance, clinicians must ensure that their patients 
with TB disease follow the recommended course of treatment. However, ensuring that patients 
adhere to treatment can be difficult because patients are often unable or reluctant to take multiple 
medications for several months. Nonadherence to treatment is a major problem in TB control. 
Inadequate treatment can lead to 
 • Treatment failure; 
 • Relapse; 
 • Ongoing transmission; and 
 • Development of drug resistance. 
Responsibility for successful treatment is assigned to the health-care provider, not the patient. 
Health-care professionals should consult their health department’s TB control program to ensure 
their TB patients are able to adhere to a prescribed treatment regimen. The TB control program 
should assist the health-care professional in evaluating patient barriers to adherence and recommend 
directly observed therapy (DOT) and the use of incentives and enablers that may assist the patient in 
completing the recommended therapy. 
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Inadequate treatment can lead to treatment failure, relapse, ongoing 
transmission, and the development of drug resistance.
Responsibility for successful treatment is assigned to 
the health-care provider, not the patient.
If these efforts are unsuccessful, the TB control program should take more restrictive action. The 
TB program should consider court-ordered DOT or, if all other measures fail, the involuntary 
isolation of a patient who is unwilling or unable to complete treatment. This is necessary to protect 
the general public from patients who are infectious, at risk of becoming infectious, or at risk for 
developing drug-resistant TB disease. A patient may be involuntarily isolated, but the patient cannot 
be forced to swallow anti-TB drugs. Involuntary isolation should only be pursued as a last resort after 
all less-restrictive measures have failed.
Patient Education
Educating patients about TB disease helps ensure their successful completion of therapy. Health-care 
providers must take the time to explain clearly to patients what medication should be taken, how 
much, how often, and when. Patients should be clearly informed about possible adverse reactions 
to the medications they are taking and when to seek necessary medical attention. Providing patients 
with the knowledge they need regarding the consequences of not taking their medicine correctly 
is very important. In addition, patients should be educated about infection control measures and 
potential need for isolation (Table 6.1). HIV testing and counseling is recommended for all patients 
with TB disease in all health-care settings. The patient must first be notified that testing will be 
performed. The patient has the right to decline HIV testing and counseling (opt-out screening). 
Table 6.1 
Patient Education
Topics to Include When Educating Patients
 • What medication should be taken, how much, how often, and when
 • Possible adverse reactions to the medications
 • When to seek necessary medical attention
 • Consequences of not taking their medicine correctly
 • TB infection control measures and potential need for isolation
HIV testing and counseling is recommended for all patients 
with TB disease in all health-care settings.
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Case Management
Case management is a strategy used to ensure that patients complete treatment for TB disease. There 
are three elements of case management: 
1. Assigning responsibility;
2. Conducting a regular systematic review; and
3. Developing a plan to address barriers to adherence.
Case managers are health department employees, usually nurses or public health professionals, who 
are assigned primary responsibility for the management of specific patients. Case managers are 
held accountable for ensuring that each patient is educated about TB and treatment, ensuring that 
therapy is continuous and complete, and confirming that all contacts are evaluated according to 
CDC/National Tuberculosis Controllers Association guidelines. Some specific responsibilities may 
be assigned to other persons such as clinic supervisors, outreach workers, health educators, social 
workers, and human service workers. Case management is a patient-centered strategy. Whenever 
possible, a worker who has the same cultural and linguistic background as the patient should be 
assigned as case manager, to be able to help develop an individualized treatment adherence plan with 
the patient. 
Case managers are held accountable for ensuring that each patient is 
educated about TB and treatment, ensuring that therapy is continuous 
and complete, and confirming that all contacts are evaluated according 
to CDC/ National Tuberculosis Controllers Association guidelines.
Directly Observed Therapy (DOT)
DOT is a component of case management that helps ensure patients adhere to therapy. It is the 
method whereby a trained health-care worker or another trained designated person watches a  
patient swallow each dose of anti-TB drugs and documents it. DOT is the preferred core 
management strategy recommended by CDC for treatment of TB disease and, if resources allow,  
for latent tuberculosis infection (LTBI) treatment. DOT can reduce the development of drug 
resistance, treatment failure, or relapse after the end of treatment. Good case management, which 
includes establishing a relationship with the patient and addressing barriers to adherence, facilitates 
successful DOT.
DOT is the preferred core management strategy recommended 
by CDC for treatment of TB disease and, if resources allow, 
for latent tuberculosis infection (LTBI) treatment.
Nearly all the treatment regimens for drug-susceptible TB disease can be given intermittently if they 
are directly observed. Using intermittent regimens reduces the total number of doses a patient must 
take, as well as the total number of encounters with the health-care provider or outreach worker, 
making these regimens more cost-effective. Drug-resistant TB disease should always be treated with 
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a daily regimen and under direct observation. There are no intermittent regimens for treatment of 
multidrug-resistant (MDR) TB. If anti-TB drugs for the treatment of MDR TB need to be given 
twice daily, then DOT should be provided twice daily as well.
Nearly all the treatment regimens for drug-susceptible TB disease 
can be given intermittently if they are directly observed.
Drug-resistant TB disease should always be treated with a daily 
regimen and under direct observation. There are no intermittent 
regimens for treatment of multidrug-resistant (MDR) TB.
It is important that DOT be carried out at times and in locations that are as convenient as possible 
for the individual patient (Figures 6.1 and 6.2). Therapy may be directly observed in a medical office 
or clinic setting, but can also be observed by an outreach worker in the field (e.g., patient’s home, 
place of employment, school, or other mutually agreed-upon place). In some situations, staff of 
correctional facilities or drug treatment programs, home health-care workers, maternal and child 
health staff, or designated community members may provide DOT. In general, family members 
should not be the providers of DOT.
Figure 6.1 
Conducting DOT in a 
Clinic Setting
Figure 6.2 
Conducting DOT in a Location  
Convenient for the Patient
DOT should be used for all children and adolescents with TB disease. Even when drugs are given by 
DOT, adherence to and tolerability of the regimen must be monitored closely. Parents should not be 
relied on to supervise DOT.
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Incentives and Enablers
Incentives and enablers should be used to ensure adherence to therapy (Figure 6.3). Incentives are 
small rewards given to patients to encourage them to take their medicines and to keep DOT or clinic 
appointments. Enablers are things that help the patient receive treatment, such as bus fare to get to 
the clinic. Incentives and enablers should be chosen according to the patient’s needs, and they are 
frequently offered along with DOT.
Figure 6.3 
Incentives and Enablers
Fixed-Dose Combination Drugs
Although there is no evidence indicating that fixed-dose combination medications are superior to 
individual drugs, expert opinion suggests that these formulations should be used when DOT is given 
daily or when DOT is not possible. The use of fixed-dose combination capsules or tablets facilitates 
DOT administration by minimizing the chance for error through the use of fewer tablets and may 
reduce the risk of acquired drug resistance since one medication cannot be selectively taken. In the 
United States, the Food and Drug Administration (FDA) has approved fixed-dose combinations 
of isoniazid and rifampin (Rifamate®) and of isoniazid, rifampin, and pyrazinamide (Rifater®). 
Clinicians should become familiar with the management of TB disease using these fixed-dose 
combination drugs.
The use of fixed-dose combination capsules or tablets facilitates 
DOT administration by minimizing the chance for error through 
the use of fewer tablets and may reduce the risk of acquired drug 
resistance since one medication cannot be selectively taken.
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Self-Administered Therapy
Patients on self-administered therapy should be asked routinely about adherence at follow-up visits. 
Pill counts should be performed consistently, and urine or blood tests can be used periodically to 
check for the presence of urine drug metabolites or appropriate blood serum level of the drugs. In 
addition, the response to treatment should be monitored closely for all patients. If culture results 
have not become negative after 2 months of treatment, the patient should be reevaluated and DOT 
should be considered for the remainder of treatment.
Study Questions
6.9 Inadequate treatment can lead to which of the following? 
(choose the one best answer)
A. Treatment failure
B. Relapse
C. Ongoing transmission
D. Development of drug resistance
E. A, B, C, and D are all correct.
6.10 The responsibility for successful treatment is assigned to which of the following? 
(choose the one best answer)
A. The patient
B. The health-care provider
C. The family of the patient
D. A, B, and C are all correct.
E. Only A and B are correct.
6.11 What should be included when educating a patient about TB treatment? 
(choose the one best answer)
A. How to take the medication
B. Adverse reactions to the medications
C. Consequences of not taking the medication correctly
D. TB infection control measures
E. A, B, C, and D are all correct.
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6.12 What is case management?  
(choose the one best answer)
A. Includes assigning responsibilities, conducting a regular systematic review of the case, and 
developing a plan to address barriers to adherence.
B. Can be used to ensure that patients complete treatment for TB disease.
C. Can be used to identify all cases of TB from a source case.
D. A, B, and C are all correct.
E. Only A and B are correct.
6.13 What is DOT?  
(choose the one best answer)
A. A supervisor watches a health-care worker give a patient a bottle of prescribed pills.
B. A physician sees the patient once a month and counts the remaining pills in the 
medication bottles.
C. A health-care worker or another designated person watches the patient swallow each dose 
of the prescribed drugs.
D. The nurse uses special urine tests to detect the presence of medicine in the patient’s urine.
6.14 Which of the following statements about DOT is true? 
(choose the one best answer)
A. Is the preferred core management strategy for treatment of TB disease.
B. Can reduce the development of drug resistance, treatment failure, or relapse after the  
end of treatment. 
C. Parents can always be relied upon to give DOT to their children. 
D. A, B, and C are all correct.
E. Only A and B are correct.
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6.15 Which of the following statements about intermittent treatment regimens and DOT is 
true? (choose the one best answer)
A. Reduces the total number of doses the patient must take.
B. Reduces the total number of encounters with the health-care provider.
C. Are always used for drug-resistant TB disease.
D. A, B, and C are all correct.
E. Only A and B are correct.
6.16 DOT should always be used for all children and adolescents with TB disease.  
(circle the one best answer)
A. True
B. False
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TB Disease Treatment Regimens
Current Anti-TB Drugs
Currently, there are 10 drugs approved by the U.S. Food and Drug Administration (FDA) for the 
treatment of TB disease (Table 6.2). In addition, the fluoroquinolones (levofloxacin, moxifloxacin, 
and gatifloxacin), although not approved by the FDA for TB disease, are commonly used to treat 
TB disease caused by drug-resistant organisms or for patients who are intolerant of some first-line 
drugs. Rifabutin, approved for use in preventing Mycobacterium avium complex disease in patients 
with HIV infection but not approved for TB disease, is useful for treating TB disease in patients 
concurrently taking drugs that interact with rifampin (e.g., certain antiretroviral drugs). Amikacin 
and kanamycin, nearly identical aminoglycoside drugs used in treating patients with TB disease 
caused by drug-resistant organisms, are not approved by the FDA for treatment of TB.
Of the approved drugs, isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide 
(PZA) are considered first-line anti-TB drugs and form the core of standard treatment regimens 
(Figure 6.4) (Table 6.2). Rifabutin (RBT) and rifapentine (RPT) may also be considered first-
line drugs under certain circumstances. RBT is used as a substitute for RIF in the treatment of all 
forms of TB caused by organisms that are known or presumed to be susceptible to this agent. RBT 
is generally reserved for patients for whom drug-drug interactions preclude the use of rifampin. 
Streptomycin (SM) was formerly considered to be a first-line drug and, in some instances, is still 
used in the initial treatment regimen. However, an increasing prevalence of resistance to SM in many 
parts of the world has decreased its overall usefulness. The remaining drugs are reserved for special 
situations such as drug intolerance or resistance. 
INH, RIF, PZA, and EMB are considered first-line anti-TB drugs 
and form the core of standard treatment regimens.
Figure 6.4 
First-line Anti-TB Agents 
From left to right: INH, RIF, PZA, and EMB 
form the core of initial treatment regimens.
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Table 6.2 
Anti-TB Drugs Currently Used in the United States
Drug 
Classes Anti-TB Drugs Comments
First-line 
drugs
Isoniazid (INH) INH, RIF, PZA, and EMB form the core of initial treatment 
regimen.
Rifampin (RIF)
Pyrazinamide (PZA)
Ethambutol (EMB)
Rifabutin* (RBT) May be used as a substitute for RIF in the treatment of 
all forms of TB caused by organisms that are known or 
presumed to be susceptible to this agent.
Rifapentine (RPT) May be used once weekly with INH in the continuation 
phase of treatment for HIV-negative patients with 
noncavitary, drug-susceptible pulmonary TB who have 
negative sputum smears at completion of the initial 
phase of treatment.
Second-
line drugs
Streptomycin (SM)  • SM was formerly considered to be a first-line drug and 
in some instances, is still used in initial treatment.
 • Increasing prevalence of resistance to SM in many 
parts of the world has decreased its overall usefulness.
Cycloserine These drugs are reserved for special situations such as 
drug intolerance or resistance.
Capreomycin
ρ-Aminosalicylic acid
Levofloxacin*
Moxifloxacin*
Gatifloxacin*
Amikacin/Kanamycin*
Ethionamide
* Not approved by the U.S. Food and Drug Administration for use in the treatment of tuberculosis.
Rating System for TB Disease Treatment Recommendations
The recommended treatment regimens are based, in large part, on evidence from clinical trials and 
are rated on the basis of a system developed by the U.S. Public Health Service (USPHS) and the 
Infectious Diseases Society of America (IDSA) (Table 6.3).
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TB Disease Treatment Regimens 
There are four basic treatment regimens recommended for treating adults with TB disease caused 
by organisms that are known or presumed to be susceptible to INH, RIF, PZA, and EMB. Each 
treatment regimen consists of an initial 2-month treatment phase followed by a continuation phase 
of either 4 or 7 months (Table 6.5). The 4-month continuation phase is used for the majority of 
patients. Although these regimens are broadly applicable, there are modifications that should be 
made under specified circumstances (Tables 6.3 and 6.4).
There are four basic treatment regimens recommended for treating 
adults with TB disease caused by organisms that are known or 
presumed to be susceptible to INH, RIF, PZA, and EMB. Each 
treatment regimen consists of an initial 2-month treatment phase 
followed by a continuation phase of either 4 or 7 months.
Initial Phase
The initial phase of treatment is crucial for preventing the emergence of drug resistance 
and determining the ultimate outcome of the regimen. Four drugs— INH, RIF, PZA, and 
EMB— should be included in the initial treatment regimen until the results of drug-susceptibility 
tests are available. Each of the drugs in the initial regimen plays an important role. INH and RIF 
allow for short-course regimens with high cure rates. PZA has potent sterilizing activity, which allows 
further shortening of the regimen from 9 to 6 months. EMB helps to prevent the emergence of 
RIF resistance when primary INH resistance is present. If drug-susceptibility test results are known 
and the organisms are fully susceptible, EMB need not be included. For children whose clarity 
or sharpness of vision cannot be monitored, EMB is usually not recommended except when the 
risk of drug resistance is high or for children who have “adult-type” (upper lobe infiltration, cavity 
formation) TB disease.
Continuation Phase
The continuation phase of treatment is given for either 4 or 7 months. The 4-month continuation 
phase should be used in patients with uncomplicated, noncavitary, drug-susceptible TB, if there 
is documented sputum conversion within the first 2 months. The 7-month continuation phase is 
recommended only for
 • Patients with cavitary or extensive pulmonary TB disease caused by drug-susceptible organisms 
and whose sputum culture obtained at the time of completion of 2 months of treatment is 
positive; 
 • Patients whose initial phase of treatment did not include PZA; or
 • Patients being treated with once-weekly INH and RPT and whose sputum culture at the time 
of completion of the initial phase (i.e., after 2 months) is positive.
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Table 6.3 
Drug Regimens for Pulmonary TB in Adults Caused by 
Drug-Susceptible Organisms*
Initial Phase Continuation Phase
Regimen Drugs Interval and Doses± § Regimen Drugs Interval and Doses± § Range of Total Doses
1 INH 
RIF 
PZA 
EMB
7 days/week for 56 doses 
(8 weeks) 
or 
5 days /week for 40 doses 
(8 weeks)¶
1a INH 
RIF
7 days/week for 126 
doses (18 weeks) 
or  
5 days/week for 90 
doses (18 weeks)
182– 130 
(26 weeks)
1b# INH 
RIF
2 days/week for 36 
doses (18 weeks)
92– 76 
(26 weeks)
1c** INH 
RPT
1 day/week for 18 doses 
(18 weeks)¶
74– 58 
(26 weeks)
2 INH 
RIF 
PZA 
EMB
7 days/week for 14 doses 
(2 weeks), then 2 days/
week for 12 doses (6 
weeks) 
or 
5 days/week for 10 doses 
(2 weeks),¶  
then 2 days/week for 12 
doses (6 weeks)
2a# INH 
RIF
2 days/week for 36 
doses (18 weeks)¶
62– 58 
(26 weeks)
2b** INH 
RPT
1 day/week for 18 doses 
(18 weeks)¶
44– 40 
(26 weeks)
3 INH 
RIF 
PZA 
EMB
3 times weekly for  
24 doses (8 weeks)
3a INH 
RIF
3 times weekly for 54 
doses (18 weeks)¶
78 
(26 weeks)
4 INH 
RIF 
EMB
7 days/week for 56 doses 
(8 weeks)  
or 
5 days/week for 40 doses 
(8 weeks)¶
4a INH 
RIF
7 days/week for 217 
doses (31 weeks) 
or 
5 days/week for 155 
doses (31 weeks)¶
273– 195 
(39 weeks)
4b# INH 
RIF
Twice weekly for 62 
doses (31 weeks)¶
118– 102 
(39 weeks)
INH = isoniazid      RIF = rifampin      PZA = pyrazinamide      EMB = ethambutol      RPT = rifapentine
 * For more information on strength of recommendation and quality of supporting evidence, refer to treatment 
of tuberculosis guidelines. MMWR 2003; 52 (No.RR-11).
± When DOT is used, drugs may be given 5 days/week and the necessary doses adjusted accordingly.
§ Patients with cavitation on initial chest x-ray and positive cultures at completion of 2 months of therapy should 
receive a 7-month continuation phase.
¶ Patients on regimens given less than 7 days a week should receive DOT.
# Regimens given less than 3 times a week are not recommended for HIV-infected patients with CD4+ counts 
less than 100
** Used only for HIV-negative patients with negative sputum smears at completion of 2 months of therapy and 
who do not have cavitation on initial chest x-ray. For patients started on this regimen and found to have 
positive culture from the 2-month specimen, treatment should be extended an extra 3 months.
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Table 6.4 
Dosage Recommendations for the Treatment of TB in Adults and Children1 
Dose in mg/kg (maximum dosage in parentheses)
Drug Adults/Children2 Daily 1 time/week3 2 times/week3 3 times/week3
INH
Adults 5 mg/kg (300 mg)
15 mg/kg  
(900 mg)
15 mg/kg 
(900 mg)
15 mg/kg 
(900 mg)
Children 10– 15 mg/kg (300 mg)
20– 30 mg/kg 
(900 mg)
RIF
Adults 10 mg/kg (600 mg)
10 mg/kg 
(600 mg)
10 mg/kg 
(600 mg)
Children 10– 20 mg/kg (600 mg)
10– 20 mg/kg 
(600 mg)
RBT
Adults 5 mg/kg (300 mg)
5 mg/kg 
(300 mg)
5 mg/kg 
(300 mg)
Children Appropriate dosing for children unknown
RPT
Adults
10 mg/kg 
(600 mg) 
(continuation phase)
Children This drug is not approved for use in children
PZA
Adults
w
ei
gh
t
40– 55 kg 18.2– 25 mg/kg (1000 mg)
36.4– 50 mg/kg 
(2000 mg)
27.3– 37.5 mg/kg 
(1500 mg)
56– 75 kg 20– 26.8 mg/kg (1500 mg)
40– 53.6 mg/kg 
(3000 mg)
33.3– 44.6  
(2500 mg)
76– 90 kg 22.2– 26.3 mg/kg (2000 mg)
44.4– 52.6 mg/kg 
(4000 mg)
33.3– 39.5 mg/kg 
(3000 mg)
Children 15– 30 mg/kg (2000 mg)
50 mg/kg 
(2000 kg)
EMB4
Adults
w
ei
gh
t
40– 55 kg 14.5– 20 mg/kg (800 mg)
36.4– 50 mg/kg 
(2000 mg)
21.8– 30 mg/kg 
(1200 mg)
56– 75 kg 16– 21.4 mg/kg (1200 mg)
37.3– 50 mg/kg 
(2800 mg)
26.7– 35.7 mg/kg 
(2000 mg)
76– 90 kg 17.8– 21.1 mg/kg (1600 mg)
44.4– 52.6 mg/kg 
(4000 mg)
26.7– 31.6 mg/kg 
(2400 mg)
Children 15– 20 mg/kg (1000 mg)
50 mg/kg 
(2500 mg)
INH= isoniazid   RIF= rifampin   RBT= rifabutin   RPT= rifapentine   PZA= pyrazinamide   EMB= ethambutol
  1 Although these regimens are broadly applicable, modifications may be needed for certain  circumstances 
(patients on antiretroviral therapy [ART]). For more information, refer to treatment of tuberculosis guidelines. 
MMWR 2003; 52 (No.RR-11).
  2 For purposes of this document, adult dosing begins at age 15 years. Children weighing more than 40 kg 
should be dosed as adults. Adjust doses as the patient’s weight changes.
  3 All patients prescribed an intermittent regimen should be given DOT.
  4 Ethambutol should be used with caution in young children since it is difficult to monitor their vision. However, 
if they have TB that is resistant to INH or RIF, a dose of 15 mg/kg per day can be used.
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Treatment Completion
Treatment completion is defined primarily as the ingestion of the total number of doses prescribed 
within the specified time frame. The duration of therapy depends on the drugs used, the drug-
susceptibility test results of the isolate, and the patient’s response to therapy (see Chapter 4,  
Drug-Susceptibility Testing). Most patients with previously untreated pulmonary TB disease can  
be treated with either a 6-month or a 9-month regimen, although the 6-month regimen is used  
for the majority of patients. All 6-month regimens must contain INH, RIF, and initially, PZA.  
The goal is to complete all doses within 1 year (Table 6.5).
The duration of therapy depends on the drugs used, the drug susceptibility 
test results of the isolate, and the patient’s response to therapy.
Most patients with previously untreated pulmonary TB disease can 
be treated with either a 6-month or a 9-month regimen, although 
the 6-month regimen is used for the majority of patients.
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Table 6.5 
TB Treatment Phases
Phase Purpose Treatment
Initial phase  • Kills most of the tubercle 
bacilli during the first 8 
weeks of treatment, but 
some bacilli can survive 
longer
 • Prevents the emergence 
of drug resistance
 • Determines the ultimate 
outcome of the regimen
Initial 2-month treatment regimen
 • Includes four drugs in the treatment 
(usually INH, RIF, PZA, and EMB)
 • Each of the drugs plays an important role 
for short-course regimens with high cure 
rates
 • Multiple drugs are needed to prevent the 
development of drug-resistant TB disease
Continuation 
phase
 • Kills remaining tubercle 
bacilli (after initial phase)
 • If treatment is not 
continued long enough, 
the surviving bacilli may 
cause TB disease in the 
patient at a later time
An addition of either 4 or 7 months of 
treatment 
 • 4 months is used for majority of patients
 • 7 months is recommended only for persons 
 » Who have drug-susceptible cavitary or 
extensive pulmonary TB disease and 
whose sputum culture obtained at 
the time of completion of 2 months of 
treatment is positive
 » Whose initial phase of treatment did 
not include PZA
 » Who are treated with once-weekly INH 
and RPT and whose sputum culture at 
the time of completion of the initial 
phase is positive
Treatment 
completion
Defines the number of 
doses ingested within a 
specified time frame
Duration depends on 
 • Drugs used
 • Drug susceptibility test 
results of the isolate
 • Patient’s response to 
therapy
Most patients with previously untreated 
pulmonary TB disease can be treated with 
either
 • 6-month regimen (preferred) containing 
INH, RIF, and initially PZA
or 
 • 9-month regimen containing INH and RIF
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Follow-Up After Treatment
Routine follow-up after treatment is not necessary for patients who have had a satisfactory response 
to a 6- or 9-month regimen with both INH and RIF (Table 6.6). Patients whose organisms were 
fully susceptible to the drugs being used should be instructed to promptly report the development of 
any symptoms, particularly prolonged cough, fever, or weight loss. Patients with resistance to both 
INH and RIF should be monitored for 2 years post-treatment. For patients with organisms resistant 
to INH or RIF, follow-up evaluation must be individualized.
Table 6.6  
Follow-Up After Treatment
Patients Type of Follow-Up
Have a satisfactory response to 6- or 9- month 
regimen with both INH and RIF
Routine follow-up after treatment is not 
necessary
Have organisms that were fully susceptible to 
drugs being used
Patients should promptly report any of the 
following symptoms: 
 • Prolonged cough
 • Fever
 • Weight loss
Have organisms resistant to INH and RIF Patients should be monitored for 2 years post-
treatment 
Have organisms resistant to INH or RIF Follow-up must be individualized
Treatment Interruptions
Interruptions in the treatment of TB disease are common. Health-care providers are responsible 
for deciding whether to restart a complete course of treatment or to continue as intended. These 
decisions should be based on when the interruption occurred and the duration of the interruption. 
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Treatment Interruption During Initial Phase
If the interruption occurred during the initial phase, the following guidelines apply (Figure 6.5) 
(Table 6.7):
 • Lapse is ≥14 days– restart treatment from the beginning 
 • Lapse is <14 days– continue treatment to complete planned total number of doses (as long as 
all doses are completed within 3 months)
Figure 6.5 
Algorithm for Management of 
Initial Phase Treatment Interruptions
Is it 
for <14 
days?
Start over from 
the beginning
Start over from 
the beginning
No Yes
Treatment is 
interrupted
Continue treatment
to complete total
doses required
Can 
the initial 
phase treatment  
be completed 
within 3 
months?
No Yes
Treatment Interruption During Continuation Phase
If the interruption occurred during the continuation phase, the following guidelines apply  
(Figure 6.6) (Table 6.7). If the patient received:
 • ≥80% of doses, and sputum was acid-fast bacilli (AFB) smear negative on initial 
testing– further therapy may not be necessary;
 • ≥80% of doses, and sputum was AFB smear positive on initial testing– continue therapy; 
 • <80% of doses, and lapse is less than 3 months in duration– continue therapy until all doses are 
completed (full course); or
 • <80% of doses, and lapse is greater than 3 months in duration– restart therapy from the 
beginning of initial phase.
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Figure 6.6 
Algorithm for Management of 
Continuation Phase Treatment Interruptions
Is the 
percentage
of doses
<80%?
If sputum smear was 
AFB negative at 
baseline, additional 
treatment may not be 
necessary
If sputum smear was 
AFB positive at 
baseline, continue 
treatment to complete 
planned total number 
of doses warranted
No Yes
Determine the total 
percentage of 
doses completed
Is the 
duration of 
interruption 
<3 months?
No Yes
Continue 
treatment
Start initial phase
 4-drug regimen 
from the beginning
Can
treatment 
be completed 
within required time 
frame for 
regimen?
No
Complete 
treatment
Yes
Start initial phase
 4-drug regimen 
from the beginning
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Table 6.7 
Treatment Interruptions
When 
Interruption 
Occurs
Situation Guidelines
During initial 
phase
Lapse is <14 days in duration Continue treatment to complete planned 
total number of doses (as long as all doses 
are completed within 3 months)
Lapse is ≥14 days in duration Restart treatment from the beginning
During 
continuation 
phase
Received ≥80% of doses 
and sputum was AFB smear 
negative on initial testing
Further therapy may not be necessary
Received ≥80% of doses 
and sputum was AFB smear 
positive on initial testing
Continue therapy until all doses are 
completed
Received <80% of doses and 
lapse is <3 months in duration
Continue therapy until all doses are 
completed (full course)
If treatment cannot be completed within 
recommended timeframe for regimen, 
restart therapy from the beginning
Received <80% of doses and 
lapse is ≥3 months in duration
Restart therapy from the beginning, new 
initial and continuation phase
Decision to Treat Culture-Negative TB Disease
Alternative diagnoses must be considered carefully with appropriate diagnostic studies undertaken in 
patients who have what appears to be culture-negative pulmonary TB disease. Patients who, based 
on careful clinical and radiographic evaluation, are thought to have pulmonary TB disease should 
have treatment initiated with INH, RIF, PZA, and EMB even when the initial sputum smears are 
negative. Figure 6.7 provides an algorithm for treatment of culture-negative TB.
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Figure 6.7 
Algorithm to Guide Treatment of Culture-Negative TB
Is initial 
culture 
positive?
No Yes
Continue treatment 
for culture-positive TB
Was there 
symptomatic 
or chest x-ray 
improvement after 
2 months of 
treatment?
No Yes
Continue treatment 
of INH/RIF daily or 
twice weekly for 
2-4 months
High clinical suspicion for active TB 
despite negative smears based on:
• Abnormal chest x-ray
• Clinical symptoms
• No other diagnosis
• Positive IGRA or tuberculin skin test
• High risk of acquiring TB infection
Patient placed on initial phase regimen: 
INH, RIF, EMB, and PZA for 2 months
• Discontinue treatment
• Patient presumed to 
have LTBI
• Treatment completed
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Study Questions
Indicate whether the following statements about the initial phase of treatment are true or false. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Statements about Initial Phase of Treatment True or False
____  6.17 Consists of 2 months of treatment.
____  6.18 Is crucial for preventing the emergence of  
drug resistance.
____  6.19 Treatment regimen usually consists of 6 drugs.
A. True
B. False
Indicate whether the following statements about the continuation phase of treatment are true 
or false. (Choose the one best answer and write the letter for the correct answer on the line next to 
the question number.) 
Statements about Continuation Phase of Treatment True or False
____  6.20 Consists of either 4 or 7 months of treatment.
____  6.21 The 4-month continuation phase is used in the 
majority of patients.
____  6.22 The 7-month continuation phase is usually only used 
for patients with extrapulmonary TB.
A. True
B. False
6.23 Treatment completion is defined primarily as the ingestion of the total number of doses 
prescribed within the specified time frame.  
(choose the one best answer)
A. True
B. False
6.24 The duration of therapy depends on which of the following?  
(choose the one best answer)
A. Drugs used
B. Drug-susceptibility test results of the isolate
C. Patient’s response to therapy
D. A, B, and C are all correct.
E. Only A and B are correct.
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6.25 Which of the following statements about follow-up after treatment is true? 
(choose the one best answer)
A. Follow-up evaluation must be individualized for patients with organisms resistant to  
INH or RIF or both.
B. Routine follow-up after treatment is not necessary for patients who have had a  
satisfactory response to a 6- or 9-month regimen with both INH and RIF.
C. Follow-up evaluation is not needed for patients with continued positive cultures.
D. A, B, and C are all correct.
E. Only A and B are correct.
The following patients have had an interruption in treatment. Match the patient with the 
treatment decision. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Patient Treatment Decision
____  6.26 During the initial phase of treatment, Perry has 
had a lapse in therapy that was less than 14 days.
____  6.27 During the initial phase of treatment, Walter has 
had a lapse in therapy that was greater than 14 
days.
____  6.28 During the continuation phase of treatment, 
Desiree has had a lapse in therapy after receiving 
more than 80% of doses. She had a negative smear 
on initial testing.
____  6.29 During the continuation phase of treatment, 
Maurine has had a lapse in therapy for cavitary TB 
after receiving less than 80% of doses. Her lapse is 
more than 3 months in duration.
____  6.30 During the continuation phase of treatment, 
Ratcliff had a lapse in therapy after receiving more 
than 80% of doses. His sputum was AFB smear 
positive on initial testing.
____  6.31 During the continuation phase of treatment, Alex 
has had a lapse in therapy after receiving less than 
80% of doses. His lapse is less than 3 months in 
duration. 
A. Restart treatment from the 
beginning
B. Continue treatment to 
complete planned total 
number of doses (as long 
as all doses are completed 
within 3 months)
C. Further treatment may not 
be necessary
D. Continue therapy until all 
doses are completed
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TB Disease Treatment Regimens for Specific Situations
TB disease treatment regimens for specific situations require special management and should be 
administered in consultation with a TB expert. Specific situations include the following people:
 • Pregnant women
 • Breast-feeding women
 • Infants and children 
 • HIV-infected persons
TB disease treatment regimens for specific situations require special 
management and should be administered in consultation with a TB expert.
Pregnant Women
Untreated TB disease represents a greater hazard to a pregnant woman and her fetus than does its 
treatment. Because of the risk of TB to the fetus, treatment of TB in pregnant women should be 
initiated whenever the probability of maternal disease is moderate to high. The initial treatment 
regimen should consist of INH, RIF, and EMB. Although all of these drugs cross the placenta, they 
do not appear to have teratogenic effects. Streptomycin is the only anti-TB drug documented to 
have harmful effects on the human fetus (congenital deafness) and should not be used. Although 
detailed teratogenicity data are not available, PZA can probably be used safely during pregnancy and 
is recommended by the World Health Organization (WHO) and the International Union Against 
Tuberculosis and Lung Disease (IUATLD). If PZA is not included in the initial treatment regimen, 
the minimum duration of therapy is 9 months. 
Untreated TB disease represents a greater hazard to a pregnant 
woman and her fetus than does its treatment.
Streptomycin is the only anti-TB drug documented to have harmful effects 
on the human fetus (congenital deafness) and should not be used.
For pregnant women with MDR TB, treatment should only be done in consultation with an MDR 
TB expert. Many of the medications currently used for treatment of MDR TB may be harmful to 
the fetus.
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Breast-feeding
Breast-feeding should not be discouraged for women being treated with first-line anti-TB drugs, 
because the small concentrations of these drugs in breast milk do not produce toxicity in the nursing 
newborn. Conversely, drugs in breast milk should not be considered to serve as effective treatment 
for TB disease or for LTBI in a nursing infant. Pyridoxine (vitamin B6) supplementation (25 mg/
day) is recommended for all women taking INH who are either pregnant or breast-feeding. The 
amount of pyridoxine in multivitamins is variable, but generally less than the needed amount. 
Infants and Children 
Infants and children with TB disease should be treated with the regimens recommended for 
adults, with the exception that EMB is not used routinely in children. For children whose clarity 
or sharpness of vision cannot be monitored, EMB is usually not recommended except when the 
risk of drug resistance is high or for children who have “adult-type” (upper lobe infiltration, cavity 
formation) TB disease. In infants, TB is much more likely to disseminate; therefore, treatment 
should be started as soon as the diagnosis is suspected. Children commonly develop primary TB 
disease which generally affects the middle and lower lung. Children should be treated with three 
(rather than four) drugs in the initial phase (INH, RIF, and PZA). In general, extrapulmonary TB in 
children can be treated with the same regimens as pulmonary disease. Exceptions are disseminated 
TB and tuberculous meningitis, for which there are inadequate data to support 6-month therapy; 
thus 9 to 12 months of treatment is recommended.
In infants, TB is much more likely to disseminate; therefore, treatment 
should be started as soon as the diagnosis is suspected.
HIV-Infected Persons
Management of HIV and TB coinfection is complex, and the clinical and public health 
consequences associated with the failure of treatment and other negative outcomes are serious. HIV-
infected patients are on numerous medications, some of which interact with anti-TB drugs. It is 
therefore strongly recommended that experts in the treatment of HIV-related TB be consulted. 
The treatment regimens listed in Table 6.3 are effective for people living with HIV, with two 
exceptions due to increased risk of developing acquired drug resistance:
 • Once-weekly administration of INH and RPT in the continuation phase should not be used in 
any HIV-infected patient; and
 • Patients with advanced HIV (CD4 counts less than 100) should be treated with daily or three 
times weekly therapy in both the initial and continuation phase.
Every effort should be made to use a rifamycin-based regimen for the entire course of therapy in 
coinfected patients. The key role of the rifamycins in the success of TB disease treatment mandates 
that the drug-drug interactions between the rifamycins and antiretroviral drugs be managed 
appropriately, rather than using TB treatment regimens that do not include a rifamycin or by 
withholding antiretroviral therapy until completion of anti-TB therapy.
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Of particular concern is the interaction of rifamycins with antiretroviral agents and other anti-
infective drugs. Rifampin can be used for the treatment of TB with certain combinations of 
antiretroviral agents. Rifabutin, which has fewer drug-drug interactions due to its decreased 
induction of the cytochrome P450 system, may also be used in place of rifampin and appears 
to be equally effective, although the doses of the rifabutin and antiretroviral agents may require 
adjustments and should be administered with expert consultation.
Therefore, patients with HIV-related TB disease should be treated with a regimen including a 
rifamycin for the full course of TB disease treatment, unless the isolate is resistant to the rifamycins 
or the patient has a severe side effect that is clearly due to the rifamycins.
HIV-infected patients are on numerous medications, some of which 
interact with anti-TB drugs. It is therefore strongly recommended 
that experts in the treatment of HIV-related TB be consulted.
Treatment Duration
Six months should be considered the minimum duration of treatment for HIV-infected adults, 
even for patients with culture-negative TB disease. If there is evidence of a slow or suboptimal 
response (e.g., cultures are still positive after 2 months of therapy), the continuation phase should be 
prolonged to 7 months (a total of 9 months of treatment). DOT and other adherence- promoting 
strategies should be used in all patients with HIV-related TB disease. 
Predicting Drug Interactions Involving Rifampin
Much is known about the interactions of antiretroviral agents and RIF. In addition, knowledge of 
the mechanisms of drug interactions can help predict the likelihood of an interaction, even if that 
specific combination of drugs has not been formally evaluated. A major concern in treating TB 
disease in HIV-infected persons is the interaction of RIF with certain antiretroviral agents (some 
protease inhibitors [PIs] and nonnucleoside reverse transcriptase inhibitors [NRTIs]). Rifabutin, 
another rifamycin that has fewer drug-drug interactions, may be used as an alternative to RIF. 
As new antiretroviral agents and more pharmacokinetic data become available, these 
recommendations are likely to be modified. For more information, see Managing Drug Interactions 
in the Treatment of HIV-Related Tuberculosis at: www.cdc.gov/tb/publications/guidelines/TB_HIV_
Drugs/default.htm
Pregnancy in HIV-Infected Women
A number of issues complicate the treatment of the HIV-infected pregnant woman who has 
TB disease. Pregnancy alters the distribution and metabolism of a number of drugs, including 
antiretroviral drugs (there is very little information on whether the metabolism of anti-TB drugs is 
altered during pregnancy). Notably, the serum concentrations of protease inhibitors are decreased 
during the latter stages of pregnancy. There are no published data on drug-drug interactions between 
anti-TB and antiretroviral drugs among pregnant women. However, it is likely that the effects of RIF 
on protease inhibitors are exacerbated during pregnancy. 
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HIV-Infected Children
HIV-infected children with TB disease are at greater risk for severe, life-threatening manifestations 
(e.g., disseminated disease, meningitis). There are very limited data on the absorption, metabolism, 
and elimination of anti-TB drugs among children, particularly among very young children (< 2 years 
of age). For more information, please see Managing Drug Interactions in the Treatment of HIV-
Related Tuberculosis at: www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/specialpop.htm
HIV-infected children with TB disease are at greater risk for severe, life-
threatening manifestations (e.g., disseminated disease, meningitis).
Persons with Additional Treatment Considerations
A number of medical conditions or disease characteristics require additional treatment considerations 
and TB treatment decisions should be made in consultation with a TB expert. These include:
 • Renal insufficiency/end-stage renal disease 
 • Hepatic disease
 • Extrapulmonary TB disease
 • Drug-resistant TB disease
 • Culture-negative TB disease
Renal Insufficiency and End-stage Renal Disease 
Renal insufficiency complicates the management of TB disease because some anti-TB drugs are 
cleared by the kidneys. Alteration in dosing of anti-TB drugs is commonly necessary in patients with 
renal insufficiency and end-stage renal disease (ESRD) requiring hemodialysis. The dosage of anti-
TB drugs should not be decreased because the peak serum concentrations may be low and smaller 
doses may decrease drug efficacy. Instead, the dosing interval of anti-TB drugs should be increased. 
Based on creatinine clearance, most anti-TB drugs can be given three times a week immediately after 
hemodialysis. Consultation with the patient’s nephrologist is advised.
Renal insufficiency complicates the management of TB disease 
because some anti-TB drugs are cleared by the kidneys.
Alteration in dosing of anti-TB drugs is commonly necessary in patients with 
renal insufficiency and end-stage renal disease (ESRD) requiring hemodialysis.
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Hepatic Disease
The treatment of TB disease in patients with unstable or advanced liver disease is problematic for 
several reasons: 
 • The likelihood of drug-induced hepatitis is greater;
 • The implications of drug-induced hepatitis for patients with marginal hepatic reserve are 
potentially serious, even life-threatening; and 
 • Fluctuations in the indicators of liver function related to the pre-existing liver disease can 
confound monitoring for drug-induced hepatitis.
Thus, clinicians may consider regimens with fewer potentially hepatotoxic agents in patients with 
advanced or unstable liver disease. Expert consultation is advisable in treating such patients. It should 
be noted that TB disease itself may involve the liver, causing abnormal liver function; thus, not all 
abnormalities in liver function tests noted at baseline should be attributed to causes other than TB 
disease. The hepatic abnormalities caused by TB disease will improve with effective treatment.
Clinicians may consider regimens with fewer potentially hepatotoxic 
agents in patients with advanced or unstable liver disease. 
Expert consultation is advisable in treating such patients.
Extrapulmonary TB Disease
As a general rule, the principles used for the treatment of pulmonary TB disease also apply to 
extrapulmonary forms of the disease. A 6-month treatment regimen is recommended for patients 
with extrapulmonary TB disease, unless the organisms are known or strongly suspected to be 
resistant to the first-line drugs. If PZA cannot be used in the initial phase, the continuation phase 
must be increased to 7 months. The exception to these recommendations is central nervous system 
TB, for which the optimal length of therapy has not been established but some experts recommend 
9 to 12 months. Most experts do recommend corticosteroids to be used as additional therapy for 
patients with TB meningitis and pericarditis. Consultation with a TB expert is recommended.
As a general rule, the principles used for the treatment of pulmonary  
TB disease also apply to extrapulmonary forms of the disease.  
A 6-month treatment regimen is recommended for patients with 
extrapulmonary TB disease, unless the organisms are known or 
strongly suspected to be resistant to the first-line drugs.
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Drug-Resistant TB Disease
Drug-resistant TB disease can develop in two different ways, called primary and secondary  
resistance. Primary resistance occurs in persons who are initially exposed to and infected with 
resistant organisms. Secondary resistance, or acquired resistance, develops during TB therapy,  
either because the patient was treated with an inadequate regimen or because the patient did not  
take the prescribed regimen appropriately or because of other conditions such as drug malabsorption 
or drug-drug interactions leading to low serum levels (see Chapter 2, Transmission and Pathogenesis 
of Tuberculosis).
Drug-resistant TB disease can develop in two different ways: 
• Primary resistance  
 » Occurs in persons who are initially exposed to and infected 
  with resistant organisms 
• Secondary resistance, or acquired resistance 
 » Develops during TB therapy because of 
  − patient being treated with an inadequate regimen,  
  − patient not taking prescribed regimen appropriately, 
  − drug malabsorption, or 
  − drug-drug interactions leading to low serum levels
Drug resistance in a patient with newly diagnosed TB disease may be suspected on the basis of 
previous treatment, contact with a known drug-resistant case, or time spent in a region in which 
drug resistance is common. Drug resistance can be proven only by drug-susceptibility testing (see 
Chapter 4, Diagnosis of Tuberculosis Disease).
Patients with strains of M. tuberculosis resistant to both INH and RIF (multidrug-resistant) are at 
high risk for 
 • Treatment failure;
 • Relapse; 
 • Further acquired resistance; or
 • Death.
These patients must be referred immediately to an expert in the management of drug-resistant TB 
disease; or consultation should be obtained from specialized treatment centers. 
Patients with strains of M. tuberculosis resistant to both INH and RIF 
(multidrug-resistant) are at high risk for treatment failure, relapse, 
further acquired resistance, or death. These patients must be referred 
immediately to an expert in the management of drug-resistant TB disease; 
or consultation should be obtained from specialized treatment centers. 
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Management of patients with drug-resistant TB disease is based on the following guidelines:
 • A single new drug should never be added to a failing regimen;
 • In patients with MDR organisms resistant to first-line drugs in addition to INH and RIF, 
regimens employing four to six drugs that are new to the patient and to which the isolate 
shows in vitro susceptibility appear to be associated with better results; 
 • Patients with multidrug-resistant organisms should receive the highest priority for DOT, which 
should be administered either in the hospital, home, or other facility;
 • The use of drugs to which there is demonstrated in vitro resistance is not encouraged because 
there is little or no efficacy of these drugs and alternative medications may be available;
 • Resistance to RIF is associated in nearly all instances with cross-resistance to rifabutin and 
rifapentine (RPT);
 • There is no cross-resistance between SM and the other injectable agents, amikacin, kanamycin, 
and capreomycin (although resistance to all may occur as independent events); cross-resistance 
between amikacin and kanamycin is not universal but frequently seen; 
 • Resistance to PZA is uncommon in the absence of resistance to other first-line drugs; if 
monoresistance to PZA is observed, consideration must be given to the possibility that the 
disease is caused by M. bovis, not M. tuberculosis; and
 • Intermittent therapy should not be used in treating TB disease caused by drug-resistant 
organisms, except perhaps for injectable agents after the initiation phase (usually 2 to 3 
months) of daily therapy. 
Table 6.8 provides information on drug classes for TB, types of drug-resistant TB, and appropriate 
anti-TB drugs for treatment. 
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Table 6.8 
Drug Classes for TB
Drug Classes Anti-TB Drugs
Drug- 
Susceptible 
TB
Multidrug- 
Resistant TB 
(MDR TB)
Extensively 
Drug Resistant 
TB (XDR TB) 
First-line oral drugs
 • Standard treatment 
for drug-
susceptible TB
 • Four drugs for  
6– 9 months
 • Safe, effective, 
inexpensive
 • 95% cure 
 • Based on solid 
scientific evidence 
from ~30 years of 
drug discovery and 
controlled clinical 
trials, 1943– 72
INH Susceptible Resistance by 
definition
Resistance by 
definition
RIF Susceptible Resistance by 
definition
Resistance by 
definition
PZA Susceptible Resistance 
possible or likely
Resistance 
possible or likely
EMB Susceptible Resistance 
possible or likely
Resistance 
possible or likely
Second-line drugs
 • Treatment based 
on laboratory 
drug-resistance 
testing and 
epidemiological 
information
 • Four to six drugs 
for 2 years
Aminoglycosides 
and 
Capreomycin
N/A Resistance 
possible
Resistance by 
definition
Quinolones N/A Resistance 
possible
Resistance by 
definition
Thioamides N/A Resistance 
possible
Resistance 
possible or likely
Cycloserine N/A Resistance 
possible
Resistance 
possible or likely
ρ-Aminosalicylic 
Acid
N/A Resistance 
possible
Resistance 
possible or likely
Culture-Negative TB Disease
Failure to isolate M. tuberculosis from appropriately collected specimens in persons who, because of 
clinical or radiographic findings, are suspected of having pulmonary TB disease does not exclude 
a diagnosis of TB disease. Low bacillary populations, temporal variations in the number of bacilli 
being expelled, and errors in specimen processing all may result in failure to isolate organisms from 
patients who have TB disease. It should be emphasized that alternative diagnoses must be considered 
carefully and appropriate diagnostic studies undertaken in patients who have what appears to be 
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culture-negative TB disease. At a minimum, patients suspected of having pulmonary TB disease 
should have three sputum specimens (using sputum induction with hypertonic saline if necessary) 
for AFB smear and culture as part of the diagnostic evaluation prior to or coincident with treatment 
initiation. Depending on the clinical features and differential diagnosis, other diagnostic testing, 
such as bronchoscopy with bronchoalveolar lavage and biopsy, should be considered before making a 
presumptive diagnosis of culture-negative TB disease. 
Failure to isolate M. tuberculosis from appropriately collected specimens in 
persons who, because of clinical or radiographic findings, are suspected of 
having pulmonary TB disease does not exclude a diagnosis of TB disease.
Patients who, on the basis of careful clinical and radiographic evaluation, are thought to have a 
high likelihood of having pulmonary TB disease should have treatment initiated with INH, RIF, 
PZA, and EMB even when the initial sputum smears are negative. If M. tuberculosis is isolated in 
culture, treatment for TB disease should be continued. Patients who have negative cultures but who 
still are presumed to have pulmonary TB disease should have a thorough follow-up clinical and 
radiographic evaluation at the time 2 months of therapy has been completed to determine whether 
there has been a response that can be attributed to anti-TB treatment. If there is either clinical or 
radiographic improvement and no other etiology is identified, treatment should be continued for TB 
disease. A 4-month INH and RIF regimen for culture-negative TB disease has been demonstrated 
to be successful. However, because the results of cultures may not be known for 3 to 8 weeks and 
because of the possibility of drug resistance, use of two-drug therapy with INH and RIF alone is not 
recommended in the initial phase of treatment (i.e., first 2 months) while culture results are pending. 
The continuation phase can be shortened to 2 months using INH and RIF for HIV-negative 
patients once it is known that cultures are negative. However, HIV-infected patients with culture-
negative pulmonary TB should be treated for a minimum of 6 months (total). Figure 6.7 provides an 
algorithm for treatment of culture-negative TB.
Patients who, on the basis of careful clinical and radiographic 
evaluation, are thought to have a high likelihood of having pulmonary 
TB disease should have treatment initiated with INH, RIF, PZA, 
and EMB even when the initial sputum smears are negative.
On occasion, patients who are being evaluated for pulmonary TB disease will be found to have 
positive AFB smears, but negative cultures. There are several potential explanations for this 
occurrence, including the possibilities that the acid-fast organisms are nontuberculous and difficult 
to culture, that they are nonviable tubercle bacilli, or that there was laboratory error. The approach 
taken in such cases should be individualized on the basis of clinical and radiographic findings. If 
suspicion of TB disease is high and the patient has positive AFB smears, even with negative cultures, 
the patient should be treated as if culture positive, using one of the recommended regimens.
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Study Questions
6.32 Which drug is harmful to the fetus and should NOT be used with pregnant women 
during the initial treatment phase?  
(choose the one best answer)
A. Isoniazid
B. Rifampin
C. Ethambutol
D. Streptomycin
6.33 Which of the following statements about infants and children is true?  
(choose the one best answer)
A. Anti-TB drugs in breast milk can be considered effective treatment for TB disease or for 
LTBI in a nursing infant.
B. EMB is routinely used to treat children for TB disease.
C. Young children should be treated with three (rather than four) drugs in the initial phase.
D. TB disease is less likely to disseminate in children than in adults.
6.34 For HIV-infected patients, which of the following statements is true?  
(choose the one best answer)
A. The minimum duration of treatment of TB disease for HIV-infected adults is 6 months.
B. If there is evidence of a slow or suboptimal response, the continuation phase should be 
prolonged to 7 months (a total of 9 months of treatment).
C. DOT and other adherence promoting strategies should be used in all patients with HIV-
related TB disease. 
D. A, B, and C are all correct.
E. Only A and B are correct.
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TB patients can have additional medical problems or presentations. Match the problem or 
presentation with the appropriate type of TB disease treatment. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Additional Medical Problems 
or Presentations Type of Treatment
____  6.35 End-stage renal disease
____  6.36 Hepatic disease
____  6.37 Extrapulmonary TB disease
A. Consider a regimen with fewer potentially 
hepatotoxic agents.
B. Alteration in dosing anti-TB drugs is 
commonly necessary. Do not decrease dose 
of anti-TB drugs. Dosing interval should be 
increased to 3 times a week.
C. Use the same principles as for pulmonary 
TB disease. A 6-month treatment regimen 
is recommended, unless the organisms are 
known or strongly suspected to be resistant 
to the first-line drugs.
6.38 Drug resistance in a patient with newly diagnosed TB disease may be suspected on the 
basis of which of the following?  
(choose the one best answer)
A. Time spent in a region in which drug resistance is common
B. Contact with a known drug-resistant case
C. Previous TB treatment
D. A, B, and C are all correct.
E. Only A and B are correct.
6.39 Joanne has an M. tuberculosis strain that is resistant to both isoniazid and rifampin.  
What is Joanne at high risk for?  
(choose the one best answer)
A. Treatment failure
B. Relapse
C. Further acquired resistance
D. A, B, and C are all correct.
E. Only A and B are correct.
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Patient Monitoring
Adverse reactions to anti-TB drugs are relatively rare, but in some patients they may be severe. 
Clinicians who treat TB disease should be familiar with the methods of monitoring for adverse 
reactions and patients’ response to treatment. In some situations (drug-resistant TB disease, 
pregnancy, HIV-infected patients), expert consultation should be sought. 
Baseline Monitoring
Before starting treatment, adult patients should have certain baseline blood and vision tests to help 
detect any underlying problems that may complicate treatment. For children, only vision tests are 
necessary unless there are other medical conditions that may complicate treatment. Recommended 
examinations for baseline monitoring are included in Table 6.9.
Before starting treatment, adult patients should have 
certain baseline blood and vision tests to help detect any 
underlying problems that may complicate treatment.
For children, only vision tests are necessary unless there are 
other medical conditions that may complicate treatment.
Table 6.9 
Recommended Examinations for Baseline Monitoring
Patient Recommended Test
All patients Measure aminotransferases (i.e., AST, ALT), 
bilirubin, alkaline phosphatase, and serum 
creatinine and a platelet count
Patients at risk for hepatitis B or C  
(e.g., injection drug user, born in Asia  
or Africa, or HIV infected)
Conduct serologic tests
Patients who are taking EMB Test visual acuity (Snellen chart) and color 
vision (Ishihara)
HIV-infected patients Obtain CD4+ lymphocyte count
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Monitoring During Treatment
Patients with TB disease should have clinical evaluations at least monthly to identify possible adverse 
reactions to medications and to assess adherence (Table 6.10). 
As a routine practice, it is not necessary to monitor liver or renal function or platelet count for 
patients being treated with first-line anti-TB drugs unless there were abnormalities at baseline or 
there are clinical reasons to obtain measurements. Patients who have stable abnormalities of hepatic 
or renal function at baseline should have repeat measurements early in the course of treatment, then 
less frequently to ensure that conditions have not worsened.
Monthly repeat testing of visual acuity (Snellen) and color vision (Ishihara) is recommended for 
patients receiving an EMB dose exceeding 15– 20 mg/kg (the recommended range) and for patients 
receiving EMB for more than 2 months. Patients receiving EMB should be questioned regarding 
visual disturbances at monthly intervals. Patients should be educated regarding the possible visual 
side effects of EMB and should be instructed to immediately report vision changes to their health-
care provider.
Table 6.10 
Monitoring During Treatment
Patient Recommended Test
All patients Repeat at least monthly clinical evaluations to
 • Identify possible adverse reactions to 
medications 
 • Assess adherence
Patients who are taking EMB  • Question monthly regarding visual 
disturbances 
 • Repeat monthly testing for visual acuity 
(Snellen chart) and color vision (Ishihara) for 
patients whose dose exceeds 15– 20 mg/kg 
and those who have been receiving EMB for 
>2 months 
Patients who have 
extrapulmonary TB disease
Evaluation depends on 
 • Sites involved
 • Ease with which specimens can be obtained
Chapter 6: Treatment of Tuberculosis Disease
178
Study Questions
6.40 For baseline monitoring, children only need vision tests unless there are other medical 
conditions that may complicate treatment. 
(circle the one best answer)
A. True
B. False
Match the patient with the type of monitoring that should occur during treatment. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Patients Monitoring During Treatment
____  6.41 Pauline is being treated with 
first-line anti-TB drugs. 
She had no abnormalities 
at baseline and no clinical 
problems.
____  6.42 Don had stable 
abnormalities of hepatic 
function at baseline.
____  6.43 Percy has been on first-line 
anti-TB drugs that include 
ethambutol for greater than 
2 months.
A. Repeat measurements early in the course 
of treatment, then less frequently to ensure 
that condition does not worsen. 
B. Repeat visual acuity and color vision.
C. Not necessary to monitor liver or renal 
function or platelet count.
Evaluating Response to Treatment
It is important for clinicians to evaluate a patient’s response to treatment to determine the efficacy 
of the treatment and to identify any adverse reactions. Clinicians use three methods to determine 
whether a patient is responding to treatment:
1. Clinical evaluation
2. Bacteriological examination
3. Chest radiograph
It is important for clinicians to evaluate a patient’s response to treatment to 
determine the efficacy of the treatment and to identify any adverse reactions.
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Clinical Evaluation
Patients should have clinical evaluations at least monthly to 
 • Identify possible adverse reactions to medications;
 • Assess adherence; and
 • Determine treatment efficacy. 
Although each patient responds to treatment at a different pace, all TB symptoms should gradually 
improve and eventually go away. Patients whose symptoms do not improve during the first 2 
months of treatment, or whose symptoms worsen after improving initially, should be reevaluated for 
adherence issues and development of drug resistance.
Adverse Reactions to Anti-TB Drugs
In addition to the microbiological evaluations, it is essential that patients have clinical evaluations to 
identify possible adverse effects of the anti-TB drugs (Table 6.11). Monitoring for adverse reactions 
must be individualized. The type and frequency of monitoring should depend on the drugs used and 
the patient’s risk for adverse reactions (e.g., age or alcohol use). At minimum, patients should be seen 
monthly during therapy and questioned by health-care providers concerning adverse reactions, even 
if no problems are apparent. 
Adverse reactions to anti-TB drugs are relatively rare, but in some patients they may be severe. 
Mild adverse effects can generally be managed with symptomatic therapy. The drug or drugs must 
be discontinued for more severe effects. It is important that first-line drugs not be stopped without 
adequate justification. Proper management of serious adverse reactions often requires expert 
consultation. 
Patients should be specifically instructed to look for symptoms associated with the most common 
reactions to the medications they are taking. They should also be instructed to seek medical 
attention immediately should these symptoms occur. All patients receiving INH, RIF, or PZA 
should immediately report any symptoms suggestive of hepatitis (nausea, loss of appetite, vomiting, 
persistently dark urine, yellowish skin or eyes, malaise, unexplained elevated temperature for more 
than 3 days, or abdominal tenderness). If the symptoms suggest adverse reactions, the patient should 
be instructed to stop the medication, and appropriate laboratory testing should be performed.
Patients should be specifically instructed to look for symptoms 
associated with the most common reactions to the medications 
they are taking. They should also be instructed to seek medical 
attention immediately should these symptoms occur.
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Table 6.11 
Common Adverse Reactions to TB Drugs
Caused 
by Adverse Reaction Signs and Symptoms
Significance 
of Reaction*
Any 
drug
Allergic  • Skin rash May be serious 
or minor
EMB Eye damage  • Blurred or changed vision
 • Changed color vision
Serious
INH 
PZA 
RIF
Hepatic toxicity  • Abdominal pain
 • Abnormal liver function test results
 • Dark urine
 • Fatigue
 • Fever for 3 or more days
 • Flu-like symptoms
 • Lack of appetite
 • Nausea
 • Vomiting
 • Yellowish skin or eyes
Serious
INH Nervous system 
damage
 • Dizziness; tingling or numbness  
around the mouth
Serious
Peripheral neuropathy  • Tingling sensation in hands and feet Serious
PZA Stomach upset  • Stomach upset
 • Vomiting
 • Lack of appetite
May be serious 
or minor
Gout  • Abnormal uric acid level**
 • Joint aches
Serious
RIF Bleeding problems  • Easy bruising
 • Slow blood clotting
Serious
Discoloration of body 
fluids
 • Orange urine, sweat, or tears
 • Permanently stained soft contact lenses
Minor
Drug interactions  • Interferes with certain medications such as 
birth control pills, birth control implants,  
and methadone treatment
May be serious 
or minor
Sensitivity to the sun  • Frequent sunburn Minor
  * Patients should stop medication for serious adverse reactions and consult a clinician immediately. 
Patients can continue taking medication if they have minor adverse reactions.
** Asymptomatic elevated uric acid levels are expected with PZA treatment. Acute gouty arthritis, which is rare 
without preexisting gout, is a contraindication to PZA use.
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Common Adverse Reactions to TB Disease Treatment
The items listed below are common adverse reactions to TB treatment: 
 • Gastrointestinal problems 
 • Hepatitis
 • Rash 
 • Drug fever 
Gastrointestinal Problems
Gastrointestinal reactions to the anti-TB drugs are common, particularly in the first few weeks of 
therapy. These reactions include:
 • Upset stomach
 • Nausea
 • Poor appetite
 • Abdominal pain
In the presence of gastrointestinal symptoms, measure
 • Serum aminotransferases (i.e., AST, ALT) and 
 • Bilirubin 
Hepatic Toxicity
Liver injury can be caused by three of the first-line TB disease drugs, INH, RIF and PZA. Significant 
liver toxicity is indicated by AST ≥3 times the upper limit of normal in the presence of symptoms, 
or ≥5 times the upper limit of normal in the absence of symptoms (Table 6.12). If the AST and ALT 
are <5 times the upper limit of normal, toxicity can be considered mild; an AST or ALT of 5– 10 
times normal defines moderate toxicity; and >10 times normal is severe. In addition to elevation 
of the AST and ALT, occasionally there are disproportionate increases in bilirubin and alkaline 
phosphatase. This pattern is more consistent with RIF hepatotoxicity. 
Table 6.12 
Hepatic Toxicity
AST and ALT Level Levels of Toxicity
AST and ALT <5 times the upper limit of normal Mild
AST or ALT 5– 10 times the normal limit Moderate
AST or ALT >10 times the normal limit Severe
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Rash 
All drugs used in treating TB disease can cause a rash. The response to a patient with a rash depends 
upon its severity. The rash may be minor, affecting a limited area or being predominantly manifested 
as itching. In this case, antihistamines should be given for symptomatic relief, but all TB disease 
medications can be continued. 
All drugs used in treating TB disease can cause a rash.
Drug Fever
Recurrence of fever in a patient who has been receiving therapy for several weeks should suggest drug 
fever, especially if the patient is showing microbiologic and radiographic improvement. It should 
be noted, however, that fever from TB may persist for as long as 2 months after therapy has been 
initiated.
Bacteriologic Examination
Important treatment decisions concerning the continuation-phase regimen are based on the 
microbacteriological status at the end of the initial phase of treatment (i.e., at least 2 months). 
Patients whose cultures have not become negative after 3 months of therapy should be reevaluated 
for potential drug-resistant disease, as well as for potential failure to adhere to the regimen. Patients 
who have positive cultures after 4 months of treatment should be considered as having failed 
treatment and managed accordingly.
Patients whose cultures have not become negative after 3 months of 
therapy should be reevaluated for potential drug-resistant disease, 
as well as for potential failure to adhere to the regimen.
Positive Sputum Cultures Prior to Treatment
For patients whose sputum culture is positive prior to treatment, the best way to measure the efficacy 
of therapy is to obtain specimens for culture at least monthly until two consecutive specimens are 
negative on culture (Table 6.13). Patients with multidrug-resistant TB should have sputum AFB 
smears and cultures performed monthly for the entire course of treatment.
Negative Sputum Cultures Prior to Treatment
For patients with negative sputum cultures prior to treatment for pulmonary disease, the major 
indicators of response to therapy are the chest radiograph and the clinical evaluation (Table 6.13). 
The intervals at which chest radiography should be repeated depend on the clinical circumstances 
and the differential diagnosis that is being considered. If the radiograph does not improve after the 
patient has received 2 months of treatment, the abnormality may be the result of either previous  
(not current) TB disease or another reason.
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Table 6.13 
Response to Treatment for Pulmonary TB Disease
Bacteriologic 
Status
Recommendations for  
Response to Treatment
Positive sputum cultures prior 
to treatment
 • Obtain specimens for culture at least monthly until two 
consecutive specimens are negative on culture
 • Perform monthly sputum AFB smears and cultures on MDR 
TB patients for entire course of treatment 
 • A repeat chest radiograph after 2 months of treatment may 
be useful but is not essential
Negative sputum cultures 
prior to treatment
 • Repeat chest radiograph at intervals based on clinical 
circumstances and differential diagnosis
 • If radiograph does not improve after patient has received 2 
months of treatment, abnormality may be due to
 » Previous (not current) TB disease
 » Another reason
Cultures have not become 
negative after 3 months  
of therapy
Reevaluate for 
 • Potential drug-resistant disease
 • Potential failure to adhere 
Cultures are still positive after 
4 months of treatment
Consider as having failed treatment and manage accordingly
Chest Radiograph
For patients with positive cultures at diagnosis, a repeat chest radiograph at completion of 2 months 
of treatment may be useful, but is not essential. For patients with culture-positive TB, a chest 
radiograph at completion of treatment provides a baseline for comparison with any future films. 
For patients with cultures that are initially negative, a chest radiograph is necessary after 2 months 
of treatment, and a radiograph at completion of treatment is desirable. Generally, follow-up after 
completion of therapy is not necessary. 
For patients with cultures that are initially negative, a chest 
radiograph is necessary after 2 months of treatment, and a 
radiograph at completion of treatment is desirable.
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Study Questions
6.44 How often should patients have clinical evaluations to identify possible adverse reactions 
to medications and to assess adherence and to determine treatment efficacy? 
(circle the one best answer)
A. Weekly
B. Twice a month
C. Once a month
D. Every 6 weeks
6.45 LaRue has been receiving TB treatment for 2 months. She is experiencing nausea, 
vomiting, abdominal pain, malaise, and persistently dark urine. What could be the cause?  
(circle the one best answer)
A. TB disease has spread to her abdomen.
B. She has hepatic toxicity due to adverse reaction to TB medications. 
C. She has an adverse reaction to EMB. 
Match the characteristic of an adverse reaction to TB therapy with the type of adverse reaction. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Characteristic Adverse Reaction
____  6.46 Can be caused by three of 
the first-line TB drugs. 
____  6.47 Can cause a recurrence of 
fever in a patient who has 
been receiving therapy for 
several weeks.
____  6.48 Is common particularly 
in the first few weeks of 
therapy.
____  6.49 Can be caused by all drugs 
used in treating TB disease.
A. Gastrointestinal problems
B. Hepatic toxicity
C. Rash
D. Drug fever
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Match the patient with the type of measures that should be taken to determine how the patient 
is responding to treatment. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Patients Measures for Determining the Patient’s Response to Treatment
____  6.50 Carol had a positive sputum 
cultures prior to treatment 
and has multidrug-resistant 
TB disease.
____  6.51 Tom’s culture has not 
become negative after 3 
months of treatment.
____  6.52 Roxanne had negative 
sputum cultures prior to 
treatment.
____  6.53 Burl had positive sputum 
cultures prior to treatment.
____  6.54 Mike had positive sputum 
cultures after 4 months of 
treatment.
A. Obtain specimens for culture at least 
monthly until 2 consecutive specimens are 
negative on culture. 
B. Repeat chest radiographs at intervals 
based on clinical circumstances and the 
differential diagnosis.
C. Perform sputum AFB smears and cultures 
monthly for the entire course of treatment.
D. Reevaluate for potential drug-resistant TB 
disease, as well as for potential failure to 
adhere to the regimen.
E. Consider as having failed treatment and 
manage accordingly.
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Chapter Summary
The major goals for treatment of TB disease include 
 • Cure the individual patient;
 • Minimize risk of death and disability; and
 • Reduce transmission of M. tuberculosis to other persons. 
To ensure that these goals are met, TB disease must be treated for at least 6 months or longer. 
Most of the bacteria are killed during the first 8 weeks of treatment; however, there are persistent 
organisms that require longer treatment. If treatment is not continued for a long enough duration, 
the surviving bacteria may cause the patient to become ill and infectious again.
There are several options for daily and intermittent therapy, but the goal of treatment for TB disease 
should be to provide the safest and most effective therapy in the shortest period of time. Given 
adequate treatment, almost all patients will recover and be cured. 
Regimens for the treatment of TB disease must contain multiple drugs to which the bacteria are 
susceptible. The standard of care for initiating treatment of TB disease is a four-drug regimen. 
Treatment with a single drug can lead to the development of a bacterial population resistant to that 
drug. Likewise, the addition of a single drug to a failing anti-TB regimen can lead to additional 
resistance. When two or more drugs to which in vitro susceptibility has been demonstrated are given 
together, each helps prevent the emergence of tubercle bacilli resistant to the others.
Responsibility for successful treatment is assigned to the health-care provider, not the patient. 
Health-care professionals should consult their health department’s TB control program to ensure 
their TB patients are able to adhere to a prescribed treatment regimen. The TB control program 
should assist the health-care professional in evaluating patient barriers to adherence and recommend 
directly observed therapy (DOT) and the use of incentives and enablers that may assist the patient in 
completing the recommended therapy. 
Currently, there are 10 drugs approved by the U.S. FDA for the treatment of TB disease. In 
addition, the fluoroquinolones (levofloxacin, moxifloxacin, and gatifloxacin), although not 
approved by the FDA for TB disease, are commonly used to treat TB disease caused by drug-
resistant organisms or for patients who are intolerant of some first-line drugs. Rifabutin, approved 
for use in preventing Mycobacterium avium complex disease in patients with HIV infection but not 
approved for TB disease, is useful for treating TB disease in patients concurrently taking drugs that 
interact with rifampin (e.g., certain antiretroviral drugs). Amikacin and kanamycin, nearly identical 
aminoglycoside drugs used in treating patients with TB disease caused by drug-resistant organisms, 
are not approved by the FDA for treatment of TB.
Of the approved drugs, INH, RIF, EMB, and PZA are considered the first-line anti-TB drugs 
and form the core of standard treatment regimens. RBT and RPT may also be considered first-
line drugs under certain circumstances. RBT is used as a substitute for RIF in the treatment of 
all forms of TB caused by organisms that are known or presumed to be susceptible to this agent. 
The drug is generally reserved for patients who have intolerance to RIF or for whom drug-drug 
interactions preclude the use of rifampin. SM was formerly considered to be a first-line drug and, in 
some instances, is still used in the initial treatment regimen. However, an increasing prevalence of 
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resistance to SM in many parts of the world has decreased its overall usefulness. The remaining drugs 
are reserved for special situations such as drug intolerance or resistance. 
There are four basic treatment regimens recommended for treating adults with TB disease caused 
by organisms that are known or presumed to be susceptible to INH, RIF, PZA, and EMB. Each 
treatment regimen consists of an initial 2-month treatment phase followed by a continuation phase 
of either 4 or 7 months. The 4-month continuation phase is used for the majority of patients. 
Although these regimens are broadly applicable, there are modifications that should be made under 
specified circumstances.
Adverse reactions to anti-TB drugs are relatively rare, but in some patients they may be severe. 
Clinicians who treat TB disease should be familiar with the methods of monitoring for adverse 
reactions and patients’ response to treatment. In some situations (drug-resistant TB disease, 
pregnancy, HIV-infected patients), expert consultation should be sought. 
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Chapter Objectives
After working through this chapter, you should be able to 
 • Describe the factors that determine the infectiousness of a tuberculosis (TB) patient;
 • Explain the main goals of a TB infection control program;
 • Discuss the three levels of an effective TB infection control program;
 • Explain the purpose and the characteristics of a TB airborne infection isolation room; and
 • Describe the circumstances when respirators and surgical masks should be used.
Chapter 7  
Tuberculosis Infection Control
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Introduction
M. tuberculosis can be transmitted in virtually any setting. Clinicians should be aware that 
transmission has been documented in health-care settings where health-care workers (HCWs) and 
patients come in contact with persons with infectious TB who 
 • Have unsuspected TB disease,
 • Have not received adequate or appropriate treatment, or
 • Have not been separated from others.
Health-care settings in this context include clinics and hospitals, as well as nontraditional facility-
based settings such as emergency medical services, correctional facilities, home-based health-care  
and outreach settings, long-term care facilities, and homeless shelters. People who work or receive 
care in health-care settings (as referenced above) are at higher risk for becoming infected with  
M. tuberculosis; therefore, it is necessary to have a TB infection control plan as part of a general 
infection control program designed to ensure the following:
 • Prompt detection of TB;
 • Airborne precautions; and
 • Treatment of persons who have been suspected or confirmed to have TB disease  
(see Chapter 2, Transmission and Pathogenesis of Tuberculosis). 
People who work or receive care in health-care settings are at 
higher risk for becoming infected with M. tuberculosis; therefore, 
it is necessary to have a TB infection control plan.
Study Question
7.1 In which of the following health-care settings can TB be transmitted?  
(circle the one best answer)
F. Where TB patients have not received adequate and appropriate treatment.
G. Where TB patients have not been separated from others. 
H. Where persons who have unsuspected TB disease come into contact with others.
I. A, B, and C are all correct.
J. Only A and B are correct.
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Infectiousness
The infectiousness of a TB patient is directly related to the number of droplet nuclei carrying  
M. tuberculosis (tubercle bacilli) that are expelled into the air. Depending on the environment, these 
tiny particles can remain suspended in the air for several hours. M. tuberculosis is transmitted through 
the air, not by surface contact. Infection occurs when a person inhales droplet nuclei containing 
M. tuberculosis, and the droplet nuclei traverse the mouth or nasal passages, upper respiratory 
tract, and bronchi to reach the alveoli of the lungs. Persons with extrapulmonary TB disease may 
have concurrent unsuspected pulmonary or laryngeal TB disease. Except for laryngeal TB disease, 
extrapulmonary TB disease is rarely infectious; however, transmission from extrapulmonary sites has 
been reported to occur during aerosol-producing procedures such as autopsies and tissue irrigation. 
The characteristics of a patient with TB disease that are associated with infectiousness include, but 
are not limited to, those listed in Table 7.1. 
The infectiousness of a TB patient is directly related to the number of droplet 
nuclei carrying M. tuberculosis (tubercle bacilli) that are expelled into the air.
Infection occurs when a person inhales droplet nuclei containing  
M. tuberculosis, and the droplet nuclei traverse the mouth or nasal passages, 
upper respiratory tract, and bronchi to reach the alveoli of the lungs.
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Table 7.1 
Infectiousness of People Known to 
Have or Suspected of Having TB Disease* 
Factors Associated with  
Noninfectiousness
Factors Associated with 
Infectiousness
No cough Presence of a cough
No cavity in the lung Cavity in the lung
No acid-fast bacilli on sputum smear Acid-fast bacilli on sputum smear
Extrapulmonary (non-pulmonary) TB disease TB disease of the lungs, airway, or larynx
Receiving adequate treatment for 2 weeks or 
longer
Not receiving adequate treatment
Not undergoing cough-inducing procedures Undergoing cough-inducing procedures 
(e.g., bronchoscopy, sputum induction, and 
administration of aerosolized medications)
Negative sputum cultures Positive sputum cultures
  * Infectiousness depends on a variety of factors. Clinicians should consider all of these factors when 
determining whether a TB patient should be considered infectious.
In general, young children with pulmonary TB disease are less likely than adults to be infectious, 
because children are sometimes unable to produce sputum when they cough, or may have 
paucibacillary TB. However, it is still possible for children to transmit M. tuberculosis to others if  
they have infectious characteristics, such as a positive AFB smear or cavity on a chest radiograph.
In general, young children with pulmonary TB disease are less likely 
than adults to be infectious, because children are sometimes unable to 
produce sputum when they cough, or may have paucibacillary TB.
For most patients, infectiousness appears to decline rapidly after adequate and appropriate 
treatment is started; however, the rate of decline varies from patient to patient. Some patients with 
unrecognized or inadequately treated drug-resistant TB disease may remain infectious for weeks or 
even months. Patients with drug-resistant TB disease may not respond to the initial drug regimen, 
acquire further drug resistance, and remain infectious until they receive adequate treatment.
Infectiousness appears to decline rapidly after adequate and appropriate 
treatment is started; however, the rate of decline varies from patient to patient.
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Persons with extrapulmonary TB disease are usually noninfectious unless they also have pulmonary 
disease, TB disease located in the oral cavity or the larynx, or extrapulmonary disease that includes 
an open abscess or lesion in which the concentration of organisms is high. Pulmonary TB should be 
ruled out when there is a diagnosis of extrapulmonary TB disease. Table 7.2 indicates the criteria for 
patients to be considered noninfectious. 
Table 7.2  
Criteria for Patients to Be Considered Noninfectious
Criteria
Patients can be considered noninfectious when they meet all of the following three criteria:
1. They have three consecutive negative AFB sputum smears collected in 8- to 24-hour intervals 
(at least one being an early morning specimen);
2. Their symptoms have improved clinically (for example, they are coughing less and they no 
longer have a fever); and
3. They are compliant with an adequate treatment regimen for 2 weeks or longer. 
It is important to consider the environmental factors that enhance the probability that M. tuberculosis 
will be transmitted (Table 7.3). 
Table 7.3 
Environmental Factors that Enhance the Probability that  
M. tuberculosis Will Be Transmitted
Factor Description
Concentration of 
infectious bacilli
The more bacilli in the air, the more probable that  
M. tuberculosis will be transmitted
Space Exposure in small, enclosed spaces
Ventilation Inadequate local or general ventilation that results in 
insufficient dilution or removal of infectious droplet nuclei
Air circulation Recirculation of air containing infectious droplet nuclei
Specimen handling Improper specimen handling procedures that generate 
infectious droplet nuclei
Air pressure Positive air pressure in infectious patient’s room that causes 
M. tuberculosis organisms to flow to other areas
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Study Questions
Indicate if the following statements about infectiousness are true or false.  
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Patients True or False
____  7.2 Children are more likely than adults to be infectious.
____  7.3 For most patients, infectiousness appears to decline 
rapidly after adequate treatment is started.
____  7.4 Some patients with unrecognized or inadequately treated 
drug-resistant TB disease may remain infectious for 
weeks or even months.
____  7.5 Patients with drug-resistant TB disease may not respond 
to the initial drug regimen, acquire further drug 
resistance, and may remain infectious until they receive 
adequate treatment.
A. True
B. False
7.6 Patients can be considered noninfectious when they meet which of the following criteria?  
(choose the one best answer)
A. They are compliant with an adequate regimen for 2 weeks or longer. 
B. Their symptoms have improved clinically.
C. They have three consecutive negative sputum smears collected in 8- to 24-hour intervals 
(at least one being an early morning specimen).
D. A, B, and C are all correct.
E. Only A and B are correct.
7.7 Which of the following environmental factors can enhance the probability that  
M. tuberculosis will be transmitted?  
(choose the one best answer)
A. Concentration of infectious bacilli in the air
B. Exposure in small, enclosed spaces
C. Inadequate local or general ventilation that results in insufficient dilution or removal of 
infectious droplet nuclei
D. A, B, and C are all correct.
E. Only A and B are correct.
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TB Infection Control Measures
TB infection control measures should be based on a careful assessment of risk for transmission of TB 
in the facility or setting. The goals of effective TB infection control programs are to 
 • Detect TB disease early and promptly;
 • Isolate those who have or are suspected of having TB disease (airborne precautions); and
 • Treat people who have or who are suspected of having TB disease.
TB infection control measures should be based on a careful 
assessment of risk for transmission of TB in the facility or setting.
Detection of TB Disease
The primary risk to health-care workers (HCWs) and the general population is the undiagnosed or 
unsuspected patient with TB disease. Within health-care settings, protocols should be implemented 
and enforced to promptly identify, isolate, separate, and either transfer or manage persons who have 
suspected or confirmed TB disease. Personnel who admit patients to facilities should be trained to 
detect signs and symptoms of TB disease. People suspected of having TB disease should be given 
a diagnostic evaluation as soon as possible (see Chapter 4, Diagnosis of Tuberculosis Disease). 
Clinicians and other HCWs should suspect TB disease in people who have any of the symptoms 
listed in Table 7.4 and isolate them until TB is excluded.
Table 7.4  
Symptoms of TB Disease
Symptoms
People who have any of the following symptoms should 
be evaluated for TB disease:
 • Persistent cough (3 weeks or longer);
 • Chest pain;
 • Bloody sputum;
 • Weight loss or loss of appetite;
 • Fever; 
 • Chills; 
 • Night sweats;
 • Malaise; or
 • Fatigue
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The primary risk to health-care workers (HCWs) and the general 
population is the undiagnosed or unsuspected patient with TB disease.
Airborne Precautions
TB airborne precautions should be initiated for any patient who has signs or symptoms of TB disease 
(suspected TB), or who has documented infectious TB disease and remains infectious in spite of 
treatment.
TB airborne precautions should be initiated for any patient who has 
signs or symptoms of TB disease (suspected TB), or who has documented 
infectious TB disease and remains infectious in spite of treatment.
Persons who have or are suspected of having infectious TB disease should be placed in an area 
away from other patients, preferably in an airborne infection isolation (AII) room. An AII room is 
a single-occupancy patient-care room in which environmental factors are controlled to minimize 
transmission of infectious agents. If a facility does not have an AII room, patients should be placed 
in a room that has been designated for isolation of persons with suspected or known infectious TB 
disease and, if possible, referred to a facility with an AII room.
A patient who has drug-susceptible TB of the lung, airway, or larynx, who is on standard multidrug 
antituberculosis treatment, and who has had a substantial clinical and bacteriologic response to 
therapy (e.g., reduction in cough, resolution of fever, and progressively decreasing quantity of AFB 
on smear result) is probably no longer infectious. However, because culture and drug-susceptibility 
results are not usually known when the decision to discontinue airborne precautions is made, all 
patients with suspected TB disease should remain under airborne precautions until they have had 
three consecutive negative AFB sputum smear results, each collected in 8- to 24-hour intervals, with 
at least one being an early morning specimen; have received standard multidrug antituberculosis 
treatment (minimum of 2 weeks); and have demonstrated clinical improvement.
Airborne precautions in a health-care or congregate setting may 
be discontinued when a patient has been on adequate therapy 
for 2 weeks or longer, symptoms improve, and there have been 
three consecutive, negative AFB sputum smear results. 
Treatment 
Patients who have confirmed TB disease, or who are considered highly probable to have TB disease, 
should promptly start appropriate treatment (see Chapter 6, Treatment of Tuberculosis Disease).
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Study Questions
7.8 Which of the following is NOT a goal of an effective TB infection control program? 
(choose the one best answer)
A. Detect TB disease early and promptly.
B. Isolate from others those people who have or are suspected of having TB disease.
C. Ensure everyone wears a personal respirator.
D. Treat people who have or are suspected of having TB disease.
7.9 The primary risk to health-care workers and the general population is the undiagnosed or 
unsuspected patient with TB disease.  
(choose the one best answer)
A. True
B. False
7.10 TB airborne precautions should be initiated for which of the following patients?  
(choose the one best answer)
A. Any patient who has signs or symptoms of TB disease
B. Any patient who has documented infectious TB disease and remains infectious  
in spite of treatment
C. Any patient who has TB meningitis
D. A, B, and C are all correct.
E. Only A and B are correct.
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TB Infection Control Program
A TB infection control program should be based on the following three levels of hierarchy (Table 7.8):
1. Administrative controls, which reduce risk of exposure;
2. Environmental controls, which prevent spread and reduce concentration of droplet nuclei; 
and
3. Respiratory-protection controls, which further reduce risk of exposure in special areas and 
circumstances.
1. Administrative Controls
The first and most important level of a TB infection control program is the use of administrative 
measures to reduce the risk of exposure to persons who might have TB disease. Administrative 
controls consist of implementing the following activities:
 • Assigning someone the responsibility and authority for TB infection control in the health-care 
setting;
 • Conducting a TB infection control risk assessment of the setting;
 • Developing and instituting a written TB infection control plan to ensure prompt detection, 
separation from others (into an AII room if possible), and treatment of persons who have 
suspected or confirmed TB disease;
 • Ensuring the availability of recommended laboratory processing, testing, and reporting of 
results;
 • Implementing effective work practices for managing patients who may have TB disease;
 • Ensuring proper cleaning, sterilization, or disinfection of equipment that might be 
contaminated (e.g., endoscopes); 
 • Educating, training, and counseling HCWs, patients, and visitors about TB infection and 
disease;
 • Testing and evaluating workers who are at risk for exposure to TB disease;
 • Applying epidemiology-based prevention principles, including the use of setting-related TB 
infection control data;
 • Using posters and signs to remind patients and staff of proper cough etiquette (covering mouth 
when coughing) and respiratory hygiene; and
 • Coordinating efforts between local health department and high-risk health-care and congregate 
settings.
The first and most important level of a TB infection control 
program is the use of administrative measures to reduce the 
risk for exposure to persons who might have TB disease.
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Health-Care Worker Education and Training
Health-care worker (HCW) education and training on TB infection and disease is an essential part 
of a TB infection control program and can increase adherence to TB infection control measures. 
Education and training should emphasize the increased risks posed by an undiagnosed person with 
TB disease in a health-care setting and the specific measures to reduce this risk. Health-care settings 
should document that all HCWs, including physicians, have received training relevant to their work 
setting. Resources for TB education and training can be found on the following websites:
 • CDC DTBE website (www.cdc.gov/tb);
 • Find TB Resources website (www.findtbresources.org); and
 • Regional Training and Medical Consultation Centers’ TB Training and Education Products 
website (https://sntc.medicine.ufl.edu/rtmccproducts.aspx.)
All health-care settings should conduct an annual evaluation for follow-up education and training 
based on the
 • Number of untrained or new HCWs;
 • Changes in the organization and services of the health-care setting; and 
 • Availability of new TB infection control information. 
Facility Risk Assessment
Health-care and congregate settings should conduct an annual evaluation of the risk for transmission 
of M. tuberculosis. The risk assessment determines the type of administrative, environmental, and 
respiratory-protection controls needed by examining the
 • Number of patients with TB disease in the setting; 
 • Promptness of detection, isolation, and evaluation of patients with suspected or confirmed TB 
disease;
 • Evidence of transmission of M. tuberculosis in the setting; and
 • Community rate of TB disease.
Health-care and congregate settings should conduct an annual 
evaluation of the risk for transmission of M. tuberculosis.
Risk Classification
The purpose of the risk classification is to determine the need for a TB testing program for HCWs 
and the frequency of testing. The risk classification, or risk level, will vary; however, all settings 
should perform risk classification as part of risk assessment to determine the need for and frequency 
of a HCW testing program, regardless of the likelihood of encountering persons with TB disease. 
Baseline TB testing should be conducted for HCWs upon hiring (see Chapter 3, Testing for 
Tuberculosis Infection and Disease). The three TB risk classifications are indicated in Table 7.5. 
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Table 7.5 
TB Risk Classifications
Risk 
Classification
Need for 
Testing
Frequency of 
Testing
Low risk Should be used for settings in 
which persons with TB disease are 
not expected to be encountered.
Exposure to M. tuberculosis in 
these settings is unlikely, and 
further testing is not needed 
unless exposure has occurred. 
Medium risk Should be used for facilities in 
which the risk assessment has 
determined that HCWs will possibly 
be exposed to persons with TB 
disease.
Repeat testing should be done 
annually.
Potential ongoing 
transmission
Should be temporarily assigned to 
any setting where there is evidence 
of person-to-person transmission of 
M. tuberculosis in the past year.
Testing should be repeated 
every 8 to 10 weeks until there 
is no evidence of ongoing 
transmission.
2. Environmental Controls
The second level of hierarchy is the use of environmental controls to prevent the spread and reduce 
the concentration of droplet nuclei and includes:
 • Primary environmental controls; and
 • Secondary environmental controls (Table 7.6).
The second level of hierarchy is the use of environmental controls to 
prevent the spread and reduce the concentration of droplet nuclei.
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Table 7.6  
Environmental Controls
Primary Environmental
Control
Secondary Environmental 
Control
Controls the source of infection by diluting 
and removing contaminated air and by using 
general ventilation
 • Uses natural ventilation (e.g., open doors, 
windows)
 • Uses mechanical ventilation equipment to 
circulate and move air in a building 
 • Uses local exhaust ventilation (e.g., hoods, 
tents, or booths) 
Controls airflow in areas adjacent to the 
source and cleans air
 • Controls the airflow to prevent 
contamination of air in areas adjacent to 
the source (AII rooms) 
 • Cleans the air by using high efficiency 
particulate air (HEPA) filtration or 
ultraviolet germicidal irradiation (UVGI)
Primary Environmental Controls
Primary environmental controls consist of controlling the source of infection by using local exhaust 
ventilation (e.g., hoods, tents, or booths) and diluting and removing contaminated air by using 
general ventilation.
Ventilation is the movement and the replacement of air in a building with air from the outside or 
with clean, recirculated air. When fresh air enters a room, it dilutes the concentration of particles in 
room air, such as droplet nuclei. There are two types of ventilation:
 • Natural ventilation 
 • Mechanical ventilation
Natural Ventilation
Natural ventilation relies on cross ventilation in a building designed for good air exchange; for 
example, the use of open doors and windows to bring in air from outside. Natural ventilation can be 
useful for nontraditional facility-based and congregate settings that do not have a central ventilation 
system. In these settings, waiting rooms, shelter dormitories, or other rooms in which people 
congregate should have an operable window, door, or skylight that is kept open as often as possible. 
Fans can be used to help distribute the air (Figure 7.1). If the direction of airflow is unknown, staff 
should sit near the fresh air source and clients should sit near the exhaust location (Figure 7.2). 
This can help protect staff from droplet nuclei expelled by patients with unidentified TB disease. 
In addition to these environmental measures, cough etiquette and respiratory hygiene should be 
encouraged to further reduce risk (Figure 7.3).
Chapter 7 – Tuberculosis Infection Control
203
Figure 7.1 
Exhaust Fan Used for Distributing Air
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Figure 7.2 
Natural Ventilation in TB Exam or Counseling Room
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Figure 7.3 
Person with Infectious TB in Waiting Room
Mechanical Ventilation
Mechanical ventilation refers to the use of equipment to circulate and move air in a building. 
Mechanical ventilation should be used by hospitals, TB clinics, and other health-care and congregate 
settings expecting to see a confirmed or suspected TB patient. Mechanical ventilation consists of
 • Local exhaust ventilation; and 
 • General ventilation.
Local exhaust ventilation stops airborne contaminants before they spread into the general 
environment. Local exhaust ventilation includes the use of
 • External hoods;
 • Booths; and
 • Tents. 
Local exhaust ventilation should be used for cough-inducing and aerosol-generating procedures 
(Figure 7.4). If local exhaust ventilation cannot be used, cough-inducing and aerosol-generating 
procedures should be performed in an AII room. If an AII room is not available, the procedures 
should be performed outdoors and away from
 • People;
 • Windows; and
 • Air intakes. 
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Figure 7.4 
Local Exhaust in Sputum Collection Booth
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General ventilation systems maintain air quality in health-care settings by the 
 • Dilution of contaminated air;
 • Removal of contaminated air; and 
 • Control of airflow patterns in the patient’s procedure room or setting  
(e.g., negative pressure in AII rooms) (Figure 7.5). 
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Figure 7.5 
Airborne Infection Isolation (AII) Room
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TB AII rooms are designed to prevent the spread of droplet nuclei expelled by a patient with TB 
disease. In TB clinics, hospitals, and other inpatient settings, patients known to have TB disease or 
suspected of having TB disease should be placed in a TB AII room immediately. Health-care facilities 
that provide care for patients with suspected or confirmed TB disease should have at least one AII 
room. Medical facilities in correctional settings should also have at least one AII room. The need for 
additional AII rooms should be based on the TB risk assessment for the setting. 
In TB clinics, hospitals, and other inpatient settings, patients 
known to have TB disease or suspected of having TB disease 
should be placed in a TB AII room immediately.
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Health-care facilities that provide care for patients with 
suspected or confirmed TB disease and medical facilities in 
correctional settings should have at least one AII room.
One characteristic of AII rooms is their negative pressure relative to other parts of the facility. 
Negative pressure causes air to flow from the corridors into the AII room. The air from the AII room 
cannot escape to the other parts of the health-care setting when the door is closed and the ventilation 
system is operating properly. The doors and windows of AII rooms must be kept closed as much as 
possible in order to maintain negative pressure, and the pressure must be checked periodically to 
make sure that it remains negative. Air from the AII room can be exhausted directly to the outdoors, 
where the droplet nuclei will be diluted in the outdoor air, or passed through a special high efficiency 
particulate air (HEPA) filter that removes most (99.97%) of the droplet nuclei before it is returned 
to the general circulation. If a HEPA filter is not used, the air should be exhausted directly to the 
outside away from air-intake vents, persons, and animals, in accordance with applicable federal, state, 
and local regulations on environmental discharges. 
One characteristic of AII rooms is the negative pressure 
relative to other parts of the facility. Negative pressure allows 
air to flow from the corridors into the AII room.
Air from the AII room can be exhausted directly to the outdoors, where 
the droplet nuclei will be diluted in the outdoor air, or passed through a 
special high efficiency particulate air filter that removes most (99.97%) 
of the droplet nuclei before it is returned to the general circulation.
In existing health-care settings, AII rooms should have airflow of six or more air changes per hour 
(ACH). In new or renovated health-care settings, AII rooms should have airflow of at least 12 ACH. 
When feasible, the airflow in existing health-care setting AII rooms should be increased to 12 ACH by
 • Adjusting or modifying the ventilation system; or
 • Using air-cleaning methods: room-air recirculation units containing HEPA filters or ultraviolet 
germicidal irradiation (UVGI) systems that increase the equivalent ACH. 
It is important that AII rooms be single-patient rooms with a private bathroom. Entry of visitors 
and HCWs should be restricted and monitored to minimize the transmission of M. tuberculosis. 
All HCWs who enter an AII room should wear N95 disposable filtering facepiece respirators (see 
Respiratory-Protection Controls). An N95 respirator should be fitted correctly before using. Visitors 
should be offered and encouraged to use respiratory protection (i.e., N95 respirator) and instructed 
by HCWs on how to use it.
Health-care settings with AII rooms should observe the policies and practices indicated in Table 7.7. 
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Table 7.7  
Policies and Practices for Airborne Infectious Isolation  
(AII) Rooms in Health-Care Settings
Policies and Practices
 • Keep doors and windows closed as much as possible;
 • Maintain an adequate number of AII rooms;
 • Check negative pressure by monitoring and recording the direction of airflow 
on a daily basis;
 • Perform diagnostic and treatment procedures in the AII room;
 • Ensure patients adhere to AII precautions;
 • Group AII rooms in one part of the health-care setting;
 • Schedule patients with suspected and confirmed infectious TB disease for 
procedures when few HCWs and no other patients are present; 
 • Provide a surgical mask for patients with suspected or confirmed infectious TB 
disease during transport, in waiting areas, and when others are present; and
 • Review environmental control maintenance procedures and logs to determine 
if maintenance is being conducted properly and regularly.
Secondary Environmental Controls
Secondary environmental controls consist of controlling the airflow to prevent contamination of air 
in areas adjacent to the source (AII rooms) and cleaning the air by using HEPA filtration (Figure 7.6) 
or ultraviolet germicidal irradiation (UVGI) (Figure 7.7). HEPA filters can be used to filter droplet 
nuclei from the air and must be used when discharging air from: 
 • Local exhaust ventilation booths or enclosures directly into the surrounding room or area; and 
 • An AII room (or other negative-pressure room) into the general ventilation system (e.g., in 
settings in which the ventilation system or building configuration makes venting the exhaust to 
the outside impossible). 
Secondary environmental controls consist of controlling the airflow  
to prevent contamination of air in areas adjacent to the source  
(AII rooms) and cleaning the air by using HEPA filtration or UVGI.
UVGI is an air-cleaning technology that consists of the use of special lamps that give off germicidal 
ultraviolet irradiation (wave length=254 nm). The lamps are used to inactivate the tubercle bacilli 
contained in the droplet nuclei. Overexposure to UV light can be harmful to the skin and eyes; 
lamps must be installed in the upper part of rooms or corridors or placed in exhaust ducts. Regular, 
appropriate maintenance is essential to ensure UVGI lamps are operating correctly.
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Figure 7.6 
HEPA Filter
Figure 7.7 
Ultraviolet Germicidal Irradiation (UVGI)
3. Respiratory-Protection Controls
Respiratory-protection control is the third level of a TB infection control program and consists of the 
use of personal protective equipment in situations that pose a high risk for exposure to TB disease 
(Figure 7.8). Use of respiratory protection can further reduce risk for exposure of HCWs to droplet 
nuclei expelled into the air. The following measures can be taken to reduce risk for exposure:
 • Implementing a respiratory-protection program;
 • Training HCWs on respiratory protection; and
 • Educating patients on respiratory hygiene and the importance of cough etiquette.
Respiratory-protection control is the third level of a TB infection 
control program and consists of the use of protective equipment 
in situations that pose a high risk for exposure to TB disease.
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Figure 7.8 
Health-Care Worker and Infectious TB Patient 
Using Respiratory Protection
All health-care settings that use respiratory-protection controls are required by the Occupational 
Safety and Health Administration (OSHA) to develop, implement, and maintain a respiratory-
protection program. 
Administrative and environmental controls minimize the number of areas in which exposure to 
M. tuberculosis might occur and therefore minimize the number of persons exposed. These control 
measures also reduce, but do not eliminate, the risk for exposure in limited areas. In these settings, 
respiratory protection should be used by all persons, including HCWs and visitors. These settings 
include:
 • TB AII rooms;
 • Rooms where cough-inducing or aerosol generating procedures are done;
 • Ambulances and other vehicles transporting infectious TB disease patients; and
 • Homes of infectious TB disease patients (for HCWs; other persons should not visit the homes 
of infectious persons).
The effectiveness of a respiratory-protection program requires the development of written standard 
procedures. Standard procedures should include information and guidance for the proper selection, 
use, and care of respirators. Settings where HCWs use respiratory protection to prevent transmission 
of M. tuberculosis should develop, implement, and maintain a respiratory-protection program. The 
program should provide HCWs with annual training on TB control, TB infection control, and 
respiratory protection, including fit-testing.
Settings where HCWs use respiratory protection to prevent 
transmission of M. tuberculosis should develop, implement, 
and maintain a respiratory-protection program.
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The minimum respiratory protection is a filtering face-piece respirator and must be selected from 
those approved by CDC/National Institute for Occupational Safety and Health (NIOSH) under 
Title 42 CFR, Part 84. It must meet one of the following specifications:
 • Nonpowered air-purifying respirators (N95, N99, N100, R95, R99, R100, P95, P99, and 
P100), including disposables; 
 • Powered air-purifying respirators (PAPRs) with high-efficiency filters; or
 • Supplied-air respirators.
It is important that respirators fit different face sizes and features properly. It is also important to 
understand the difference between respirators and surgical masks.
Respirators are designed to protect HCWs and other individuals from inhaling droplet nuclei (Figure 
7.9). Surgical masks are designed to reduce the number of droplets being exhaled into the air by 
persons with infectious TB disease when they breathe, talk, cough, or sneeze (Figure 7.10). Persons 
suspected or confirmed to have infectious TB disease should be given, and encouraged to use, a 
surgical mask to minimize the risk of expelling droplet nuclei into the air. 
Respirators are designed to protect HCWs and other 
individuals from inhaling droplet nuclei. 
Surgical masks are designed to reduce the number of droplets 
being exhaled into the air by persons with infectious TB 
disease when they breathe, talk, cough, or sneeze. 
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Figure 7.9 
Respirator for 
Health-Care Workers
Figure 7.10 
Surgical Mask for  
Persons with Infectious TB Disease
Health-care worker wearing 
a respirator
Infectious TB patient wearing 
a surgical mask
Respirators
 • Designed to filter out droplet nuclei from 
being inhaled by the health-care worker 
and other individuals.
 • Should properly fit different face sizes and 
features.
 • Should NOT be worn by the patient.
Surgical masks
 • Designed to stop droplet nuclei from 
being spread (exhaled) by the patient.
 • Should NOT be worn by the health-care 
worker
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Table 7.8 
TB Infection-Control Program: Level of Controls
Administrative Controls
 • Assign responsibility for TB infection control 
 • Conduct TB risk assessment  
 • Develop and institute a written TB infection-control plan 
 • Ensure the timely availability of recommended laboratory processing, testing, and  
reporting of results
 • Implement effective work practices for the management of patients with suspected  
or confirmed TB disease
 • Ensure proper cleaning and sterilization or disinfection of potentially contaminated 
equipment  
 • Train and educate health-care workers 
 • Test and evaluate health-care workers for TB infection and disease
 • Apply epidemiology-based prevention principles 
 • Use posters and signs demonstrating and advising respiratory hygiene and cough 
etiquette
 • Coordinate efforts with the local or state health department.
Environmental Controls
 • Reduce concentration of infectious droplet nuclei through the following technologies:
 » Ventilation technologies, including
 − Natural ventilation
 − Mechanical ventilation
 » High efficiency particulate air filtration (HEPA) 
 » Ultraviolet germicidal irradiation (UVGI)
Respiratory Protection Controls
 • Implement a respiratory-protection program 
 • Train health-care workers on respiratory protection
 • Educate patients on respiratory hygiene and the importance of covering their cough
 • Test HCWs for mask fit and functionality
Chapter 7 – Tuberculosis Infection Control
215
Study Questions
Case study– Jose 
Jose, the Harris County TB Control Manager, is conducting a risk assessment to determine 
the type of administrative, environmental, and respiratory-protection controls that are 
needed in his area .
7.11 What things should Jose examine?  
(choose the one best answer)
A. Number of patients with TB disease in the setting and the community rate of TB disease
B. Evidence of transmission of M. tuberculosis in the setting
C. Promptness of detection, isolation, and evaluation of patients with suspected or confirmed 
TB disease. 
D. A, B, and C are all correct.
E. Only A and B are correct.
Match the setting and testing characteristics for each type of TB risk classification. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Setting and Testing Characteristics TB Risk Classification
____  7.12 Temporarily assigned to any setting with evidence 
of person-to-person transmission of M. tuberculosis 
in the past year.
____  7.13 Setting where persons with TB disease are not 
expected to be encountered.
____  7.14 Facilities in which the risk assessment has 
determined that health-care workers will  
possibly be exposed to persons with TB disease.
____  7.15 Repeat testing is not needed unless exposure  
has occurred.
____  7.16 Repeat testing should be done every 8 to 10 weeks 
until there is no evidence of ongoing transmission. 
____  7.17 Repeat testing should be done annually.
A. Low-risk 
classification
B. Medium-risk 
classification
C. Potential ongoing 
transmission 
classification
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Indicate whether the types of environmental controls below are primary or secondary controls. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Environmental  
Controls
Primary/Secondary 
Controls
____  7.18 HEPA filtration
____  7.19 Natural, mechanical, and local exhaust  ventilation
____  7.20 Ultraviolet germicidal irradiation 
____  7.21 Controls airflow in areas adjacent to the source and 
cleans air
____  7.22 Controls the source of infection by diluting and 
removing contaminated air and by using general 
ventilation
A. Primary control
B. Secondary control
Indicate if the following statements about TB airborne infection isolation (AII) rooms are true 
or false. (Choose the one best answer and write the letter for the correct answer on the line next to 
the question number.) 
Statements about TB AII Rooms True or False
____  7.23 Designed to prevent the spread of the droplet nuclei 
to other rooms in the facility.
____  7.24 Have positive pressure relative to other parts of the 
facility.
____  7.25 Air from the AII room is exhausted directly to the 
outdoors, or passes through a special filter that 
removes all of the droplet nuclei.
____  7.26 Entry of visitors and health-care workers should 
be restricted and monitored to minimize the 
transmission of M. tuberculosis.
____  7.27 Patients staying in AII rooms should wear N95 
disposable filtering face-piece respirators.
____  7.28 AII rooms can be used for multiple patients.
A. True
B. False
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7.29 Which of the following respiratory protection measures reduces risk for exposure to TB 
disease? (choose the one best answer)
A. Implementing a respiratory-protection program
B. Training health-care workers on respiratory protection
C. Educating patients on respiratory hygiene and the importance of cough etiquette
D. A, B, and C are all correct.
E. Only A and B are correct.
7.30 Which of the following statements about respiratory protection is true?  
(choose the one best answer)
A. Respirators are designed to protect health-care workers and other individuals from 
inhaling droplet nuclei.
B. Surgical masks are designed to reduce the number of droplets being exhaled into the air by 
persons with infectious TB disease. 
C. Health-care workers can wear surgical masks for protection against droplet nuclei, and 
persons with infectious TB disease can wear respirators to prevent the spread of TB.
D. A, B, and C are all correct.
E. Only A and B are correct.
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Match the activities with the type of TB infection control. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Activities TB Infection Controls
____  7.31 Use natural exhaust ventilation and mechanical 
ventilation to remove contaminated air.
____  7.32 Use personal protective equipment in situations that 
pose a high risk for exposure to TB disease.
____  7.33 Assign someone the responsibility and authority for 
TB infection control in the health-care setting.
____  7.34 Ensure the availability of recommended laboratory 
processing, testing, and reporting of results.
____  7.35 Control the airflow to prevent contamination of air 
in areas adjacent to the source and clean the air by 
using HEPA filtration or UVGI.
____  7.36 Conduct a TB infection control risk assessment of 
the setting.
A. Administrative 
controls
B. Environmental 
controls
C. Respiratory 
protection controls
TB Infection Control in  
Nontraditional Facility-Based Settings
All nontraditional facility-based settings where patients with TB disease receive care should establish 
and follow a TB infection control program. These settings include but are not limited to
 • Correctional facilities;
 • Homeless shelters;
 • Long-term care facilities; 
 • Home-based health-care and outreach settings; and
 • Emergency medical services (EMS) (Table 7.9).
All nontraditional facility-based settings where patients with TB disease 
receive care should establish and follow a TB infection control program.
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Correctional Facilities
TB disease can be a substantial health concern in correctional facilities. TB outbreaks in correctional 
facilities can lead to transmission in surrounding communities. Health-care settings in correctional 
facilities should be classified as at least medium risk based on the possibility of exposure to persons 
with TB disease. Correctional facilities overall are classified as minimal risk or non-minimal risk 
based on the TB risks of the population housed in the facility. A respiratory-protection program 
should be implemented with at least one AII room available where inmates with suspected or 
confirmed TB disease can be isolated immediately. Those inmates who must be transported should 
wear a surgical mask during transport. Correctional facilities should maintain a tracking system for 
inmate TB testing and treatment, and establish a mechanism for sharing this information with state 
and local health departments and other correctional facilities. 
Homeless Shelters
TB disease is more common in the homeless population than in the general population. Several 
factors in the shelter environment can influence the likelihood of M. tuberculosis transmission, 
including crowding and the state of the ventilation system. The absolute number and population 
density of persons sharing the same breathing space is important. If all other factors are constant, 
the size of the shelter population is directly proportional to the likelihood that someone with 
infectious TB will be present and that someone else will become infected. Conversely, the smaller 
the population and less crowded the shelter, the lower the risk. Homeless shelters should implement 
a tracking system for clients and establish a mechanism for sharing this information with state and 
local health departments when appropriate.
Long-Term Care Facilities
TB disease poses a health risk in long-term care facilities (LTCFs) such as hospice and skilled-nursing 
facilities. Transmission of M. tuberculosis has occurred in LTCFs and pulmonary TB disease has been 
documented in HIV-infected patients and other immunocompromised patients residing in hospices. 
LTCFs must have adequate administrative and environmental controls if they accept patients with 
suspected or confirmed infectious TB disease. These include airborne precaution capabilities and a 
respiratory-protection program. People most at risk in LTCFs include
 • Patients;
 • HCWs;
 • Visitors; and
 • Volunteers
Home-Based Health-Care and Outreach Settings
Transmission of M. tuberculosis has been documented in home-based health-care and outreach 
settings. HCWs in these settings should be able to
 • Evaluate signs and symptoms of TB disease for early detection and treatment;
 • Educate patients on the importance of reporting symptoms and signs of TB disease; and
 • Wear an N95 personal respirator when entering homes of persons with suspected or confirmed 
infectious TB disease or when transporting such persons in an enclosed vehicle.
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Emergency Medical Services (EMS)
Although the overall risk is low, there has been documented transmission of M. tuberculosis in EMS 
occupational settings. EMS personnel should be included in
 • Comprehensive training, education, and testing programs for TB infection; and
 • Follow-up testing as indicated by the risk classification of the setting. 
Drivers, HCWs, and other staff transporting patients with suspected or confirmed TB should wear 
an N95 respirator, and the patients should wear a surgical mask. In addition, ambulances should 
allow for the maximum amount of outdoor air to be circulated in the vehicle.
Table 7.9 
TB Infection Control for Nontraditional Settings
Setting Transmission of M. tuberculosis Screening/testing Recommendations
Correctional 
facilities
 • Substantial health 
concern
 • TB outbreaks in 
these settings can 
lead to transmission 
in surrounding 
communities
 • Heath-care settings 
in these facilities are 
at least medium risk
 • All correctional 
staff should be 
screened and 
tested for TB 
annually
 • Implement a respiratory-
protection program with at 
least one AII room or have a 
transfer policy
 • Inmates with suspected or 
confirmed TB disease should 
be isolated immediately and 
wear a surgical mask when 
being transported outside of 
an AII room
 • Facilities should maintain a 
tracking system for sharing 
information with state and 
local health departments and 
other correctional facilities
Homeless 
shelters
 • Occurs in these 
settings
 • More common in 
homeless shelters 
than in general 
population
 • Frequent visitors are 
at risk of exposure
 • Symptom 
screening
 • Evaluate the resident for 
signs and symptoms of TB 
disease for early detection and 
treatment
 • Educate staff on importance of 
reporting signs and symptoms 
of TB disease
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Setting Transmission of M. tuberculosis Screening/testing Recommendations
Long-
term care 
facilities
 • Occurs in these 
settings
 • Poses a health 
risk to patients, 
health-care workers, 
visitors, and 
volunteers
 • New employees 
and residents 
should receive  
symptom 
screening and 
possibly testing 
upon entry
 • Must have adequate 
administrative and 
environmental controls that 
include 
 » Airborn precaution 
capabilities
 » Respiratory-protection 
program
 • Patients with suspected 
or confirmed infectious TB 
disease should not stay 
in LTCFs unless adequate 
administrative and 
environmental controls  
are in place
Home-
based 
health-
care and 
outreach 
settings
 • Occurs in these 
settings
 • Symptom 
screening
 • Employees should 
receive annual 
screening and/or 
testing
 • Evaluate the resident for 
signs and symptoms of TB 
disease for early detection and 
treatment
 • Educate patients and staff on 
importance of reporting signs 
and symptoms of TB disease 
 • Wear an N95 respirator when 
entering homes of persons 
suspected of having infectious 
TB disease
Emergency 
medical 
services
 • Low health concern  • Include a 
comprehensive 
employee 
screening 
program to test 
for TB infection
 • Conduct follow-
up testing as 
indicated by the 
risk classification 
of the setting
 • Drivers, health-care workers, 
and other staff should wear an 
N95 respirator in a high-risk 
situation
 • Persons with suspected TB 
who are transported in an  
ambulance  should wear a 
surgical mask
 • Ambulances should allow for 
maximum amount of outdoor 
air to circulate in the vehicle
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Study Question
7.37 Which of the following statements about TB infection control in nontraditional  
settings is true?  
(choose the one best answer)
A. All nontraditional settings where patients with TB disease receive care should establish and 
follow a TB infection control program.
B. Nontraditional settings include correctional facilities, homeless shelters, long-term care 
facilities, home-based health-care, and emergency medical services. 
C. Emergency medical services has a documented overall high level of transmission of M. 
tuberculosis. 
D. A, B, and C are all correct.
E. Only A and B are correct.
TB Infection Control in the Home
Patients who are suspected to have, or have, confirmed TB disease are frequently sent home after 
starting treatment, even though they may still be infectious. Patients with TB disease can be sent 
home even if they do not have three negative sputum smears, if the following criteria are met:
 • A follow-up plan has been made with the local TB program;
 • The patient is on standard TB treatment, and directly observed therapy (DOT) has been 
arranged;
 • No infants or children less than 5 years of age or persons with immunocompromising 
conditions are present in the household; and
 • The patient is willing to remain isolated in the home except for health-care associated visits 
until the patient has negative sputum smear results.
Patients who have suspected or confirmed TB disease are more likely to have already transmitted 
TB infection to members of their household before their TB disease was diagnosed and treatment 
was started. However, TB patients and members of their household should take steps to prevent the 
further spread of TB infection after they return home (Table 7.10). Patients with TB disease should
 • Be instructed to cover their mouth and nose when coughing or sneezing;
 • Sleep alone and not in a room with other household members; and
 • Refrain from having visitors in the home until they are noninfectious.
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HCWs who visit TB patients in their homes should take the following precautions to protect 
themselves from exposure to M. tuberculosis (Table 7.10):
 • Instruct patients to cover their mouth and nose with a tissue when coughing or sneezing;
 • Wear a respirator when visiting the home of a patient with infectious TB disease or when 
transporting a patient with infectious TB disease in a vehicle; and
 • Collect specimens in a well ventilated area, away from other household members
In addition, HCWs whose responsibilities include visiting infectious patients should participate in 
an annual TB testing program.
Table 7.10 
TB Infection Control in the Home
Steps that 
Patients Can Take to Prevent the 
Further Transmission of TB  
in the Home
Precautions for 
Health-Care Workers to 
Take to Protect Themselves from 
Exposure to M. tuberculosis
 • Cover their mouth and nose when coughing 
or sneezing 
 • Sleep alone and not in a room with other 
household members
 • Refrain from having visitors in the home 
until they are noninfectious.
 • Instruct patients to cover their mouth 
and nose with a tissue when coughing or 
sneezing
 • Wear a respirator when visiting the home of 
a patient with infectious TB disease or when 
transporting a patient with infectious TB 
disease in a vehicle
 • Collect specimens in a well-ventilated area, 
away from other household members
Study Questions
7.38 Elton was just diagnosed with TB and is considered infectious. Lilian, his nurse, is 
instructing him about steps he can take to prevent the spread of TB infection to others 
when he returns home today. Which of the following steps should Lilian mention? 
(choose the one best answer)
A. Cover his mouth and nose when coughing or sneezing.
B. Do not have visitors until he is noninfectious.
C. It is ok to sleep in the same room with his wife.
D. A, B, and C are all correct.
E. Only A and B are correct.
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Lilian will be conducting DOT at Elton’s home starting tomorrow. Which of the following 
precautions should Lilian take to protect herself from exposure to TB? 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.) 
Precautions for Health-Care Workers 
Visiting the Home of a TB Patient 
Who May Be Infectious
Yes or No
____  7.39 Spray the room where they will meet with a 
disinfectant before Elton enters it.
____  7.40 Wear a respirator when visiting Elton’s home.
____  7.41 Wear a surgical mask when visiting Elton’s home.
____  7.42 Collect specimens in a well-ventilated area, away 
from other household members.
____  7.43 Refrain from touching any surfaces in the home.
A. Yes 
(take this precaution)
B. No 
(this is not an 
effective precaution)
Chapter Summary
M. tuberculosis can be transmitted in virtually any setting. Clinicians should be aware that 
transmission has been documented in health-care settings where HCWs and patients come in 
contact with persons with infectious TB who 
 • Have unsuspected TB disease,
 • Have not received adequate treatment, or
 • Have not been isolated from others.
The infectiousness of a TB patient is directly related to the number of droplet nuclei carrying  
M. tuberculosis (tubercle bacilli) that are expelled into the air. Depending on the environment, 
these tiny particles can remain suspended in the air for several hours. M. tuberculosis is transmitted 
only through the air, not by surface contact. Infection occurs when a person inhales droplet nuclei 
containing M. tuberculosis, and the droplet nuclei traverse the mouth or nasal passages, upper 
respiratory tract, and bronchi to reach the alveoli of the lungs. Persons with extrapulmonary 
TB disease may have concurrent unsuspected pulmonary or laryngeal TB disease. Except for 
laryngeal TB disease, extrapulmonary TB disease is rarely infectious; however, transmission from 
extrapulmonary sites has been reported to occur during aerosol-producing procedures such as 
autopsies and tissue irrigation.
For most patients, infectiousness appears to decline rapidly after adequate and appropriate 
treatment is started; however, the rate of decline varies from patient to patient. Some patients with 
unrecognized or inadequately treated drug-resistant TB disease may remain infectious for weeks or 
even months. Patients with drug-resistant TB disease may not respond to the initial drug regimen 
and may remain infectious until they receive adequate treatment.
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TB infection control measures should be based on a careful assessment of risk for transmission of TB 
in the facility or setting. The goals of effective TB infection control programs are to
 • Detect TB disease early and promptly;
 • Isolate those who have or are suspected of having TB disease (airborne precautions); and
 • Treat people who have or are suspected of having TB disease. 
The primary risk to HCWs and the general population is the undiagnosed or unsuspected patient 
with TB disease. Within health-care settings, protocols should be implemented and enforced to 
promptly identify, isolate, and either transfer or manage persons who have suspected or confirmed 
TB disease. Personnel who admit patients to facilities should be trained to detect signs and 
symptoms of TB disease.
A TB infection control program should be based on the following three levels of hierarchy:
1. Administrative controls, which reduce risk of exposure;
2. Environmental controls, which prevent spread and reduce concentration of droplet  
nuclei; and
3. Respiratory-protection controls, which further reduce risk of exposure in special  
areas and circumstances.
The first and most important level of a TB infection control program is the use of administrative 
measures to reduce the risk for exposure to persons who might have TB disease.
The second level of hierarchy is the use of environmental controls to prevent the spread and reduce 
the concentration of infectious droplet nuclei and includes primary and secondary controls.
Respiratory-protection control is the third level of a TB infection control program and consists  
of the use of protective equipment in situations that pose a high risk for exposure to TB disease.  
Use of respiratory protection can further reduce HCW risk of exposure to droplet nuclei expelled 
into the air.
All nontraditional facility-based settings where patients with TB disease receive care should establish 
and follow a TB infection control program. These settings include but are not limited to
 • Correctional facilities;
 • Homeless shelters;
 • Long-term care facilities; 
 • Home-based health-care and outreach settings; and
 • Emergency medical services;
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Patients who are suspected to have, or have, confirmed TB disease are frequently sent home after 
starting treatment, even though they may still be infectious. Patients with TB disease can be sent 
home even if they do not have three negative sputum smears, if the following criteria are met:
 • A follow-up plan has been made with the local TB program;
 • The patient is on standard TB treatment, and DOT has been arranged;
 • No infants or children less than 5 years of age or persons with immunocompromising 
conditions are present in the household unless they have been evaluated and started on 
treatment; and
 • The patient is willing to remain isolated in the home except for health-care associated visits 
until the patient has negative sputum smear results.
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Chapter Objectives
After working through this chapter, you should be able to 
 • Describe the roles and responsibilities for tuberculosis (TB) control and prevention  
in the public health sector; and
 • Describe the roles and responsibilities for TB control and prevention in the private  
health sector.
Chapter 8  
Community Tuberculosis Control
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Introduction
State and local health departments have the primary responsibility for preventing and controlling 
TB. However, TB control is a complex undertaking and requires the collaborative efforts of a broad 
range of persons, organizations, and institutions both inside and outside the public health sector. 
These various persons and organizations have a role in improving the detection of TB cases, one of 
the most important responsibilities of TB control, and include
 • Clinicians;
 • Community health centers;
 • Hospitals;
 • Academic institutions;
 • Medical professional organizations;
 • Community-based organizations;
 • Correctional facilities;
 • Civil surgeons; and
 • Pharmaceutical and biotechnology industries.
State and local health departments have the primary responsibility 
for preventing and controlling tuberculosis (TB).
Roles and Responsibilities of the Public Health Sector Providers
The essential role of the public health sector in TB control is to plan, coordinate, and evaluate TB 
control and prevention efforts. This role requires that state and local health departments focus and 
provide oversight on the following critical elements:
 • Planning and policy development;
 • Contact investigation; 
 • Clinical and diagnostic services for patients with TB and their contacts;
 • Training and education;
 • Surveillance data and information management; and
 • Monitoring and evaluation.
The essential role of the public health sector in TB control is to plan, 
coordinate, and evaluate TB control and prevention efforts.
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Planning and Policy Development
State and local TB control programs have the responsibility for developing TB control policies and 
procedures. A TB control plan should be developed in collaboration with community stakeholders 
and experts in medical and nonmedical TB management. Laboratory directors and professional 
organizations also make excellent partners to collaborate with when developing TB control policies. 
A TB control plan should be developed in collaboration with community 
stakeholders and experts in medical and nonmedical TB management.
The plan should be based on an understanding of local epidemiologic data and on the capabilities 
and capacities of clinical and support services for clients. Fiscal resources available for TB control 
also determine the plan’s scope and direction, as well as ongoing indicators of program performance 
(program evaluation). Policies and procedures should reflect national, state, and local standards of 
care and should offer guidance in the management of LTBI and TB disease. 
A written TB control plan should be updated regularly and distributed widely to partners. The TB 
control plan should
 • Assign specific roles and responsibilities; 
 • Define essential pathways of communication between providers, laboratories, and the public 
health system;
 • Assign sufficient resources, both human and financial, to ensure its implementation, including 
a responsible case manager for each suspected and verified case of TB disease;
 • Provide provisions for expert consultation and oversight for TB-related matters to clinicians, 
institutions, and communities;
 • Provide special guidance to local laboratories that process TB-related samples;
 • Assist local authorities in conducting contact or outbreak investigations and directly observed 
therapy (DOT); and 
 • Provide culturally appropriate information to patients, persons at risk, and the community.
A written TB control plan should be updated regularly 
and distributed widely to partners.
Systems to minimize or eliminate financial and cultural barriers to TB control should be integral 
to the plan. Persons with TB disease and persons at high risk for TB should receive culturally 
appropriate education about TB and clinical services, including treatment, without consideration for 
their ability to pay. 
The plan should be consistent with current legal statutes related to TB control. Relevant laws 
and regulations should be reviewed periodically and updated as necessary to ensure consistency 
with currently recommended clinical and public health practice (e.g., mandatory reporting laws, 
institutional infection control procedures, hospital and correctional system discharge planning, 
and involuntary confinement laws). The health department is legally responsible for ensuring that 
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a complete and timely contact investigation is done for the TB cases reported in its jurisdiction. 
Health departments should work closely with providers in the nonpublic health sector to ensure 
prompt reporting of suspected TB cases. They should understand the public health aspects of TB, 
including the need for prompt reporting and the facilitating role of the jurisdictional health agency 
in case management. Federal agencies should take the lead in resolving interstate TB-control issues, 
including movement of TB patients across state lines and multistate TB outbreaks. 
The health department is legally responsible for ensuring that a complete 
and timely contact investigation is done for the TB cases reported in its area. 
Health departments should work closely with providers in the nonpublic 
health sector to ensure prompt reporting of suspected TB cases. 
Clinical and Diagnostic Services for Patients with TB Disease  
and Their Contacts
TB control programs should ensure that patients with suspected or confirmed TB disease have ready 
access to diagnostic and treatment services that meet national standards. These services are often 
provided by state and/or locally supported TB specialty clinics and staffed by health department 
personnel or by contracted service providers. However, persons may seek medical care for TB 
infection or disease in the private medical sector. Regardless of where a person receives medical 
care, the primary responsibility for ensuring the quality and completeness of all TB-related services 
rests with state and local public health agencies. To ensure that standards of care are met, health 
departments should develop and maintain close working relationships with 
 • Local laboratories; 
 • Pharmacies; and 
 • Health-care providers.
Regardless of where a person receives medical care, the primary  
responsibility for ensuring the quality and completeness of all  
TB-related services rests with state and local public health agencies.
Clinical facilities should provide screening, diagnostics, and monitoring tests, including  
radiology services.
Radiology services include access to radiograph equipment, trained radiograph technicians,  
and radiograph interpretation by a qualified person. Radiograph findings and reports should be 
available within 24 hours.
Radiograph findings and reports should be available within 24 hours.
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Coordinating care with other health-care providers and facilities is crucial to the prevention and 
control of TB. TB patients often receive care in a variety of settings, including
 • Private practices;
 • Hospitals;
 • HIV clinics; 
 • Community clinics;
 • Correctional facilities; and 
 • Nursing homes. 
Treatment plans must be specific to individual patient needs. As patients move among these settings, 
continuity of care may be compromised unless a system is in place to provide coordination of care.
Expert medical consultation in TB should be available to the health-care community, especially 
for pediatric TB cases and for patients who have drug-resistant disease. Consultants may be health 
department employees or clinicians with TB expertise who are under contract with the health 
department.
Laboratory services should also be readily accessible to perform and provide results of AFB smear 
examinations within 24 hours of specimen collection. TB prevention and control programs should 
work closely with laboratories to ensure the rapid delivery of specimens to the laboratory and prompt 
reporting of AFB smear results, culture results, and results of drug-susceptibility tests to the clinician 
and health department. Laboratory services should also be available to provide monitoring of 
bacteriologic response to therapy.
Laboratory services should be readily accessible to 
perform and provide results of acid-fast bacilli (AFB) smear 
examinations within 24 hours of specimen collection.
Training and Education
TB control programs should provide education and training in the clinical and public health 
aspects of TB to all program staff. Staff members should receive education at regular intervals on 
their particular responsibilities in the program and should demonstrate proficiency in those areas. 
Based on the local epidemiology and needs, TB programs should also educate health-care providers 
(both public and private), community members, public health officials, and policy makers on TB 
prevention and control.
Based on the local epidemiology and needs, TB programs should educate 
health-care providers (both public and private), community members, 
public health officials, and policy makers on TB prevention and control.
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To ensure the availability of a competent TB workforce that understands and meets the needs of its 
community, state TB programs should use resources from CDC, the CDC-funded Regional Training 
and Medical Consultation Centers (RTMCCs), National Institutes of Health (NIH)-supported TB 
curriculum centers, the National TB Controllers Association (NTCA), and other national and local 
agencies to create and implement education activities. State and local TB programs should develop 
education and training programs with groups such as those listed in Table 8.1.
Table 8.1 
Groups Needing TB Education and Training Programs 
Agencies and Other Organizations Schools
 • Local health-care providers
 • Community-based organizations
 • Health-care institutions
 • Medicine
 • Nursing
 • Pharmacy
 • Dentistry
 • Public health
Surveillance and Information Management 
Surveillance and information management systems should be a priority of all TB control programs. 
Information technology can improve care of patients with TB disease through standardized 
collection of data and tracking of test results. Other benefits include ready access to details of 
treatment regimens, administration of DOT, and drug-drug interactions. Advancements in 
information technology allow for the analysis and rapid distribution of epidemiologic data, as  
well as management of individualized treatment plans.
Monitoring and Evaluation 
The systematic monitoring and evaluation of TB program activities is a critical factor in enhancing 
program performance. Evaluation techniques provide TB programs with an evidence-based means of 
assessing and improving their TB-control strategies by helping them understand what causes good or 
bad program performance. Evaluation can also be used for the following:
 • Program advocacy;
 • Assessing staffing needs;
 • Focusing training and capacity building;
 • Directing limited resources to the most productive activities;
 • Accounting for available resources;
 • Generating additional resources; and
 • Recognizing achievement. 
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TB control programs should develop priorities for program evaluation based on the TB issues or 
challenges in their jurisdiction and the way services are organized. In general, the first priority for 
evaluation efforts should be to focus on those activities and outcomes that relate most directly to the 
key strategies of TB control, which include:
 • Identifying patients with infectious TB disease and administering a complete course  
of treatment; 
 • Finding TB patient contacts and other persons at high risk with LTBI and treating them; and
 • Interrupting transmission of M. tuberculosis in high-risk settings. 
TB control programs should develop priorities for program 
evaluation based on the TB issues or challenges in their 
jurisdiction and the way services are organized.
Targets for program performance have been established by CDC to assist TB control programs in 
treating TB patients, identifying and examining their contacts, and improving the quality of case 
reporting for national surveillance. In addition, national objectives have been set for completing 
treatment for LTBI among contacts of infectious cases of TB disease. These national objectives 
for program performance provide a starting point for state and local TB control programs to use 
for program evaluation, but each TB control program should establish methods to evaluate its 
performance; for additional information, go to www.cdc.gov/tb/ .
Targets for program performance have been established by CDC to assist TB 
control programs in treating TB patients, identifying and examining their 
contacts, and improving the quality of case reporting for national surveillance.
National objectives have been set for completing treatment for 
LTBI among contacts of infectious cases of TB disease.
Other program areas that should be monitored through formal evaluation methods are
 • Timeliness and completeness of reporting of TB cases and suspected cases;
 • How often a recommended treatment regimen for patients with TB disease and  
LTBI is used; and
 • The quality of the program’s databases for surveillance and case management.
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Study Questions
8.1 What should a written TB control plan be based on?  
(choose the one best answer)
A. Local epidemiologic data and ongoing indicators of program performance.
B. Fiscal resources available for TB control.
C. Capabilities and capacities of clinical and support services for clients.
D. A, B, and C are all correct.
E. Only A and B are correct.
8.2 Which of the following is legally responsible for ensuring that a complete and timely 
contact investigation is done for the TB cases reported in its area/agency?  
(choose the one best answer)
A. Health department
B. Hospitals 
C. Private physicians
D. A, B, and C are all correct.
E. Only A and B are correct.
8.3 What should clinical facilities provide for TB patients and their contacts?  
(choose the one best answer)
A. Screening, diagnosis, and monitoring tests. 
B. Radiology services including access to radiograph equipment, trained radiograph 
technicians, and radiograph interpretation by a qualified person.
C. Radiograph findings and reports within 24 hours.
D. A, B, and C are all correct.
E. Only A and B are correct.
8.4 Laboratory services should provide results of AFB smear examinations within what time 
period? (choose the one best answer)
A. 24 hours
B. 72 hours
C. 1 week
D. 2 weeks
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8.5 TB programs are responsible for educating health-care providers (both public and 
private), community members, public health officials, and policy makers on TB 
prevention and control. (choose the one best answer)
A. True
B. False
8.6 Surveillance data and information management systems should be a priority for all TB 
programs. (choose the one best answer)
A. True
B. False
Roles and Responsibilities of  
Specific Private Health Sector Providers
The private health sector plays an important role in TB prevention and control and includes the 
following stakeholders: 
 • Clinicians;
 • Community health centers;
 • Hospitals;
 • Academic institutions;
 • Medical professional organizations;
 • Community-based organizations;
 • Correctional facilities;
 • Civil surgeons; and
 • Pharmaceutical and biotechnology industries.
To the extent possible, this varied group of providers should look for new ways to educate medical 
practitioners, and promote clinical and public health expertise necessary for TB elimination.
To the extent possible, this varied group of providers should look 
for new ways to educate medical practitioners, and promote clinical 
and public health expertise necessary for TB elimination.
Clinicians 
Clinicians in medical practice in the non-public health sector play a vital role in TB control 
throughout communities in the United States. Hospital or clinic-based medical practitioners, 
including those working in emergency departments, are usually the first source of medical care for 
persons with TB disease. These providers may also provide ongoing management of TB patients. 
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The role of medical practitioners in TB control will increase as TB morbidity in the United States 
decreases and jurisdictions reduce or even eliminate public health clinical services for TB. Private 
medical providers should strive for the following goals:
 • Understand prevalent medical conditions, including those with public health implications, of 
populations within their practice; 
 • Be aware of applicable state laws and regulations for reporting diseases and the need to report 
TB cases; 
 • Recognize the range of responsibilities that arise when TB disease is suspected in a patient 
under medical evaluation, including the following:
 » The need for prompt establishment of diagnosis; 
 » Use of consultants and hospitalization if indicated; 
 » Reporting the suspected TB case to the state and local public health agency and 
cooperating with subsequent public health activities; and 
 » Developing, in partnership with the public health agency, a treatment plan that optimizes 
the likelihood that the patient will complete the recommended course of therapy; 
 • Incorporate current recommendations for diagnosis, standard treatment of TB disease, and 
targeted testing and treatment of LTBI;
 • Be able to place and read tuberculin skin tests or administer blood tests for TB infection, rule 
out suspected TB disease, and administer and monitor treatment for LTBI;
 • Screen all new patients for symptoms of TB disease and risk factors for LTBI and give those 
with risk factors a TB skin or blood test; and
 • For patients receiving treatment, review risk factors that can suppress the immune system 
Expert medical consultation in TB should be available to the health-care community, especially for 
patients who have drug-resistant disease or medical diagnoses that might affect the course or the 
outcome of treatment. Consultants may be employees of the health department or clinicians with 
expertise who are under contract with the health department. 
The role of medical practitioners in TB control will increase as TB 
morbidity in the United States decreases and jurisdictions reduce 
or even eliminate public health clinical services for TB.
Community Health Centers
Community health centers typically provide primary health-care services to populations  
that encounter barriers to those services at other sites in the health-care system, and include  
persons who are
 • Low-income and their families; 
 • Immigrants and refugees;
 • Uninsured;
 • Homeless; and
 • Poor women and children. 
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Patients at high risk for TB disease often receive primary and emergency health care in emergency 
rooms or in community health centers. For example, community health centers in certain inner-city 
areas might serve primarily homeless persons, whereas centers in neighborhoods in which certain 
racial and ethnic populations are concentrated might become predominant health-care providers 
for immigrants and refugees. Newly arriving refugee families are frequently directed to community 
health centers to receive federally supported health-screening services, which might include targeted 
testing and treatment for LTBI. Persons with symptoms of TB disease might go first for evaluation 
and care to a community health center. For these reasons, community health centers are a critical 
part of efforts to control and prevent TB disease, and, therefore, need to perform the following tasks:
 • Provide their medical staff with the skills and knowledge needed to conduct a TB risk 
assessment of their clients, diagnose and initiate treatment for TB disease, and diagnose  
and treat LTBI;
 • Develop close working relationships with consultant physicians, hospitals, and clinical 
laboratories;
 • Develop close working relationships with the public health agency that serves their jurisdiction; 
 • Arrange for reporting patients with suspected TB disease, ensuring availability of diagnostic 
services (e.g., sputum smears for acid-fast bacilli, cultures for M. tuberculosis, and chest 
radiographs), and providing consultation and referral of patients for diagnosis, treatment,  
and hospitalization, as indicated; 
 • Understand federal and state programs that support screening, diagnostic, and treatment 
services for patients at high risk and make prevention, diagnosis, and treatment of TB disease  
a high priority; 
 • Educate patients about the personal and public health implications of TB disease and LTBI, 
and motivate them to accept prevention and curative services; and
 • Establish recommended TB infection control practices to protect patients and staff.
Community health centers typically provide primary health-
care services to populations that encounter barriers to receiving 
those services at other sites in the health-care system.
Community health centers are a critical part of 
efforts to control and prevent TB disease.
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Hospitals 
Hospitals play a critical role in TB control and prevention and provide multiple services that are 
instrumental to the diagnosis, treatment, and control of TB infection and disease. Hospitals with 
active outpatient and emergency room services often serve as sites of acute and primary medical 
care for homeless persons, inner-city residents, immigrants and refugees, and other persons at high 
risk for TB disease. Also, hospital staff members often provide medical consultation services for the 
diagnosis and management of TB disease by public health and community clinicians. Laboratory 
services provided by hospitals for community-based medical care providers might include key 
diagnostic tests for TB disease. To prevent further spread of infection, hospitals should perform the 
following tasks:
 • Develop TB infection control policies to ensure that patients suspected of having infectious TB 
disease are isolated in airborne infection isolation (AII) rooms and that effective TB infection 
control measures are implemented;
 • Report any patient with a suspected or confirmed diagnosis of TB disease to their state and 
local public health agency promptly;
 • Develop a written policy and plan for prevention of the nosocomial transmission of TB disease 
in their facility; 
 • Provide training and ongoing education of their medical and house staff in the prevailing 
diseases of the populations to which they provide care; and
 • Ensure patients with TB are discharged on a standard anti-TB regimen with advance 
arrangements coordinated between the hospital and the jurisdictional public health agency to 
enhance patient follow-up.
Hospitals with active outpatient and emergency room services 
often serve as sites of acute and primary medical care for 
homeless persons, inner-city residents, immigrants and 
refugees, and other persons at high risk for TB disease.
Academic Institutions 
Academic institutions (including schools of medicine, pharmacy, public health, and nursing) 
have the obligation and the opportunity to contribute to TB control in the United States and 
worldwide. Students from diverse disciplines, including the clinical and laboratory sciences, nursing, 
epidemiology, and health services, should be introduced to applicable concepts of public health in 
general and, because TB is a major cause of preventable illness and death in developing countries, to 
TB in particular. 
Academic institutions can provide benefits to other participants in TB control. Conferences, 
grand rounds, and other presentations are a source of continuing education for private medical 
practitioners and other community-based health-care workers. Also, trained specialists and 
researchers at academic institutions can provide clinical, radiographic, and epidemiologic 
consultation to medical practitioners and public health agencies. A majority of academic institutions 
manage university-based hospitals, which often serve populations at high risk for TB infection and 
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disease. University hospitals can become models for TB risk assessment of patients, inpatient care, 
and infection-control practice, and they can serve as tertiary care sites for an entire community or 
region. To aid communities in the fight against TB, academic institutions have a responsibility to 
perform the following tasks:
 • Incorporate TB education into their curricula;
 • Serve as repositories of expertise in the treatment and management of TB infection and  
disease, and as a resource for public health and community-based clinicians and other  
health-care workers;
 • Partner with public health agencies to improve TB control, which can include providing 
additional sites for education and training, opportunities for clinical research, and, for patients 
with TB disease, a systematic transition from hospital to outpatient care, including DOT; and
 • Provide leadership in conducting research in diagnostics, drugs, and vaccines for TB infection 
and disease. 
University hospitals can become models for TB risk assessment of 
patients, inpatient care, and infection-control practice, and they can 
serve as tertiary care sites for an entire community or region.
Medical Professional Organizations 
Medical professional organizations are critical partners in TB control efforts owing to their 
involvement with medical practice, research, education, advocacy, and public health. Greater 
participation of the nonpublic health medical sector is needed to maintain clinical expertise in 
the diagnosis and management of TB in an era of declining incidence. Organizations whose 
memberships include primary-care medical practitioners can make significant contributions to the 
control, prevention, and elimination of TB by performing the following tasks:
 • Training and educating their members and other health professionals regarding the clinical and 
public health aspects of the risk assessment, diagnosis, treatment, control, and prevention of 
TB disease;
 • Providing professional leadership on clinical practice and control of TB by participating in 
the development or endorsement of guidelines, influencing professional school curricula, and 
establishing and supporting fellowship training programs, as applicable;
 • Providing support for adequate funding for TB control and research through public education 
campaigns; and
 • Endorsing the importance of greater U.S. involvement in global control of TB by linking U.S.-
based health professionals with those from other parts of the world.
Greater participation of the nonpublic health medical sector 
is needed to maintain clinical expertise in the diagnosis and 
management of TB in an era of declining incidence.
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Community-Based Organizations
Community-based organizations (CBOs) can be particularly effective in providing information and 
education on TB disease to their constituencies. As part of the communities they serve, CBOs are 
often highly regarded, and their messages might be accepted more positively than those delivered by 
the state and/or local health department. Organizations providing services to populations at risk for 
TB disease should perform the following tasks:
 • Partner with the state and local public health TB program and medical care providers from  
the community to facilitate access to diagnostic, treatment, and prevention services for the 
target population;
 • Become involved in support initiatives, such as state and local TB advisory committees and 
coalitions; and
 • Coordinate with public health agencies and educational institutions to develop education 
programs that are tailored culturally and linguistically to their populations. 
As part of the communities they serve, CBOs are often highly 
regarded, and their messages might be accepted more positively than 
those delivered by the state and/or local health department.
Correctional Facilities 
Correctional facilities are common sites of TB transmission. Prevalence of TB disease and LTBI are 
substantially higher in prisons and jails than in the general population. TB disease is believed to be 
the leading cause of death for prisoners worldwide. 
Targeted testing and treatment of LTBI in correctional facilities have been demonstrated to have 
a substantial public health impact. Testing and treatment activities for LTBI are carried out more 
easily in prisons because the length of stay is generally sufficient to permit completion of a course 
of treatment. Jails are convenient sites for targeted testing, but subsequent treatment of LTBI has 
proved challenging. 
Correctional facilities have the responsibility of limiting the transmission of TB within the 
institution and protecting their inhabitants and staff from exposure because of their communal 
living arrangements. This is a particular challenge in jails because of the short lengths of stay for the 
majority of detainees. Abrupt and unexpected transfers of detainees among institutions might occur 
with little consideration for health issues; therefore, correctional facilities have a responsibility in the 
community to perform the following tasks:
 • Coordinate with the jurisdictional public health agency to develop and maintain an accurate 
epidemiologic profile of the risk for TB infection and disease in the inmate population;
 • Develop written polices based on the local epidemiology of TB, establish effective programs to 
screen for TB disease, respond promptly when cases occur within the facility, provide targeted 
testing and treatment programs for inhabitants and detainees with LTBI, and provide ongoing, 
competency-based education for all staff members;
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 • Establish ongoing working relations with public health agencies, hospitals, and other 
community partners for policy development, consultation and referral;
 • Develop firm linkages for referral of persons under treatment for TB disease and LTBI  
upon discharge;
 • Develop TB infection control programs to protect inhabitants, detainees, staff, and visitors 
from exposure to TB disease following requirements of the Occupational Safety and Health 
Administration (OSHA) and other regulatory agencies; 
 • Evaluate, in coordination with the local health department, the effectiveness of the institutional 
TB-control program to eliminate transmission within the facility on a continual basis; and
 • Develop ongoing education programs for staff and inmates regarding TB.
Correctional facilities have the responsibility of limiting the transmission of TB 
within the institution and protecting their inhabitants and staff from exposure.
Civil Surgeons 
Civil surgeons are licensed physicians who are certified by the U.S. Citizenship and Immigration 
Services (CIS) to conduct a required health screening examination, including testing for LTBI and 
TB disease, of foreign-born persons living in the United States who apply for permanent residency. 
CDC has responsibility for providing guidance on screening and treatment, but has no regulatory 
role in monitoring the quality or outcomes of these examinations. 
Civil surgeons are a critical component of TB control because of their access to a high-risk 
population. U.S.-based immigration screening can identify foreign-born persons with LTBI for 
whom treatment is indicated and detect TB disease. Although civil surgeons receive immigration-
focused training, little information is available on the knowledge, attitudes, and practices of civil 
surgeons. To further the cause of TB elimination, civil surgeons should perform the following tasks:
 • Understand current guidelines for the diagnosis and treatment of TB disease and LTBI;
 • Establish a working relationship with state and local public health agencies, and report 
suspected and confirmed cases of TB; and
 • Develop a referral mechanism for evaluation for TB disease and LTBI of persons seeking 
adjustment of immigration status.
Because of their access to foreign-born persons at high risk, 
civil surgeons are a critical component of TB control.
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Pharmaceutical and Biotechnology Industries
Pharmaceutical and biotechnology industries are partners in TB control because of their essential 
role in developing new diagnostics, drugs, and vaccines. Although development of new tools for 
diagnosis, treatment, and prevention of TB has been deemed essential to the effort to combat the 
disease globally and to move toward its elimination, progress in these fields has been slow. New non-
profit organizations are working with public and private partners to facilitate the development of 
essential new tools. These organizations include 
 • The Global Alliance for Tuberculosis Drug Development (www.tballiance.org);
 • The Aeras Global Tuberculosis Vaccine Foundation (www.aeras.org); and 
 • The Foundation for Innovative New Diagnostics (www.finddiagnostics.org).
Although development of new tools for diagnosis, treatment, and prevention 
of TB has been deemed essential to the effort to combat the disease globally 
and to move toward its elimination, progress in these fields has been slow.
These organizations have provided venues for identifying and addressing obstacles to the 
development of new tools against TB among private industry, public and academic researchers, 
and philanthropic organizations. To further contribute to TB control and prevention efforts, the 
pharmaceutical and biotechnology industries should perform the following tasks:
 • Understand the dimensions of the global TB epidemic and realize their key role in developing 
the necessary tools for diagnosis, treatment, and prevention of TB disease; 
 • Respond to the current surge of interest in TB globally by reexamining the costs of new 
product development and by considering potential new public and private funding and the 
markets for such products in developing countries; 
 • Contribute their perspectives and become involved in coalitions such as the Global Partnership 
to Stop Tuberculosis, the Global Alliance for Tuberculosis Drug Development, and the 
Foundation for Innovative New Diagnostics; and 
 • Coordinate with other stakeholders to ensure access to essential products for those whose  
lives are at stake. 
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Study Questions
8.7 The role of medical practitioners in TB control will decrease as TB morbidity in the 
United States decreases and jurisdictions reduce or even eliminate public health clinical 
services for TB. 
(choose the one best answer)
A. True
B. False
8.8 Why do community health centers play a critical role in efforts to control and  
prevent TB disease? (choose the one best answer)
A. They provide primary health-care services to populations that may encounter barriers to 
those services at other sites in the health-care system.
B. Persons with symptoms of TB disease might go there first for evaluation and care.
C. They have the primary responsibility for coordinating TB program integration  
in their area.
D. A, B, and C are all correct.
E.  Only A and B are correct.
8.9 Which of the following tasks should hospitals perform to prevent the further  
spread of infection?  
(choose the one best answer)
A. Develop a written policy and plan for prevention of the nosocomial transmission of TB 
disease in their facility.
B. Develop TB infection control policies to ensure that patients suspected of having 
infectious TB disease are isolated in AII rooms.
C. Report any patient with a suspected or confirmed diagnosis of TB disease to their state 
and local public health agency promptly.
D. A, B, and C are all correct.
E.  Only A and B are correct.
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8.10 Which of the following is NOT a responsibility of academic institutions?  
(choose the one best answer)
A. Incorporate TB education into their curricula.
B. Serve as repositories of expertise in the treatment and management of TB infection and 
disease.
C. Develop questionnaires for screening all new patients in the community.
D. Partner with public health agencies to improve TB control.
E. Provide leadership in conducting research in diagnostics, drugs, and vaccines for TB 
infection and disease.
8.11 Why are medical professional organizations critical partners in TB control efforts?  
(choose the one best answer)
A. They are involved with medical practice and research.
B. They provide TB education.
C. They provide support for adequate funding for TB control and research. 
D. A, B, and C are all correct.
E.  Only A and B are correct.
8.12 Why are community-based organizations particularly effective in providing information 
and education on TB disease to their constituencies? 
(choose the one best answer) 
A. They are often highly regarded by the populations they serve.
B. Their messages might be accepted more positively than those delivered by the state  
and/or local health department.
C. They have unlimited funds to purchase quality educational materials.
D. A, B, and C are all correct.
E.  Only A and B are correct.
8.13 TB is believed to be the leading cause of death for prisoners worldwide.  
(choose the one best answer)
A. True
B. False
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8.14 Which of the following statements about civil surgeons is true?  
(choose the one best answer)
A. Are a critical component of TB control because of their access to foreign-born  
persons at high risk for TB.
B. Conduct required health screening examinations, including testing for LTBI  
and TB disease in foreign-born persons living in the United States who apply for  
permanent residency.
C. Provide treatment for all TB patients that they identify.
D. A, B, and C are all correct.
E. Only A and B are correct.
8.15 Which of the following statements is true about pharmaceutical and biotechnology 
industries involved in TB?  
(choose the one best answer)
A. Their essential role is to develop new diagnostics, drugs, and vaccines.
B. New public-private partnerships can help identify and address obstacles to developing new 
tools for TB.
C. New tools for diagnosis, treatment, prevention and elimination of TB are being developed 
quite rapidly to meet the need both domestically and internationally. 
D. A, B, and C are all correct.
E. Only A and B are correct.
Match the primary responsibility with the appropriate health sector. 
(Choose the one best answer and write the letter for the correct answer on the line next to the 
question number.)
Primary Responsibility Health Sector 
____  8.16 Plan, coordinate, and evaluate TB control 
and prevention efforts.
____  8.17 Ensure the quality and completeness of all 
TB-related services.
____  8.18 Are usually the first sources of medical care 
for persons with TB disease and need to be 
able to provide appropriate diagnostic and 
treatment services or referral.
A. Public health sector (TB 
programs, state and local 
public health agencies)
B. Private health sector 
(clinicians, community 
health centers, hospitals, 
academic institutions, 
correctional facilities, 
homeless shelters, etc.)
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Chapter Summary
State and local health departments have the primary responsibility for preventing and controlling 
TB. However, TB control is a complex undertaking and requires the collaborative efforts of a broad 
range of persons, organizations, and institutions both inside and outside the public health sector. 
These various persons and organizations have a role in improving the detection of TB cases, one of 
the most important responsibilities of TB control, and include:
 • Clinicians;
 • Community health centers;
 • Hospitals;
 • Academic institutions;
 • Medical professional organizations;
 • Community-based organizations;
 • Correctional facilities;
 • Civil surgeons; and
 • Pharmaceutical and biotechnology industries.
The essential role of the public health sector is to plan, coordinate, and evaluate TB control and 
prevention efforts. This role requires that state and local health departments focus on the following 
critical elements:
 • Planning and policy development;
 • Clinical and diagnostic services for patients with TB and their contacts;
 • Training and education;
 • Surveillance data and information management; and
 • Monitoring and evaluation.
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Appendix A 
Glossary
Acid-fast bacilli (AFB) smear 
An examination of a specimen (e.g., sputum) that has been spread onto a glass slide, stained, washed 
in an acid solution, and then placed under the microscope for examination; used to detect acid-fast 
bacilli in a specimen. Acid-fast bacilli are not decolorized by acid-alcohol after having been stained 
with dyes such as basic fuchsin. 
Active case finding 
Identifying unreported cases of TB disease by actively searching for them (e.g., laboratory and 
pharmacy audits). 
Adenopathy 
Swelling or enlargement of the lymph nodes. 
Adult-type TB 
A clinical presentation of TB disease more typical of an adult. Characterized by upper lobe 
infiltration and cavitation associated with sputum production. 
Airborne infection isolation (AII) 
Isolation of patients infected with organisms that are spread via airborne droplet nuclei <5 microns 
in diameter. 
Airborne infection isolation (AII) room 
Single-occupancy patient-care room in which environmental factors are controlled to minimize the 
transmission of infectious agents that are usually spread from person to person by droplet nuclei 
associated with coughing or aerosolization of contaminated fluids. AII rooms typically have specific 
requirements for controlled ventilation, air pressure, and air filtration. 
Alveoli 
The small air sacs at the end of airways in the lung. 
Amikacin 
An injectable second-line drug in the aminoglycoside class that is used for patients with drug-
resistant tuberculosis whose isolate has demonstrated or presumed susceptibility to the drug. 
Aminoglycoside 
A class of broad-spectrum antibiotics active against gram-negative bacteria; can cause renal toxicity 
and ototoxicity. Aminoglycosides used to treat TB include streptomycin, amikacin, and kanamycin. 
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Amprenavir 
An inhibitor of HIV-1 protease. It is used in combination with other antiretroviral agents for the 
treatment of HIV-1 infection. 
Anergy 
Inability to react to skin-test antigens because of a weakened immune system. (Anergic) 
Anergy testing 
Conducted by giving skin tests using two substances other than tuberculin; done to determine 
whether a person is anergic. People who do not react to any of the substances, including tuberculin, 
after 48 to 72 hours (that is, people who have less than 5 mm of induration to all of the skin tests) 
are considered to have cutaneous anergy to those antigens. 
Antiretroviral agents 
The categories of antiretroviral agents currently available for the treatment of HIV-1 infection 
are nucleoside reverse transcriptase inhibitors (NRTI), nucleotide reverse transcriptase inhibitors 
(NtRTI) and nonnucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI). 
Apex 
The narrow, somewhat conical upper part of a lung. (Plural: apices) 
Bacille Calmette-Guérin (BCG) vaccine 
Vaccine made from biologic substances derived from a strain of Mycobacterium bovis that was 
attenuated by Calmette and Guérin at the Pasteur Institute in Lille, France. An early version of BCG 
was first administered to humans in 1921. It is widely used in the World Health Organization’s 
(WHO) immunization programs in highly TB-prevalent countries to reduce risk of life-threatening 
TB meningitis and disseminated disease in children and adolescents. 
Boosted reaction 
An increased response of the immune system to a second or subsequent occasion on which it 
encounters a specific antigen. 
Bronchiectasis 
Persistent and progressive dilation of bronchi or bronchioles as a consequence of inflammatory 
disease, obstruction, or congenital abnormality. Symptoms include fetid breath and paroxysmal 
coughing, with the expectoration of mucopurulent matter. 
Bronchoscopy 
An examination of the interior of the tracheo-bronchial tree with a flexible fiberoptic device; it is 
used for inspection, performance of endobronchial diagnostic tests, taking of specimens for biopsy 
and culture, or removal of foreign bodies. 
Capreomycin 
A second-line injectable drug that is used for patients with drug-resistant tuberculosis.
Cavity 
A hollow space within the lung, visible on a chest radiograph, which may contain many tubercle 
bacilli; often occurs in people with severe pulmonary TB disease. 
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Close contacts 
Persons who had prolonged, frequent, or intense contact with a person with TB while he or she was 
infectious. Close contacts are more likely to become infected with M. tuberculosis than contacts who 
see the person with TB less often. 
Creatinine 
A waste product of protein metabolism that is found in the urine. It can be measured to assess overall 
kidney function. An abnormally elevated blood creatinine level is seen in those individuals with 
kidney insufficiency and kidney failure. 
Culture 
Organisms grown on or in media (liquid or solid substances containing nutrients) so that they can 
be identified; a positive culture for M. tuberculosis contains tubercle bacilli, whereas a negative culture 
contains no detectable tubercle bacilli. 
Cycloserine 
A second-line drug that is used for treating patients with drug-resistant tuberculosis.
Delavirdine 
A nonnucleoside reverse transcriptase inhibitor of the human immunodeficiency virus type 1 (HIV-1). 
It is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. 
Delayed-type hypersensitivity 
An increased reactivity to specific antigens mediated by lymphocytes and not by antibodies. 
Demographic factors 
Factors such as country of origin, age, gender, ethnic or racial group, and occupation. 
Directly observed therapy (DOT) 
A strategy used to help patients adhere to treatment; it means that a health-care worker or another 
designated person watches the TB patient swallow each dose of the prescribed drugs. 
Droplet nuclei 
Very small droplets, 1 to 5 microns in diameter, that may be expelled when a person who has 
infectious TB coughs or sneezes; they can remain suspended in the air for several hours, depending 
on the environment. 
Drug-resistant TB 
TB disease caused by Mycobacterium tuberculosis organisms that are resistant to at least one first-line 
antituberculosis drug. 
Efavirenz 
A nonnucleoside reverse transcriptase inhibitor of the human immunodeficiency virus type 1 (HIV-1). 
It is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. 
Ethambutol (EMB) 
A first-line drug for treating all forms of TB. It is included in initial treatment regimens primarily  
to prevent emergence of rifampin (RIF) resistance when primary resistance to isoniazid (INH)  
may be present. 
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Ethionamide 
A second-line drug used for patients with drug-resistant tuberculosis disease. 
Extensively drug-resistant TB (XDR TB) 
Extensively drug-resistant TB is a rare type of MDR TB that is resistant to isoniazid and rifampin, 
plus any fluoroquinolone and at least one of three injectable second-line drugs. 
Extrapulmonary TB 
TB disease that occurs in places other than the lungs, such as the lymph nodes, the pleura, the brain, 
the kidneys, the larynx, or the bones. 
False-negative reaction 
A negative skin test reaction in a person infected with M. tuberculosis. 
False-positive reaction 
A positive skin test reaction in a person not infected with M. tuberculosis. 
Fluorochrome staining 
The use of any fluorescent dye (e.g., auramine, rhodamine) used to label or stain. Must be viewed 
using a fluorescence microscope. 
Fluoroquinolones 
A class of synthetic broad-spectrum antibacterial drugs. Examples of fluoroquinolones used to treat 
TB are levofloxacin, moxifloxacin, gatifloxacin, and ofloxacin. 
Gatifloxacin 
A fluoroquinolone used as a second-line drug in the treatment of TB. 
Granuloma 
Chronic inflammatory lesion characterized by large numbers of cells of various types  
(e.g., macrophages, lymphocytes, fibroblasts, and giant cells). 
Hemoptysis 
The expectoration of blood or of blood-stained sputum. 
Hepatotoxicity 
Injury to the liver; can be a side effect of medications. 
High-risk congregate settings 
Settings where there is a high risk of TB transmission; examples may include correctional facilities, 
nursing homes, homeless shelters, hospitals, residential facilities for persons living with AIDS, and 
other health care facilities. 
High-risk racial or ethnic minority populations 
Populations that have higher rates of TB infection or disease. This may include Asians and Pacific 
Islanders, Hispanics, African Americans, Native Americans. 
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Hilar 
Relating to, affecting, or located near the depression in the medial surface of a lung that forms the 
opening through which the bronchus, blood vessels, and nerves pass. Seen in the center of a chest 
radiograph. 
Indinavir 
An inhibitor of HIV-1 protease. It is used in combination with other antiretroviral agents for the 
treatment of HIV-1 infection. 
Induration 
A palpable, raised, hardened area. 
Infectiousness 
The infectiousness of a person with TB disease is directly related to the number of tubercle bacilli 
that he or she expels into the air. Persons who expel many tubercle bacilli are more infectious than 
patients who expel few or no bacilli. 
Interferon gamma release assay (IGRA) 
A test that detects the presence of M. tuberculosis infection by measuring the immune response to the 
TB bacteria in whole blood. 
Isoniazid (INH) 
A first-line drug for treatment of all forms of TB. 
Kanamycin 
An injectable second-line drug in the aminoglycoside class that is used for patients with drug-
resistant tuberculosis. 
Latent TB infection (LTBI) 
Persons with latent TB infection have M. tuberculosis organisms in their bodies but do not have TB 
disease, have no symptoms, and are noninfectious. Such persons usually have a positive reaction to 
the TST or IGRA. 
Levofloxacin 
A fluoroquinolone used as a second-line drug in the treatment of TB. 
Lymphadenopathy 
Swelling of the lymph nodes. 
Macrophage  
A type of white blood cell that ingests foreign material; found in the alveoli of the lungs. 
Mantoux tuberculin skin test (TST) 
Skin test used to detect TB infection. In the United States, it is performed by using a 27-gauge 
needle and syringe to inject 0.1 ml containing 5 tuberculin units of purified protein derivative (PPD) 
between the layers of the skin (intradermally), usually on the forearm; the reaction to this test, the 
induration (palpable hardened area), is measured 48 to 72 hours after the injection and is classified as 
positive or negative depending on the size of the induration and the patient’s risk factors for TB. 
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Mediastinal 
Pertaining to the space in the thoracic cavity behind the sternum and between the two pleural sacs 
(containing the lungs). 
Miliary TB 
TB disease that occurs when tubercle bacilli enter the bloodstream and are carried to all parts of the 
body, where they grow and cause disease in multiple sites; so named because the chest radiograph of 
patients with miliary TB often looks as though millet seeds are scattered throughout the lung. 
Moxifloxacin 
A fluoroquinolone used as a second-line drug in the treatment of TB. 
Multidrug-resistant TB (MDR TB) 
TB disease caused by Mycobacterium tuberculosis organisms that are resistant to more than one anti-
TB drug. MDR TB is defined as resistance to at least isoniazid and rifampin. It is more difficult to 
treat than drug-susceptible TB. 
Mycobacterium avium 
A nontuberculous mycobacteria (NTM) causing disease primarily in domestic fowl and other birds. 
This bacterium can also cause opportunistic infections in immunocompromised persons; often 
disseminated infections. 
Mycobacterium bovis 
A type of tuberculous mycobacteria; the bovine variety of the tubercle bacillus. Before the 
pasteurization of milk became common practice, these mycobacteria were often spread to humans 
through contaminated milk; in the United States today, M. bovis rarely affects humans. 
Mycobacterium gordonae 
A type of nontuberculous mycobacteria (NTM); M. gordonae is one of the least pathogenic of the 
mycobacteria. 
Mycobacterium intracellulare 
A nontuberculous mycobacteria (NTM) found in lung lesions and sputum of humans; may cause 
bone and tendon-sheath lesions in rabbits; some strains are pathogenic for mice. 
Mycobacterium tuberculosis 
A type of tuberculous mycobacteria; a gram-positive bacterium that causes tuberculosis. It is 
sometimes called the tubercle bacillus. 
Mycobacterium tuberculosis complex 
The M. tuberculosis complex includes seven other TB-causing mycobacteria: M. bovis, M. africanum, 
M. microti, M. canetti, M. caprae, M. pinnipedii, and M. mungi. 
Nelfinavir 
An inhibitor of HIV-1 protease. It is used in combination with other antiretroviral agents for the 
treatment of HIV-1 infection. 
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Nevirapine 
A nonnucleoside reverse transcriptase inhibitor of the human immunodeficiency virus type 1 (HIV-1). 
It is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. 
Nonnucleoside reverse transcriptase inhibitors (NNRTI) 
Antiretroviral agents used for the treatment of HIV-1 infection. 
Nontuberculous mycobacteria (NTM) 
Mycobacteria other than those comprising the M. tuberculosis complex. NTM may cause pulmonary 
disease resembling TB; however, NTM are NOT usually spread from person to person. Just how and 
why people become infected with NTM is not clear. Although the germs are found easily in water 
and soil, they do not affect most people. 
Nucleotide reverse transcriptase inhibitors (NtRTI) 
Antiretroviral agents used for the treatment of HIV-1 infection. 
Palpating 
A light feathery touch with the fingertips to feel for any induration. A sweeping motion is used to 
search the forearm for the indurated reaction. 
Para-amino salicylic acid (PAS) 
An oral drug used in treatment of drug-resistant tuberculosis. 
Paradoxical reaction 
A temporary exacerbation of symptoms, signs, or radiographic manifestations after initiation of 
treatment for TB disease. 
Pathogenesis 
The origin and development of disease. 
Paucibacillary 
Having or made up of few bacilli. 
Peripheral neuropathy 
Injury to the nerves that supply sensation to the arms and legs, causing a tingling sensation or a 
weakened sense of touch in the hands and feet. 
Pleural effusion 
The collection of fluid (including blood) in the pleural space. 
Polymerase chain reaction (PCR) 
The first practical system for in vitro amplification of DNA and, as such, one of the most important 
recent developments in molecular medicine. 
Primary TB 
TB disease occurring soon after the initial infection with M. tuberculosis. Occurs commonly in 
children or in immunocompromised hosts. Primary TB is characterized by intrathoracic adenopathy, 
mid- and lower-lung zone infiltrates, and the absence of cavitation. 
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Protease inhibitors (PI) 
Antiretroviral agents used for the treatment of HIV-1 infection. 
Pyrazinamide (PZA) 
A first-line drug for the treatment of all forms of TB. 
QuantiFERON-TB Gold In-Tube test (QFT-GIT) 
A whole-blood test for diagnosing TB infection. QFT-GIT measures the patient’s immune reactivity 
to Mycobacterium tuberculosis, the bacterium that causes TB. 
Reticuloendothelial diseases 
Diseases of the phagocytic system of the body, including the fixed macrophages of tissues,  
liver, and spleen. 
Rifabutin 
Used as a substitute for rifampin (RIF) in the treatment of all forms of TB caused by organisms  
that are known or presumed to be susceptible to this drug. The drug is generally reserved for patients 
who are receiving any medication having unacceptable interactions with RIF or have experienced 
intolerance to RIF. 
Rifampin (RIF) 
A first-line drug for treatment of all forms of TB. Rifamycins are an essential component of all  
short-course regimens. 
Rifamycin 
A class of drugs that include rifampin, rifabutin, and rifapentine. 
Rifapentine (RPT) 
May be used once weekly with INH in the continuation phase of treatment for HIV-seronegative 
patients with noncavitary, drug-susceptible pulmonary TB who have negative sputum smears at 
completion of the initial phase of treatment. 
Ritonavir 
An inhibitor of HIV-1 protease. It is used in combination with other antiretroviral agents for the 
treatment of HIV-1 infection. 
Saquinavir 
An inhibitor of HIV-1 protease. It is used in combination with other antiretroviral agents for the 
treatment of HIV-1 infection. 
Silicosis 
A form of lung disease resulting from occupational exposure to and inhalation of silica dust over a 
period of years, usually associated with concurrent tobacco use; characterized by a slowly progressive 
fibrosis of the lungs, it results in impairment of lung function. 
Skin-test conversion 
A negative tuberculin skin test reaction which increases in size by ≥10 mm within 2 years; indicative 
of recent infection with M. tuberculosis. 
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Streptomycin (SM) 
An aminoglycoside used as a second-line drug in the treatment of TB. Among patients likely to have 
acquired M. tuberculosis in a high-incidence country, the relatively high rate of resistance to SM 
limits its usefulness. 
Symptoms suggestive of hepatitis or hepatotoxicity 
Symptoms include nausea, loss of appetite, vomiting, persistently dark urine, yellowish skin, malaise, 
unexplained elevated temperature for more than 3 days, or abdominal tenderness.
T-SPOT®.TB test  
A cellular in vitro blood test for the diagnosis of active and latent TB infection that enumerates the 
response of effector T-cells that have been sensitized to Mycobacterium tuberculosis. 
Targeted testing 
Targeting testing is the tuberculin skin testing of groups for which rates of TB are substantially 
higher than for the general population. 
Transmission 
Transmission occurs when a person inhales droplet nuclei containing M. tuberculosis, and the droplet 
nuclei traverse the mouth or nasal passages, upper respiratory tract, and bronchi to reach the alveoli 
of the lungs. 
Tubercle bacilli 
Mycobacterium tuberculosis organisms. 
Ultraviolet germicidal irradiation (UVGI) 
A sterilization method that uses ultraviolet light to break down microorganisms. 
Virulence 
The ability of any agent of infection to produce disease. The virulence of a microorganism (such as a 
bacterium or virus) is associated with the severity of the disease it is capable of causing. 
Volar surface 
Palm-side-up surface of the forearm, about 2 to 4 inches below the elbow. 
Ziehl-Neelsen or Kinyoun 
Methods for staining acid-fast bacteria; acid-fast organisms appear red, other tissue elements light 
blue; basic fuchsin dye.
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Appendix B 
Answers to the Study Questions 
Chapter 1 
Overview of Tuberculosis Epidemiology in the United States
# Answer
1.1 B
1.2 B
1.3 B
1.4 A
1.5 A
1.6 C
1.7 E
1.8 D
1.9 C
1.10 E
1.11 D
1.12 E
1.13 C
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Chapter 2 
Transmission and Pathogenesis
# Answer # Answer
2.1 B 2.18 B
2.2 E 2.19 B
2.3 A 2.20 B
2.4 B 2.21 A
2.5 E 2.22 A
2.6 B 2.23 E
2.7 C 2.24 D
2.8 B 2.25 B
2.9 C 2.26 A
2.10 B 2.27 B
2.11 A 2.28 A
2.12 B 2.29 C
2.13 B 2.30 F
2.14 A 2.31 E
2.15 A 2.32 B
2.16 B 2.33 A
2.17 B 2.34 D
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Chapter 3 
Testing for Tuberculosis Infection and Disease
# Answer # Answer
3.1 E 3.17 A
3.2 E 3.18 A
3.3 A 3.19 B
3.4 C 3.20 A
3.5 B 3.21 B
3.6 C 3.22 A
3.7 A 3.23 B
3.8 D 3.24 A
3.9 A 3.25 A
3.10 E 3.26 A
3.11 B 3.27 A
3.12 C 3.28 B
3.13 A 3.29 A
3.14 D 3.30 A
3.15 C 3.31 A
3.16 B 3.32 B
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Chapter 4 
Diagnosis of Tuberculosis
# Answer # Answer
4.1 A 4.18 D
4.2 B 4.19 B
4.3 A 4.20 A
4.4 B 4.21 A
4.5 B 4.22 A
4.6 A 4.23 B
4.7 A 4.24 A
4.8 A 4.25 C
4.9 A 4.26 A
4.10 A 4.27 B
4.11 B 4.28 A
4.12 A 4.29 A
4.13 C 4.30 D
4.14 D 4.31 D
4.15 E 4.32 D
4.16 B 4.33 B
4.17 A
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Chapter 5 
Treatment of Latent Tuberculosis Infection
# Answer # Answer
5.1 B 5.15 E
5.2 B 5.16 D
5.3 A 5.17 B
5.4 B 5.18 A
5.5 B 5.19 B
5.6 A 5.20 C
5.7 A 5.21 E
5.8 C 5.22 D
5.9 B 5.23 E
5.10 B 5.24 D
5.11 A 5.25 A
5.12 B 5.26 E
5.13 E 5.27 D
5.14 D 5.28 E
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Chapter 6 
Treatment of Tuberculosis Disease
# Answer # Answer
6.1 D 6.28 C
6.2 A 6.29 A
6.3 B 6.30 D
6.4 A 6.31 D
6.5 B 6.32 D
6.6 A 6.33 C
6.7 A 6.34 D
6.8 D 6.35 B
6.9 E 6.36 A
6.10 B 6.37 C
6.11 E 6.38 D
6.12 E 6.39 D
6.13 C 6.40 A
6.14 E 6.41 C
6.15 E 6.42 A
6.16 A 6.43 B
6.17 A 6.44 C
6.18 A 6.45 B
6.19 B 6.46 B
6.20 A 6.47 D
6.21 A 6.48 A
6.22 B 6.49 C
6.23 A 6.50 C
6.24 D 6.51 D
6.25 E 6.52 B
6.26 B 6.53 A
6.27 A 6.54 E
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Chapter 7 
Tuberculosis Infection Control
# Answer # Answer
7.1 D 7.23 A
7.2 B 7.24 B
7.3 A 7.25 A
7.4 A 7.26 A
7.5 A 7.27 B
7.6 D 7.28 B
7.7 D 7.29 D
7.8 C 7.30 E
7.9 A 7.31 B
7.10 E 7.32 C
7.11 D 7.33 A
7.12 C 7.34 A
7.13 A 7.35 B
7.14 B 7.36 A
7.15 A 7.37 E
7.16 C 7.38 E
7.17 B 7.39 B
7.18 B 7.40 A
7.19 A 7.41 B
7.20 B 7.42 A
7.21 B 7.43 B
7.22 A
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Chapter 8 
Community Tuberculosis Control
# Answer
8.1 D
8.2 A
8.3 D
8.4 A
8.5 A
8.6 A
8.7 B
8.8 E
8.9 D
8.10 C
8.11 D
8.12 E
8.13 A
8.14 E
8.15 E
8.16 A
8.17 A
8.18 B
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Appendix C  
PowerPoint Slide Set
PowerPoint Slide Set
The Core Curriculum is accompanied by a PowerPoint slide set for use in presentations and training 
programs. Images of the slides are included in this appendix. The slide set may be downloaded from 
the CDC DTBE website at www.cdc.gov/tb.  
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